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1 Introduction 
 
Neurons are large post-mitotic cells with a highly complex morphology, 
characterized by a dendritic tree that consists of a network of processes with a 
length up to 100 fold the diameter of the cell body, and an axon that can have a 
length of up to 104 times the diameter of the cell body (i.e. 1 m and 100 µm 
respectively). Therefore, the maintenance of the functional and structural integrity 
of neurons throughout life is a complex task that requires sophisticated transport, 
damage control and repair machineries. Hence, it is not surprising that aging is 
associated with structural and functional deterioration of the central nervous 
system and that neurodegenerative diseases (diseases that cause the premature 
loss of neurons) are among the dominant disorders associated with aging. 
Identifying the mechanisms underlying the aging and degeneration of neurons is 
an important task in clinical neuroscience. Genetic studies in the past decades 
have considerably increased our understanding of proteins that play a role in 
familial forms of neurodegenerative diseases [153]. However, our knowledge about 
how these protein abnormalities lead to neuronal degeneration is still very 
incomplete, and, more importantly, there has been little advance in the 
development of effective treatments for neurodegenerative disorders. 
In general, neurodegenerative disease are characterized by the degeneration of 
specific groups of neurons, e.g. cortical neurons in Alzheimer's disease, 
dopaminergic neurons of the substantia nigra in Parkinson's disease, and medium-
size spiny neurons of the striatum in Huntington's disease. The subject of this 
thesis is amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder of 
motoneurons. A major breakthrough in ALS research came with the identification of 
mutations in the superoxide dismutase 1 (SOD1) gene in 1993 [128]. This has 
enabled the production of transgenic mutant SOD1 expressing mice that develop 
an ALS-like motoneuron disease. The ALS-mutant SOD1 mice provided the first 
realistic animal model for ALS [60]. In the studies presented in this thesis we use 
this mouse model to unravel factors that contribute to the pathogenesis of ALS 
focusing on two potential pathogenic factors: oxidative stress and proteolytic 
stress. 
This chapter provides an introduction on ALS and experimental ALS models. 
 
1.1 Amyotrophic lateral sclerosis 
 
1.1.1 Upper and lower motoneurons  
The term motoneurons is used for those neurons in the spinal cord and the brain 
stem that innervate skeletal muscle fibers. These neurons are also referred to as α-
motoneurons. A single α-motoneuron innervates multiple muscle fibers. An α-
motoneuron and its muscle fibers are called a motor unit, which is the smallest 
contractile unit of a muscle. The number of muscle fibers innervated by a 
motoneuron, i.e. the size of a motor unit, varies, in most muscles, from 100 up to 
2000 depending on the type and function of the muscle. α-Motoneurons are usually  
GENERAL INTRODUCTION 
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Figure 1: Upper motoneurons (white circles, upper left) are situated in the motor cortex (dotted line, 
upper left) and connect via the corticospinal or corticobular tract to respectively the spinal cord or 
brainstem. Lower motoneurons (white circles in right part) are situated in the brainstem or ventral horn 
(dotted line) of the spinal cord. Lower motoneurons connect directly with the muscles in all parts of the 
body. (from Rowland et al., 2001) 
 
grouped into three classes depending on their the size and firing properties and the 
properties of their muscle fibers: small tonically active α-motoneurons innervate 
muscle fibers that contract relatively slowly and generate small forces, but are 
fatigue resistant. These slow motor units are involved in 'background' muscle 
activity such as those required for the control of posture. Large α-motoneurons 
innervate muscle fibers that are rapidly fatigued but are fast and produce large 
forces as required for running or jumping. A third class of α-motoneurons is 
intermediate in size and innervates muscle fibers with intermediate properties. The 
small α-motoneurons are relatively unaffected in ALS [112]. Also α-motoneurons 
innervating the extra-ocular muscles and the bladder are relatively spared [22]. In 
addition, γ-motoneurons, a class of small motoneurons that innervate muscle fibers 
within amuscle spindle (a specialized structure in the muscle that senses its length 
and tension), are mostly unaffected in ALS. 
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In the clinic, α-motoneurons are referred to as 'lower motoneurons' (figure 1). 
'Upper motoneurons' are neurons primarily localized in the motor cortex that control 
movement by directly or indirectly controlling the activity of α-motoneurons. 
Symptoms due to loss of upper motoneurons are distinct from lower motoneuron 
symptoms. Lower motoneuron symptoms include paresis (weakness), atrophy of 
muscles, loss of reflexes, loss of muscle tone, and fasciculations (spontaneous 
twitches of denervated muscle fibers). Upper motoneuron symptoms are spasticity 
due to increase in muscle tone, and increased reflexes, which may lead to 
pathological reflexes like the Babinski sign. 
 
There is a continuum of disorders affecting lower and/or upper motoneurons. 
These various diseases are usually distinguished can be further distinguished on 
the basis of criteria like the part of the motoneurons that are primarily affected 
(axon versus cell body), the extent of non-motor system pathology, age of onset, 
and rate of disease progression. Diseases of the axon of lower motoneurons 
include the various forms of Charcot Marie Tooth type 2 (CMT2), which are 
peripheral axonopathies without demyelinisation, usually characterized by both 
sensory and motor defects. Similarly, disorders of the axons of upper motoneurons 
usually show both sensory and motor deficits. Disorders that selectively affect 
lower motoneurons include spinal muscular atrophy (SMA) and Kennedy disease. 
SMA is one of the most common autosomal recessive disorders in childhood, with 
an incidence of 1 in 6,000–10,000 births. Pure upper motoneuron disorders, i.e. 
primary lateral sclerosis (PLS), are rare. The identification of the genetic defects 
underlying many of these disorders has revealed valuable information about the 
molecular pathways that are important for the structural and functional integrity of 
motoneurons (Table 1).  
 
1.1.2 Clinical and pathological features of ALS 
Amyotrophic lateral sclerosis (ALS) is defined as an adult onset progressive 
disease that (eventually) involves both lower and upper motoneurons. It is the most 
common adult onset motoneuron disease, and often the term motor neuron 
disease is used instead of ALS. Other names are Charcot disease after the French 
neurologist who first described the disease, or, in the USA, Lou Gehrig’s disease 
after the New York Yankees baseball player who died of the disorder in 1936. The 
distinction between ALS and late onset pure upper or pure lower motoneuron 
diseases, (i.e. late onset PLS, late onset spinal muscular atrophy (SMA) and 
progressive bulbar palsy (PBP)) is not always clear [93,162]. It is a matter of 
debate whether it is useful to differentiate between late onset upper or lower 
motoneuron diseases and ALS, since genetic forms of motoneuron disease do not 
seem to obey such a classification (see below). On the other hand a more refined 
classification of ALS based on upper or lower motoneuron onset, disease 
progression and the presence of other symptoms is useful in clinic. 
The incidence of ALS in most European countries is between 2 and 3 per 100.000 
persons, which means that approximately 300-450 people per year are diagnosed 
with ALS in the Netherlands. In total there are 750-1200 ALS patients in the 
Netherlands. ALS-patients die on average 3 years after disease onset, although 
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20% of the patients survive for more than 5 year [159]. The first symptoms are 
usually fatigue, muscle cramps, and weakness in the muscles of one of the limbs, 
progressing to paralysis and spreading to other parts of the body. These symptoms 
are accompanied by fasciculation (muscular twitching) and atrophy (decrease in 
size) of the muscles involved, and by hypertonia and hyperreflexia due to 
involvement of upper motoneurons. In some cases symptoms start with difficulties 
in swallowing or slurred speech (bulbar ALS) [131]. In clinically 'unaffected' 
muscles, electromyography may reveal denervation activity. In a subset of ALS, in 
particular in familiar forms, atypical features such as sensory deficits or dementia 
occur.  
Neuropathologically ALS is characterized by degeneration of the corticospinal 
tracts, loss of motoneurons, astrogliosis in the ventral horn of the spinal cord and 
the motor cortex and atrophy of the ventral roots. Different types of subcellular 
abnormalities have been identified in surviving motoneurons, including an 
abnormal Golgi apparatus and the appearance of various abnormal intracellular 
structures. A constant and characteristic pathological feature in ALS motoneurons 
is the presence of ubiquitinated structures, consisting of irregular loosely arranged 
bundles ('skeins') of filamentous-appearing material and/or spherical inclusions 
[95]. These ubiquitin-immunoreactive inclusions are more prevalent than Bunina 
bodies that are small (2-3 µm) granular inclusions found in the majority of sALS 
and some fALS patients but not in other neurodegenerative diseases. Bunina 
bodies contain tubules and vesicular structures, but except for cystatin C the 
composition of these inclusions is still unclear. Another pathological feature is the 
accumulation of phosphorylated neurofilament in the proximal axon [68]. 
 
1.1.3  Familial ALS 
The pathogenesis of ALS is still poorly understood [22,132]. In the majority of the 
patients (90%) the disease is sporadic, i.e. without a clear inheritance pattern, 
whereas in 10% of the cases ALS is familial, usually with autosomal dominant 
inheritance. This distribution of familial and sporadic disease is similar to other 
adult-onset neurodegenerative diseases, such as Parkinson disease and 
Alzheimer disease. In general, familial ALS is clinically and pathologically similar to 
sporadic ALS. The genetic causes underlying familial ALS are now beginning to be 
unraveled [89]. 
At the moment of writing this chapter, 5 ALS genes and 6 additional disease loci 
were identified [89] (see table 3). A major breakthrough came in 1993 with the 
identification of SOD1 mutations in familial ALS [128]. which more than a decade 
later, are still the main known cause of ALS. Recently, mutations in other genes 
have been uncovered, but these genes, so far, are associated with small numbers 
of patients and relatively atypical forms of ALS (see table 2). 
Superoxide dismutase 1 (SOD1)-gene: Mutations in SOD1 were the first causes of 
familial ALS that were identified and SOD1-mutations represent 20% of familial 
ALS [6]. SOD1 is small dimeric copper and zinc-containing enzyme constitutively 
expressed in all eukaryotic cells. Its dominant function is believed to be the 
detoxification of super oxide radicals in most compartments of the cell with 
exception of the mitochondrial matrix where super oxide radicals are detoxified by 
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SOD2. Although SOD1 is a highly abundant protein that comprises as much as 1% 
of total cytosolic protein, studies with SOD1 knockout mice have shown that its 
complete absence has no effect on viability and life span [48]. In contrast mice with 
targeted deletion of SOD2 die shortly after birth because of oxidative stress 
mediated damage to mitochondria that can be attenuated by SOD mimetics [109]. 
Studies with transgenic mice and rats overexpressing SOD1 have suggested that 
SOD1 may be important in conditions of ischemia, hypoxic stress, and after 
oxidative insults like paraquat intoxication [29]. However, extra SOD1 does not 
influence life span [73], and may be deleterious [77]. Thus the precise advantage 
of expressing very high levels of SOD1 in mammals remains to be determined. In 
this context it should be noted that in yeast and invertebrates cytosolic SOD is a 
relevant protein for survival and aging. Significantly, studies in Drosophila have 
shown that transgenic expression of different ALS-related mutant SOD1 in 
motoneurons increases life span [42]. 
How SOD1 mutations cause ALS is not yet understood. Currently, more than 110 
mutations (mostly missense point mutations) spanning all five exons have been 
identified. Mutant SOD1s show a great variability of biochemical and biophysical 
properties, varying from highly unstable mutants to mutants with virtual identical 
properties as wild-type SOD1 [6]. The commonality among mutants may be their 
conformational instability and increased tendency to aggregate in a monomeric or 
metal-free configuration or after disulfide reduction [157]. Structure analysis has 
confirmed that mutant SOD1s can form stable aggregates [157]. 
Significant advance in identifying the disease mechanism has come from a recent 
study with spinal cord tissue from ALS patients and transgenic mice expressing 
SOD1 with the G127insTGGG mutation, which shows that minute quantities of 
mutant SOD1 (below 0.5% of control SOD1 levels) are sufficient to cause 
motoneuron degeneration [81]. This offers an explanation why wild-type-like and 
unstable mutants cause a similar disease, since these mutants may generate 
different levels of total SOD1, but the same levels of SOD1 in a toxic configuration 
[81]. Another recent finding indicate that the toxic effect of mutant SOD1 may not 
be caused by a direct effect on motoneurons, but rather indirectly via an effect on 
neighboring cells [32]. 
Since mild genetic modifications in almost any of its amino acid residues can cause 
ALS, mechanisms can be envisioned in which wild-type SOD1 may also become 
toxic. For instance, various post-translational modifications that may afflict its 
stability or degradation have been identified in wild-type SOD1 [157]. In addition, 
transgenic expression of a high level of wild-type SOD1 causes mitochondrial 
pathology and axonal degeneration in aged mice, and dramatically accelerates the 
disease phenotype in transgenic mice expressing ALS-mutant SOD1 [77]. Wild-
type SOD1 transgenic mice like ALS-mutant SOD1 mice also develop insoluble 
aggregated SOD1 species while aging (Jaarsma, unpublished observation). 
In sum, data so far suggest a mechanism where a small fraction of misfolded, 
possibly oligomerised or aggregated mutant SOD1 causes the disease [157]. 
There are many ways for misfolded and aggregated proteins to disturb cell function 
[140], but which organelles or cell biological processes are affected by mutant 
SOD1 and why it selectively afflicts motoneurons is still unknown (see below). 
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However, neuropathological and biochemical studies in ALS-mutant SOD1 mice 
indicate that the mitochondrial outer membrane and intermembrane space are sites 
of early mutant SOD1 accumulation [79][Liu, 2004] resulting in malfunction of 
mitochondria. 
ALS2/alsin gene: Mutations in the Alsin gene (also known as ALS2) have been 
identified as the second cause of ALS. Two different mutations in alsin have been 
linked to a rare autosomal recessive juvenile form of familial ALS but they can also 
lead to juvenile hereditary spastic paraplegia [44,61,170]. Alsin is a 184-kDa 
protein with a yet unknown function. It has three putative guanine-nucleotide-
exchange factor (GEF) domains, and it can act as a guanine nucleotide exchange 
factor for Rac1, and alsin can also influence endosomal dynamics [88,155]. Like 
SOD1, alsin is not selectively expressed in motoneurons, but in most, if not all, 
cells of the body. ALS-related mutant alsin is highly unstable, which together with 
its recessive inheritance suggests a loss of function mechanism of disease. Alsin-
knockout mice do not develop a motor neuron disease-like phenotype (reviewed in 
[89]). 
Senataxin gene: 3 different missense mutations in the Senataxin gene have been 
linked to ALS4; an autosomal dominant form of juvenile ALS with an unusual slow 
disease progression [30]. Senataxin is a large protein with a superfamily I 
DNA/RNA helicase domain. However, the majority of the protein has no domain 
conservation or homology to other proteins. The exact function of senataxin is not 
known, but DNA/RNA helicases are generally involved in DNA repair, replication, 
recombination, transcription, RNA processing, transcript stability, and the initiation 
of translation. The nature of the mutations and pattern of inheritance suggest a 
toxic gain-of-function mechanism of disease. Interestingly, recessive loss-of-
function mutations in senataxin are associated with another neurodegenerative 
disorder: ataxia-oculomotor apraxia type 2, a heterogeneous disorder 
characterized by cerebellar ataxia/atrophy, oculomotor apraxia, loss of reflexes, 
late peripheral neuropathy, and immunodeficiency [113].  
VAPB gene: Recently, a missense mutation in the vesicle-associated membrane 
protein B (VAPB) gene has been linked to ALS in a number of Brazilian families 
probably derived from a single Caucasian founder [119]. Interestingly, the clinical 
presentation of disease was variable among families, varying from typical ALS to a 
mild slowly progressing adult onset spino-muscular atrophy. Members of the 
vesicle-associated proteins are intracellular membrane proteins that can associate 
with microtubules and have a function in membrane transport [149]. Preliminary 
transfection studies in HEK 293 cells and hippocampal neurons show that mutant 
VAPB is mislocalized and may aggregate [119]. Like SOD1, alsin and senataxin, 
VAPB is ubiquitously distributed throughout the body, again raising the question 
about the selective vulnerability of motoneurons. 
p150 dynactin (DCTN1): A heterozygous missense mutation (G59S) in the p150 
dynactin subunit was first reported in a patient with a slowly progressing autosomal 
dominant form of lower motoneuron disease [123]. More recently, a genetic screen 
with 250 ALS patients and 150 controls has revealed 3 new heterozygous 
missense mutations in conserved portions of p150 dynactin [116]. The mutations 
were found in both sporadic and familial ALS patients, and one of the mutations 
was also found in unaffected relatives. Dynactin is an essential protein in dynein-
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dependent trafficking linking the cargo to the dynein motor complex (see below). 
Recent studies with mutant mouse models have shown that abnormalities in dynein 
trafficking cause motoneuron disorders in these mice. Together these data indicate 
that dynein trafficking is important for the health of motoneurons, and that 
abnormalities afflicting this trafficking machinery may be one of the risk factors of 
ALS [70]. 
 
1.1.4 Susceptibility factors in ALS 
Aging is a dominant risk factor for ALS. In addition, there is slight male to-female 
predominance. Multiple studies have been devoted at identifying other risk or 
modifying factors (e.g. heavy metal intoxication, physical activity), but no consistent 
data have emerged. Table 3 summarizes a number of potential genetic 
susceptibility factors linked to ALS, but again the data are still inconclusive 
[22,132]. For instance, the apoE4 allele which is a risk factor in Alzheimer's 
disease, has been associated with earlier onset and faster disease progression in 
ALS [40,96,115], but no association was found in other studies [143,147]. 
Other potential susceptibility factors are the survival of motor neuron protein (SMN) 
genes. SMN is a ubiquitous 38 kDa protein that is important for cellular survival. 
SMN is involved in mRNA processing but in neurons also may be important in  
 
Table 3: Potential genetic susceptibility factors in ALS  
Gene 
 
Normal function Variant Effect of 
variation 
Effect on fenotype ALS-
type 
Ref 
NF-H Neurofilament 
subunit 
Repeat shortening accumulation High probability sALS 
(fALS?) 
[4] 
VEGF Growth factor Homozygous promoter 
mutation → decreased 
expression 
decreased 
protein levels 
High probability sALS [91] 
CNTF Growth factor Homozygous truncation inactive Early onset fALS 
(SOD1) 
[51] 
SMN1 Pre-mRNA 
transport and 
splicing 
Heterozygous deletion or 
extra gene copy 
unknown High probability sALS [33] 
SMN2 Pre-mRNA 
transport and 
splicing 
Heterozygous deletion unknown Short survival sALS [161] 
allele 4 Unknown Earlier onset, short 
survival, high 
probability 
sALS [40] ApoE Lipid transport and 
metabolism 
allele 2 Unknown Delays onset, 
longer survival 
sALS 
fALS 
[96] 
mtDNA Mitochondrial DNA haplogroup I Unknown Decreased 
probability 
sALS [103] 
EAAT2 Glutamate 
transporter 
Decreased expression, 
different splicing 
Decreased 
activity 
High probability? sALS, 
fALS 
[19] 
GluR2 AMPA receptor 
subunit 
Altered RNA-editing Ca2+-permeable 
AMPA-R 
High probability? sALS [152] 
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controlling mRNA transport of specific proteins. SMN is encoded by two highly 
homologous genes on chromosome 5, SMN1 and SMN2, but full-length transcripts 
are derived almost exclusively from the SMN1 gene because of a nucleotide 
replacement in exon 7 of SMN2 [49]. Homozygous deletions or loss-of-function 
mutations of SMN1 cause spinal muscular atrophy (SMA). In contrast, SMN2 is 
dispensable since it is homozygously deleted in 5-10% of the population. However, 
the presence of SMN2 attenuates disease in SMA patients [49]. A recent study 
indicates that homozygous SMN2 deletions are over-represented in patients with 
sporadic ALS and hence may form a risk factor for this disease [161]. However, 
others failed to reproduce these findings and instead found heterozygous SMN1 
deletions to correlate with ALS [89]. 
Another approach aimed at identifying susceptibility and pathogenic factors of ALS 
(and other neurodegenerative diseases) is the analysis of the proteomes and 
transcriptomes of ALS patients. Usually this is done with postmortem spinal cord 
and brain tissue, but as an alternative blood cells of living patients may be 
considered. One of the rationales underlying these approaches is the hope that the 
disease-inducing factors may leave a molecular signature in the tissue of ALS 
patients. Unfortunately, no consistent data providing new insights in the disease 
mechanisms have been reported so far (reviewed in [102]). The main problem 
associated with the analysis of postmortem spinal cord and brain tissue from ALS 
patients is that only tissue from end-stage disease can be analyzed, when there is 
complete tissue reorganization due to loss of neurons and proliferation of glial cells. 
This causes a complete reshuffling of the proteome and transcriptome.  
Accordingly, analysis of protein and mRNA expression in the spinal cord of SOD1-
ALS mice shows that at end stage disease many neuron and glia-specific proteins 
show a differential expression, whereas prior to disease onset no changes in gene 
expression have occurred (Jaarsma, non-published observations; [102]). One way 
to resolve this problem is to selectively isolate mRNA from surviving motoneurons 
using the laser capture technique [98]. 
 
1.2 Disease mechanisms in sporadic and familial ALS 
 
Many pathological mechanisms have been suggested to play a role in the etiology 
of sporadic ALS, including virus intoxication, autoimmunity, heavy metal 
intoxication, accumulation of oxidative stress mediated damage, accumulation of 
misfolded and aggregated proteins (proteolytic stress), excessive excitation of 
motoneurons (excitotoxicity), abnormalities in intracellular transport, abnormal 
activation of cell death pathways, lack of trophic support, and insufficient 
mitochondrial function [22,132]. It has been repeatedly proposed that several of 
these pathogenetic factors may operate together or sequentially and that 
therapeutic approaches should be designed to target all these different factors 
[22,132]. Below we will discuss the hypotheses that have been most influential in 
the past decade. 
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1.2.1 Impaired retrograde trafficking 
The genetic defects identified so far in ALS and other diseases of upper and lower 
motoneurons (tables 1 and 2) can be grossly linked to a number of related cell 
biological processes, i.e. intracellular transport (p150 dynactin, KIF1B, kinesin 
heavy chain (KIF5A), alsin, spartin, spastin, atlastin, VAPB, seipin; mitofusin, rab7, 
SMN, NIPA1); RNA-processing and transport (SETX, SMN, GARS) cytoskeleton 
maintenance (neurofilament L, neurofilament H, lamin, L1-CAM, Hsp27); and 
mitochondrial maintenance and transport (Hsp60, mitofusin1, paraplegin, SOD1). 
The many mutations involved in intracellular transport are consistent with the 
notion that transport may represent the Achilles heel of long-axon neurons like 
motoneurons [69,70]. 
The long distance transport machinery of neurons (and other cells) consists of 
multiple anterograde motor proteins, the kinesin superfamily proteins (KIFs), which 
transport their cargo from the cell body to the periphery, and one retrograde motor 
complex, the dynein-dynactin complex [69,70]. The specificity, direction and 
dynamics of the transport of different types of cargo depend on cargo-specific 
adaptors and a network of regulatory factors. Knowledge about the control of 
motors-cargo interactions is still preliminary [69,70]. It is important to note that 
abnormalities in anterograde transport do not lead to motoneuron death but cause 
diseases of the axon and usually affect both sensory and motor neurons (table 1). 
In contrast, several lines of evidence have linked impaired dynein-dynactin 
dependent (i.e. retrograde) trafficking to ALS.  1) mutations in the p150 dynactin 
subunit have been identified in ALS and late onset SMA patients [116,123]. 2) 
Mutations in dynein causing impaired retrograde axonal transport cause motor 
neuron disease in two lines of induced mouse mutants [62]. 3) Overexpression of 
the p50 dynactin subunit (dynamitin), which impairs dynactin trafficking, causes 
motoneuron disease in mice [92]. 4) Dynein-dynactin plays an important role in 
proteolytic waste product management by transporting misfolded and aggregated 
proteins to the cell body [85]. This links misfolded protein stress (see below) to 
impaired retrograde trafficking. 5) Abnormalities in dynein-dynactin trafficking can 
be induced by expressing mutant SOD1 in vitro and has also been observed in 
mutant SOD1 mice [22,80]. 6) Finally, aberrant neurofilament aggregation, a 
common pathological hallmark in ALS motoneurons, has been linked to abnormal 
dynein trafficking [22]. Why impairment of dynein trafficking selectively afflicts 
motoneurons is not understood. A possible explanation is that motoneurons more 
than other cells depend on retrograde trophic signaling [69,70].  
 
1.2.2 Misfolded protein stress 
Improperly folded and unfolded proteins are an inevitable byproduct of protein 
synthesis and degradation.  Misfolded proteins also arise through oxidation, 
isomerization, or glycation and by transcriptional or translational errors [148,166]. 
Unfolded proteins are potentially dangerous since they can engage in non-native 
interactions and aggregate to form oligomeric complexes that are insoluble and 
metabolically stable, ultimately harm the cell [148,166]. To prevent damage from 
unfolded and aggregated protein the cell has a quality control machinery that 
consists of 1) molecular chaperones that chaperone nascent and unfolded proteins  
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Figure a: E1, E2, E3, and E4 enzymes 
work together to connect ubiquitin (ub) 
to substrate proteins. De-ubiquitinizing 
proteins can remove ub from substrates, 
preventing their degradation. 
Box 1: The ubiquitin-proteasome (UPS) proteolytic system 
The degradation of proteins plays an important role in many cellular processes like cell 
division and differentiation, stress responses, transcription regulation and biogenesis of 
organelles. Proteins can be degraded by two different systems. The lysosomal system is 
mainly involved in degradation of extracellular proteins, while intracellular and cell surface 
proteins are mostly degraded by the ubiquitin-proteasome system (UPS). The UPS works in 
two main steps: polyubiquitination of proteins and subsequent degradation of ubiquitinated 
proteins by the proteasome. 
Ubiquitination is a multi-step process in which ubiquitin is coupled to a substrate protein 
that is coupled to a protein from the E3 enzyme family (see figure a). The E3 enzymes, 
sometimes with the help of other proteins, recognize 
which proteins are candidates for degradation. 
Substrate proteins are recognized for example because 
they are phosphorylated or oxidized, their NH2-
terminal is modified, or because they are already 
bound to an intermediary protein (e.g. a molecular 
chaperone). How mutated and misfolded proteins are 
recognized is still unknown, but it has been 
hypothesized that the exposure of hydrophobic 
domains is a factor. Once one ubiquitin protein is 
attached to a protein more ubiquitin is attached to that 
complex by ubiquitin chain assembly factors (E4s), 
forming a poly-ubiquitin chain. Ubiquitination can be 
reversed: de-ubiquitinating enzymes (DUBs) can 
specifically cleave ubiquitin from substrates, thereby 
preventing degradation of specific proteins. 
[45,52,111]. 
Once the substrate-protein is ubiquitinated, the actual 
degradation is performed by the proteasome. The 
proteasome cleaves proteins into peptides varying 
between 3 and 23 amino acids long. The proteasome 
consists of multiple proteins; the 20S proteasome, 
which is the catalytic part of the proteasome, and a 
regulatory protein complex. The 20S proteasome 
consists of a stack of four rings, making it barrel-
shaped (see figure b). The proteasome has 3 different 
types of proteolytic active sites (each with a 
preference for different cleavage sites) that face the 
core of the barrel. Without regulatory proteins the 
channel through the proteasome is internally blocked, 
but even if the channel is forced in an open 
conformation the 20S proteasome alone can only 
degrade small peptides and some unfolded proteins. 
[10,52,65]. 
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Figure b: The main catalytic part of the proteasome, the 
20S proteasome, is a barrel-shaped protein consisting of 
2 x 7 α subunits and 2x 7 β subunits. The 20S 
proteasome can together with the 19S regulatory 
complex form the 26S proteasome, which has full 
proteolytic functionality. 
The 19S regulatory complex (PA700) is 
involved in recognition of poly-
ubiquitinated proteins, unfolding the 
substrate protein and feeding the protein 
into the 20S proteasome. The 19S 
regulatory complex may also be involved 
in closing of the opening of the barrel, in 
that way inhibiting proteolysis. The 20S 
and 19S together form a complex that is 
also known as the 26S proteasome. 
Mammalian cells also contain another 
regulatory complex that associates with 
the 20S proteasome: the 11S regulator 
(PA28). Unlike the 19S complex, 11S 
does not catalyze the degradation of large 
proteins. Evidence indicates a role for the 
11S complex in promoting the production 
of antigenic peptides or perhaps in 
facilitating the delivery of peptides to the lumen of the endoplasmic reticulum. In some 
cases the proteasome consists of 19S-20S-11S complexes forming a hybrid proteasome 
[1,10,38]. 
 
 
and assist in their folding or refolding; 2) the ubiquitin proteasome proteolytic 
pathway that recognizes and degrades misfolded proteins (see box 1); and 3) the 
aggresome-autophagosome pathway that degrades aggregated proteins 
[86,108,140,171]. The rate of misfolded protein production can increase markedly 
upon exposure of cells to oxidative or thermal stress, or increase as a result of 
mutations, and in these conditions the amount of misfolded protein production may 
exceed the capacity of the protein quality control machinery, disturb cell function 
and induce cell death [140].  
Several disorders including most neurodegenerative disorders (Alzheimer's 
disease, Parkinson's disease, Huntington's disease, several cerebellar ataxias, and 
ALS) are characterized by the presence of insoluble aggregates of proteins that 
are deposited in intracellular inclusions or extracellular plaques, which generally 
are characteristic for the diseases. This and other findings have led to the notion 
that most neurodegenerative diseases are misfolded protein disorders (also termed 
conformational disorders), where accumulation of misfolded aggregate-prone 
proteins is the central pathogenic event. Mechanisms by which misfolded and 
aggregated proteins may afflict cell function include trapping of essential proteins, 
inhibition of the proteolytic and quality control machinery, induction of apoptotic 
pathways, or hindrance of transport processes. It should be noted that although the 
presence of inclusions containing aggregated proteins are a sign of misfolded 
protein stress, these inclusions themselves do not necessarily harm the cell, but 
may also reflect a  protective response of the cell to detoxify aggregated proteins 
[86,140]. For instance Lewy bodies as identified in Parkinson's disease may 
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represent aggresomes, an organelle that 'stores' aggregated proteins prior to 
degradation by the autophagosome pathway [86,108,171]. 
A number of data indicate that misfolded protein stress may contribute to the 
pathogenesis of ALS: 1) Ubiquitinated structures, consisting of irregular loosely 
arranged bundles ('skeins') or spherical inclusions, are a constant and 
pathognomic feature in ALS [95]. Ultrastructurally, these ubiquitinated structures 
consist of various types of filamentous or amorphous material consistent with 
protein aggregation. In SOD1-linked ALS patients inclusions contain mutant SOD1 
[141], but in sporadic ALS patients SOD1 usually is not present in ubiquitinated 
structures. 2) In the case of SOD1 mutations conformational instability and an 
increased propensity to aggregate is the only property shared by the more than 
110 mutant forms of SOD1 that are linked to ALS [157]. 3) Ubiquitinated and non-
ubiquitinated aggregates of SOD1 are a constant feature prior to the death and 
disappearance of motoneurons in transgenic mutant SOD1 mice (see chapters 4 
and 5). However, the presence of ubiquitinated structures in mutant SOD1 mice 
should be interpreted with care since studies in chimeric mutant SOD1 mice (see 
below) have shown that also motoneurons that do not express mutant SOD1 may 
become strongly immunoreactive for ubiquitin ([32]; see also discussion of chapter 
5). 4) Because of their size and high metabolic activity motoneurons may be 
relatively vulnerable to misfolded protein stress. In addition, there is evidence 
suggesting that motoneurons are relatively deficient in protein-quality control 
management, since they show a high threshold for induction of heat shock protein 
70 (Hsp70), a stress inducible factor that can detoxify misfolded proteins including 
mutant SOD1 [11]. However, this does not explain the selective vulnerability of 
motoneurons towards mutant SOD1, since Hsp70 is not induced in any cell in 
mutant SOD1 mice with the exception of very sick motoneurons (see chapter 5), 
whereas motoneurons are among the few cells in the brain that express high levels 
of another heat shock protein, the small heat shock protein Hsp27, that can 
'detoxify' mutant SOD1 (see chapter 4).  
 
1.2.3  Oxidative stress 
Oxidative stress is implicated in the pathogenesis of both normal aging and 
neurodegenerative diseases. Oxidative stress is a condition where the 
concentration of oxidants in the cell is higher than normal. Most oxidants are free 
radicals which are molecules containing at least one unpaired electron. Free 
radicals have an intrinsic ‘need’ to gain or lose an electron and in that process they 
can damage almost everything in the cell, including proteins, membranes, and 
DNA. Because of cellular metabolism most biological free radicals contain oxygen. 
Other oxygen-containing molecules like hydrogen peroxide (H2O2) and peroxynitrite 
(ONOO-) can easily form oxygen free radicals and are therefore together with 
oxygen free radicals called reactive oxygen species (ROS). ROS are formed as a 
by-product of normal mitochondrial metabolism and are sometimes even produced 
specifically for physiological functions. An example of this is the production of NO• 
by nitric oxide synthases, which has a function in neurotransmission, vascular 
relaxation and in inflammatory processes [12]. Free radical scavenging proteins 
like SOD1, mitochondrial manganese SOD (SOD2), catalase, and cytochrome c 
can neutralize free radicals but this cannot prevent cellular damage by ROS. It has 
GENERAL INTRODUCTION 
23 
been shown that during normal aging the amount of damage caused by oxidative 
stress increases [120,146]. The rate of oxidation of proteins increases dramatically 
in the last decades of life, such that an average of 1 in 3 proteins is affected [12]. 
Some of the processes involved in normal aging are thought to be caused by this 
oxidative damage. Since ROS seem to be selective in inactivating particular 
proteins preferentially [9,101], it is possible that oxidative stress is involved in 
degenerative processes in neurodegenerative diseases like Alzheimer’s disease, 
Parkinson’s disease, and ALS. Levels of damaged proteins are higher in these 
diseases than in age-matched controls [2,66,138] indicating that oxidative stress is 
taking place.  
One toxic effect of oxidative stress is the oxidation of amino acids, e.g. the 
carbonylation of lysine, proline, arginine, and threonine, the glycoxidation of lysine, 
and the nitration of tyrosine [156]. Products of these processes have been found in 
both familial ALS and sporadic ALS patients, and much attention has been paid 
especially to tyrosine nitration (see chapter 2). Because 3-nitrotyrosine is bulkier 
and more hydrophilic than tyrosine, nitration of protein-linked tyrosine residues can 
impair the function of proteins [14,55,136]. Nitration of tyrosine is caused by a sub-
group of the ROS that is called the reactive nitrogen species (RNS). ONOO- is the 
reactive nitrogen species thought to be responsible for the formation of most 3-
nitrotyrosine under physiological conditions. RNS mediated toxic actions have been 
considered as a dominant pathogenic factor in SOD1-linked ALS [14,55,136].  
However, several lines of evidence including data presented in this thesis (see 
chapter 2) favor against their involvement in SOD1-ALS pathogenesis. 
 
1.2.4 Mitochondrial dysfunction 
There are now several observations which suggest that energy metabolism, and 
more specifically mitochondria, are involved in ALS. Abnormalities in mitochondrial 
function have been found in familial ALS- and some sporadic ALS patients 
[17,18,20]. In ALS-mutant SOD1 mice swelling and vacuolization of mitochondria 
are the first signs of pathology [76]. Oxidative stress and mitochondrial dysfunction 
are strongly interlaced, since oxidative stress can cause mitochondrial dysfunction 
[27,172] and vice versa free radical production can directly and indirectly be 
caused by mitochondrial (dys)function [41,107]. 
 
1.2.5 Glutamate excitotoxicity 
This hypothesis poses that excessive synaptic glutamate has a toxic effect on 
motoneurons. Elevated glutamate levels have been found in at least a subset of 
ALS patients [129,137]. This could be explained by a selective loss of the astroglial 
glutamate transporter EAAT-2 in spinal cord and motor cortex of ALS patients 
[130]. This means that less glutamate is removed from the synaptic cleft after 
neurotransmission, which can lead to over-activation of the post-synaptic glutamate 
receptors. The specific vulnerability of motoneurons in comparison with other 
glutamatergic neurons can be explained by a difference in the combination of 
subunits that form the AMPA-type glutamate receptor. The AMPA-receptor in 
human motoneurons lacks the GluR2 subunit [139,167], which normally makes the 
ion channel from this receptor Ca2+-impermeable. This means that activation of the 
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AMPA receptor by excessive amounts of glutamate cause a high rise in [Ca2+]i, 
which does not happen in other types of neurons.  
Several therapies to either reduce the amount of glutamate or inhibit the AMPA-
type glutamate receptor have had moderate effects on the survival of mutant 
SOD1-ALS mice [25,50,59,145,158]. Only 2 of those have been tested in clinical 
trial with ALS-patients. Riluzole inhibits pre-synaptic glutamate release, but has 
also been shown to inhibit NMDA-type and AMPA-type glutamate receptors [3,39]. 
Clinical trials showed that riluzole can slow the progression of ALS, and improve 
survival by several months [15,90]. However, topiramate, another anti-exitotoxic 
drug that has the ability to diminish pre-synaptic glutamate release and 
antagonizes the activation of the AMPA-type glutamate receptor by kainate [144], 
had no effect on the survival of SOD1-ALS mice [104]. Furthermore, it had a 
negative effect in ALS patients [34]. 
  
1.3 Experimental models in ALS research 
 
Prior to the discovery of SOD1-mutations and the generation of SOD1-transgenic 
mice as a dominant ALS research model there was no good animal model for ALS.  
Several spontaneous mutant mouse lines (wobbler, pmn, wasted, mnd) were used 
in ALS research, but their phenotype was more consistent with early onset SMA or 
axonopathy and effects of drugs poorly predicted the effect in ALS patients (table 
4). Recently, new mouse models have appeared based on abnormalities in dynein 
trafficking (table 4). Their value as disease models for ALS remains to be 
determined.The main characteristics of mutant SOD1-ALS mice are summarized 
below. Since a number of experiments have also been performed with 
motoneurons in culture, also different systems with cultured motoneurons are 
reviewed 
 
1.3.1 SOD1-transgenic mice 
After the discovery of SOD1-mutations in ALS, transgenic mice expressing mutant 
SOD1 were created [21,60,127,168]. The transgene constructs used for these mice 
consisted of 12 to 15-kb genomic fragments of the human [21,60,168] or mouse 
[127] SOD1 gene containing the glycine-93-to-alanine (G93A) [60], glycine-37-to-
arginine (G37R) [168], or the arginine-85-to-alanine (G85R) [21] mutations, and in 
case of the murine SOD1 construct the arginine-86-to-alanine mutation (G86R, 
which corresponds to the G85R substitution in human SOD1) [127]. All these mice 
showed high-level expression of mutant SOD1 in all cells of the body, and they all 
developed an adult onset motoneuron disease [21,60,127,168]. The mice 
developed normally and non-motor systems were usually unaffected until a very 
late phase of disease [21,60,127,168].  
In 1995 the G93A mice generated by Gurney et al. [60] were made commercially 
available by Jackson Laboratories and subsequently have become a tool in many 
ALS labs. All G93A mice reported in the literature are derived from the G1 line [60]. 
However, due to intra-locus recombination events, changes in the transgene copy 
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number have generated different subtypes of G1-G93A mice (reviewed in [57]): 
The original G1-G93A mice have 25 transgene copies, develop motor symptoms at 
90 days of age, and die at 135 days of age. These mice are often referred to as the 
G1H mice and are used in most studies with G93A mice. Another subline of G1-
G93A mice used in many laboratories, including ours, has 8 transgene copies, 
develops muscle weakness at 6-8 months and dies 6-8 weeks after symptom onset 
[79,87]. This line is referred to as the G1del or the low-copy G1 line, and is 
sometimes confused with the G1L line, which is a second 'low-copy' line with about 
18 transgene copies that has been used in a highly cited paper on the effects of 
Riluzole, gabapentin and vitamin E on survival of G93A mice [58]. Our G1del 
colony bred at the Erasmus MC in a FVB background has shown a stable 
phenotype for over 40 generations. Nevertheless, in view of the possibility of 
recombination events, it is important to keep track of survival of the mice used for 
breeding [57]. The low and high-copy G1 sublines each have their specific 
advantages: The high copy line is suited for rapid screening of potential drugs 
because of their short survival. However, the high copy mice develop atypical 
neuropathological features that do not occur in other lines of SOD1-ALS mice and 
in human ALS patients. Hence for studies aimed at identifying disease 
mechanisms low copy mice are more suitable. 
In addition to early lines of transgenic ALS-mutant SOD1 mice, more recently other 
lines of transgenic ALS mice have been reported (see table 5), and transgenic 
SOD1-ALS rats were generated [72,117]. The transgenic rat models show the 
same clinical and pathological features as transgenic SOD-ALS mice, but may be 
more suited to test interventional approaches requiring surgery, like for instance 
chronic intraventricular infusions. 
 
Several important data have been obtained so far with ALS-SOD1 mice: 
1) Within a single line there is a linear correlation between the level of transgene 
expression and the severity of motoneuron disease. This has been established by 
generating 'homozygote' transgenics [77] and by comparing distinct sublines of G1-
G93A mice (see above; [5]). This linear relationship between the level of transgene 
expression and disease phenotype has some important implications: First, low 
expressing ALS-SOD1 lines may not develop disease within their normal life span. 
Second, any pharmacological or genetic intervention that influences transgene 
expression in motoneurons will affect survival of the mice. This may explain, for 
instance, why crossing mutant SOD1 mice with mutant mice with compromised 
motoneurons because of neurofilament abnormalities has a dramatic and 
surprisingly beneficial effect on survival [22]. 
2) Comparison between ALS-SOD1 transgenic expressing wild-type like mutant 
(G93A, G37R, D90A) and unstable mutants (G85R, G127X), respectively, show 
that the severity of disease does not correlate with the absolute levels of mutant 
SOD1 protein, since these mice show similar life spans in spite of more than a 
tenfold difference in the amount of mutant SOD1 protein. In fact, only minute 
quantities of mutant SOD1 protein are needed to express a phenotype as in 
G127X-SOD1-ALS mice [81]. 
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Table 5:. Lines of mutant SOD1 ALS mice.  
 
3)  Studies with chimeric SOD1-ALS mice, generated by injecting non-transgenic 
embryonic stem cells in blastocysts from G85R or G93A mice or by fusion of non-
transgenic and transgenic morulae, have shown that motoneuron degeneration in 
SOD1-ALS mice strongly depends on mutant SOD1 expression in surrounding glial 
cells. Furthermore, data from some chimeric mice indicate that also motoneurons 
that do not express mutant SOD1 may die, because of mutant SOD1 expression in 
surrounding cells [32]. These data indicate that toxicity to motoneurons requires 
damage from mutant SOD1 acting within non-neuronal cells. The same 
conclusions have been drawn from studies with transgenic mice in which mutant 
SOD1 expression is driven by cell specific promoters. These studies showed 
neuron-specific [97,122] nor glia-specific [54] expression of mutant SOD1 was 
sufficient to cause motor neuron disease. These studies, however, were not 
conclusive since the level of mutant SOD1 expression in these cell-specific 
transgenic mice may have been too low to induce disease.  
4)  A series of studies including experiments in yeast and a study with mice 
deficient in copper chaperone for SOD1 (CCS) have shown that CCS is a critical 
protein for the delivery of the catalytic copper in SOD1 [169]. CCS has two 
Mutation 
Ratio mutant SOD1 / 
mouse SOD1 
Motoneuron loss
Mitochondrial 
vacuolization
Ubiquitin pathology Astrogliosis Ref 
Wild-type like 
  G93A 3-6 yes yes yes yes [31,60] 
  G37R 5-12 yes yes yes yes [168] 
  D90A 10 yes yes yes yes [82] 
Unstabe mutants 
  G85R 0.8-1 yes no yes yes [21,114] 
  G127X 0.45-1 yes no yes yes [81] 
Cu-binding site 
  H46R + H48Q 3-5 yes no yes yes [165] 
  Quad His 3-5 yes no yes yes [164] 
  G93A +  
  CCS knockout 
3-6 yes yes yes yes [151] 
Cell type specific 
  Thy1.2-G93A 3-5 ? no no none no [97] 
  Thy1.2-G85R <1 no no none no [97] 
  NFL-G37R 3-4? no no none no [122] 
  GFAP-G85R ? no no none yes [54] 
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domains. The N-terminal domain is very similar to the metallochaperone protein 
Atx1 and likely plays a role in copper delivery and/or uptake. The second domain is 
homologous to SOD1 and is involved in the recognition of SOD1. CCS knockout 
mice possess normal levels of SOD1 protein, but have marked reductions in SOD1 
activity [169]. Importantly, crossing mutant SOD1 transgenes into CCS knockout 
mice does not influence disease progression and survival [151]. These findings 
challenge hypotheses suggesting that mutant-SOD1 toxicity is linked to abnormal 
catalytic copper-mediated activities of mutant SOD1, although alternative sources 
of copper have been proposed for SOD1 [13]. 
Mutations in the copper-binding site (H46R and H48Q) have been found in ALS-
patients. Transgenic mice expressing mutant SOD1 containing both these 
mutations [165], or SOD1 in which all histidine residues in the copper-binding site 
have been mutated (Quad His-SOD1) [164] also develop motoneuron disease. 
Together the data indicate the toxicity of mutant SOD1 is not linked to the presence 
of the catalytic copper. 
5)  A constant feature among distinct lines of SOD1-ALS mice is the age-related 
accumulation of oligomeric and aggregated SOD1 species, and the appearance of 
ubiquitinated structures prior to the onset of motoneuron degeneration [22]. The 
subcellular localization of oligomeric and aggregated SOD1 species is still poorly 
understood. However, abnormal SOD1 in part is associated with mitochondria [79]. 
Hence, mitochondria may be the primary target of mutant-SOD1 toxicity. Another 
part of abnormal SOD1 is associated with ubiquitinated structures that appear prior 
to the onset of motoneuron degeneration. The precise identity of these 
ubiquitinated structures and their role in motoneuron degeneration is still poorly 
understood (see chapters 4 and 5). 
6)  All transgenic ALS-SOD1 mice, like many familial SOD1-ALS patients, 
develop a 'lower-motoneuron-first disease'. Thus in an early 'preclinical' phase of 
disease prior to the onset of motor symptoms, neurodegenerative changes are 
predominantly associated with α-motoneurons. In a late phase of disease 
neurodegenerative changes also spread to specific subsets of 'pre-motoneurons' 
and glia [77-79,100].  
 
1.3.2  Motoneurons in culture 
In addition to in vivo models, a number of techniques to study motoneurons in 
culture have been used in ALS research. These in vitro systems offer an ease of 
manipulation by the possibility of direct pharmacological administration or simple 
gene transfections that cannot be attained in live animals.  
Neuroblastoma cell lines are derived from tumors composed of cells derived from 
precursors of the autonomic nervous system, and are capable of unlimited 
proliferation in vitro. These cell lines have the ability to differentiate into neuronal 
cell types after treatment with various agents. The advantage of using 
neuroblastoma cell lines is that they proliferate and can be used for a long time. 
The disadvantage is that, although it is possible to differentiate the cells to specific 
neuron types, it is not sure that those cells will may ever get the same 
characteristics as differentiated neurons since they originate from tumor cells. 
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Primary cultures of motoneurons are usually derived from embryonic mouse or rat 
spinal cord, although newborn animals can also be used [7,24]. The isolation of 
motoneurons is based on differences between the buoyant density of motoneurons 
and other cells. Large motoneurons stay afloat on a cushion of dense material 
while being centrifuged whereas smaller neurons sink into the cushion [24,84]. This 
method results in cultures that consist of ~95% neurons with ~80% motoneurons. 
Sometimes this selection is combined with a cell selection method using antibodies 
to the p75 growth factor receptor only present on motoneurons, which enriches the 
cultures to ~95% motoneurons [24]. Although working with motoneuron 
monocultures makes it easy to experiment with motoneurons without the influence 
of glia, a very big disadvantage is that motoneurons in these cultures survive only 
for ~4 days. The survival can be extended for 3 more days by adding neurotrophic 
factors (usually in the form of horse blood serum or embryonic chicken muscle 
extract) to the cultures [84]. If the conditions in which the motoneurons are cultured 
are closer to the natural conditions the survival increases. This can be achieved by 
combining the motoneuron cultures with glial cultures, which is usually done by 
growing the motoneurons on a layer of glia (direct glial-neuronal contact). Neurons 
in these co-cultures seem healthier because they develop larger cell bodies, 
extensively branched dendrites and an axon-like process, which are all less 
developed in monocultures [160]. Survival in these cultures is ~2 weeks. These 
cultures are very useful in acute studies but if more chronic effects, which might be 
of importance in slow degenerative processes, have to be studied than the survival 
is too short. Furthermore the relationship between neurons and glia is still non-
natural in these co-cultures. 
Organotypic spinal cord cultures consist of 350 µm thick slices of spinal cord from 
5-9-day-old mice or rats. The first method that was developed was the organotypic 
roller tube culture [37]. The slices are attached on a glass coverslip using a 
combination of chicken plasma and thrombin. The coverslip with the slice is then 
placed inside a culture tube that is incubated in a roller drum. Because the tube is 
rotated at an angle the culture media that is placed in the tube flows over the slice 
with every rotation while the rest of the time the slice is exposed to the air in the 
tube. The other technique is the organotypic interface technique, which was 
developed by Stoppini et al. [150]. In these cultures the slices of spinal cord grow 
on a membrane; on the interface of CO2-enriched air and fluid, providing the tissue 
with sufficient access to both culture medium and oxygen (see fig 2). If the roller 
tube and interface technique are compared there is less glial proliferation in 
interface cultures than in roller tube cultures. When using this method tissues retain 
an adequate three-dimensional organization [23]. 
 
Figure 2: Side-view of a culture dish. Spinal cord slices are 
cultured on a microporous membrane (dotted line), which is placed 
in a dish containing culture medium 
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1.4 Outline of this thesis 
 
As explained in this introduction multiple factors have been implicated in SOD1-
linked and sporadic ALS. The overall aim of the studies in this thesis to unravel 
factors that contribute to the pathogenesis in SOD1-ALS mice, focusing on two 
potential pathogenic factors: oxidative stress and misfolded protein stress. The 
study in chapter 2 was intended to further clarify the role of reactive nitrogen 
species in ALS. Reactive nitrogen species have been frequently implicated in the 
pathogenesis of SOD1-linked and sporadic ALS. Evidence favoring this hypothesis 
predominantly consists of the demonstration of nitrosylated tyrosine residues in 
post-mortem tissue. However, increased tyrosine nitrosylation in SOD1-ALS mice 
predominantly affects free nitrotyrosine residues. We show that these free 3-
nitrotyrosine residues, even at high doses, are harmless to the cell. In the studies 
presented in this thesis we use this mouse model  
The studies in chapters 3 to 5 were aimed to clarify the role of proteolytic stress in 
SOD1-ALS mice.  The proteolytic stress hypothesis is partly triggered by the 
presence of ubiquitinated structures in motoneurons of ALS patients suggestive of 
abnormalities in the ubiquitin-proteasome proteolytic pathway. In chapter 3 we 
have studied the effect of prolonged mild proteasome inhibition in spinal cord 
organotypic cultures of normal and SOD1-ALS mice. In chapter 4 we show that 
simultaneously with the appearance of ubiquitinated pathology in SOD1-ALS mice 
there is a reduction in expression of the heat shock protein Hsp27, a multifunctional 
protein that may protect cells against misfolded and aggregated proteins. In 
chapter 5 using immunohistological techniques we have correlated the appearance 
of ubiquitinated structures with the expression of injury transcription factors in 
motoneurons. As discussed in chapter 6, together the data indicate that reactive 
nitrogen species do not play a significant role in motoneuron degeneration in 
SOD1-ALS mice, whereas abnormalities in protein quality control machinery occur 
relatively early in the degeneration process.  
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2.1 Abstract 
 
3-Nitrotyrosine is a modified amino acid that is formed by a reaction between nitric 
oxide-derived reactive species and tyrosine. Because of a number of studies 
indicating that 3-nitrotyrosine may be neurotoxic to particular populations of 
neurons, we have examined the effect of acute and prolonged application of 3-
nitrotyrosine in the brain of mice and in murine organotypic spinal cord cultures. 
Using an antibody that labels 3-nitrotyrosine injected into the brain, we showed that 
after a single microinjection into the cortex, striatum or hippocampus, 3-
nitrotyrosine is predominantly distributed in neurons, but subsequently disappears 
within 60 min. Neither single microinjections nor prolonged intra-striatal delivery of 
3-nitrotyrosine via osmotic minipumps resulted in any evidence for neuronal 
degeneration. Also prolonged exposure of organotypic spinal cord cultures to high 
doses of 3-nitrotyrosine did not influence neuronal viability. We conclude that 
increased levels of free 3-nitrotyrosine as reported for various neurodegenerative 
diseases, are unlikely to contribute to neuronal degeneration. 
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2.2 Introduction 
 
3-Nitrotyrosine is a modified amino acid that is formed by a reaction between nitric 
oxide-derived reactive species and tyrosine [3,11]. Because of its relative stability, 
3-nitrotyrosine has been widely used as a marker for damage left by nitric oxide-
derived species in vivo [7,11]. Increased levels of both free and protein-linked 3-
nitrotyrosine have been reported for a wide array of disorders, including 
neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease and 
amyotrophic lateral sclerosis (ALS) [11,14]. A number of studies have indicated 
that 3-nitrotyrosine, in addition of being a marker of reactive nitrogen species 
formation, also may be noxious by itself and contribute to cell death. Because 3-
nitrotyrosine is bulkier and more hydrophilic than tyrosine, nitration of protein-linked 
tyrosine residues can impair the function of proteins [3,11,25]. Furthermore, 
nitration may play a role in oligomerization of specific proteins, such as synuclein in 
synucleopathies and tau in tauopathies, and hence contribute to the formation of 
intracellular inclusions [10,12]. Nitration also may involve free tyrosine residues, 
and increased levels of free 3-nitrotyrosyne have been reported in 
neurodegenerative diseases [2,11]. A number of data suggest that free 3-
nitrotyrosine may affect cell function and contribute the pathogenesis of these 
diseases [11,25]. One putative deleterious action of 3-nitrotyrosine is caused by its 
post-translational incorporation into α-tubulin, which affects microtubule dynamics 
and cell function [1,8,30]. However, it also has been reported that nitrotyrosination 
of tubulin has no effect on many cell lines at doses up to 500 µM [4]. Alternatively, 
a deleterious action independent from α-tubulin incorporation was suggested by a 
recent study with cultured motoneurons, which showed that 3-nitrotyrosine induced 
apoptotic death in these cells, without incorporation of 3-nitrotyrosine into α-tubulin 
[23]. A neurotoxic action of 3-nitrotyrosine also has been found in vivo after a 
striatal 3-nitrotyrosine injection which resulted in degeneration of nigral 
dopaminergic neurons [22]. The mechanism underlying this toxicity was not 
investigated, although on the basis of immunocytochemical data the authors 
concluded that micro-injected 3-nitrotyrosine was not incorporated into proteins 
[22]. In the present study we have further investigated potential neurotoxic action of 
3-nitrotyrosine in vivo and in organotypic spinal cord culture. Our data indicate that 
3-nitrotyrosine microinjected into the brain is predominantly distributed in neurons, 
but rapidly disappears. However, prolonged exposure to elevated levels of 3-
nitrotyrosine did not cause neuronal degeneration in vivo and in cultures. 
 
 
2.2 Materials and Methods 
 
2.2.1 Animals and surgery  
Experiments were performed with Fvb/N mice that were housed at a 12-12 h dark-
light cycle, and were fed ad libitum with a standard diet. Animal procedures were 
performed in accordance with the ‘NIH Guide for the Care and Use of Laboratory 
Animals’ and were approved by the local ethical committee of the Erasmus MC 
(protocol # 115-02-05 and 115-03-01). For acute 3-nitrotyrosine injections mice 
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were anesthetized with a mixture of O2, N2O and 2% halothane, and a small hole 
was drilled in the skull.  1-10 nmol of 3-nitro-L-tyrosine (10 -100 mM diluted in 100 
nl saline; Sigma) was injected stereotactically during 2 min in hippocampus (n=6) 
or in the striatum (n=18) using a glass micropipette  (tip diameter 20-25 µm). 
Following injection animals were perfused transcardially with 4% paraformaldehyde 
in 0.1 M phosphate buffer (pH 7.3) immediately (n=6), or 15 min (n=3), 30 min 
(n=3), 1 h (n=2), 2 h (n=2), 1 day (n=2) and 2 days (n=6) after injection. 
For the chronic intra-striatal 3-nitrotyrosine injection mice were anesthetized and a 
stainless steel cannula (30 G) was implanted in the striatum through a small hole in 
the cranium, fixed with dental cement, and connected via a polyvinylchloride 
catheter to an Alzet micro-osmotic pump (1007 D; Alza, Mountainview, CA), which 
had been filled with 3-nitro-L-tyrosine (100 mM in saline) or L-tyrosine (100 mM in 
saline; Sigma) and implanted under the skin on the back as described before [5]. 
After 7 days the mice were perfused transcardially with 4% paraformaldehyde, the 
brain was carefully dissected out and further processed for immunocytochemistry. 
 
2.2.2 Immunocytochemistry  
Brains were cryoprotected overnight in 30% sucrose, and cut into 40 µm coronal 
sections on a freezing microtome. Every tenth section was collected in 4% 
paraformaldehyde, and processed with a Nadler-Gallyas silver staining procedure 
that selectively labels degenerating neurons and their processes [15]. An additional 
series of sections was processed for acetylcholine esterase histochemistry. Other 
sections were collected in Tris-buffered saline (TBS), pH 7.6, and processed free-
floating, employing standard avidin-biotin-immunoperoxidase-diaminobenzidine or 
immunofluorescence methods [16]. The following primary antibodies diluted in TBS 
containing 2% normal horse serum and 0.4% Triton X-100 were used: rabbit anti-
ATF3 (Santa Cruz, 1:1000), rabbit anti-GFAP (DAKO, 1:10000), mouse anti-MAP2 
(Sigma, 1:2000), mouse anti-nitrotyrosine (clone 1A6, Upstate Biotechnology, 1: 
100 - 1: 400), rabbit anti-nitrotyrosine (cat# 06-284, Upstate Biotechnology, 1: 500 - 
1: 2.000), mouse anti-SMI32 (Sternberger Monoclonals, 1:7.000), and sheep anti-
tyrosine hydroxylase (Novus Biologicals, 1: 2.000). For avidin-biotin-peroxidase 
immunocytochemistry biotinylated secondary antibodies from Vector Laboratories 
diluted 1:200 were used. For immunofluorescence FITC and Cy3-conjugated 
secondary antibodies raised in donkey (Jackson Immunoresearch, USA) were 
used. In control experiments for 3-nitrotyrosine-staining sections were pretreated 
with sodium dithionite (100 mM in 100 mM sodium borate) [28]. Alternatively, 3-
nitro-tyrosine (1 µM - 100 mM) or L-tyrosine (100 mM) were included during the 
primary antibody incubations step. 
 
2.2.3 Organotypic spinal cord culture  
350 µm thick slices from spinal cord of 7-day-old mice were cultured on 0.4 µm 
Millicell-CM culture plate inserts (Millipore, UK) as described before [29]. After two 
weeks cultures were treated with 3-nitrotyrosine (50, 100 or 150 µM) for one week. 
3-Nitrotyrosine was dissolved in physiological salt solution in a concentration of 10 
mM and 5, 10 or 15 µl of this solution or 15 µl physiological salt solution for controls 
was added to 1 ml of culture medium. After treatment cultures were rinsed with 
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Figure 1:  Polyclonal rabbit anti-nitrotyrosine antibody immunoreacts with different affinities to 
endogenous 3-nitrotyrosine epitopes and micro-injected 3-nitrotyrosine. 
Immunostaining of 3-nitrotyrosine in the hippocampus and overlying neocortex after microinjection of 1 
nmol 3-nitrotyrosine (solved in 100 nl saline, pH 7.4) using different concentrations of the rabbit-
nitrotyrosine antibody (A, 1:1.000, B 1:3.000, C 1:10.000) or the antibody diluted 1:1000 and pre-
incubated with 10 µM (D) or 10 mM (E) 3-nitrotyrosine. Note that 10 µM of free 3-nitrotyrosine blocks the 
staining of the micro-injected 3-nitrotyrosine, but not endogenous 3-nitrotyrosine-immunoreactivity (D), 
whereas 10 mM of free 3-nitrotyrosine inhibits both. (F) Section stained with an antibody against non-
phosphorylated neurofilament (SMI32) to evaluate whether the injection procedure causes tissue 
damage. Scale bar = 1 mm 
 
PBS, fixed for 1 h in 3.5% paraformaldehyde in 0.1 M phosphate buffer. The slices 
were immunostained with SMI32 antibody (Sternberger Monoclonals, USA 
1:3.000), ChAT  polyclonal antibody (Chemicon, USA, 1:800) 3-nitrotyrosine rabbit 
polyclonal antibody (cat# 06-284, Upstate Biotechnology, USA 1:10.000) and/or 3-
nitrotyrosine monoclonal antibody (clone 1A6 cat # 05-233, Upstate Biotechnology, 
USA 1:750), using avidin-biotin-immunoperoxidase-diaminobenzidine or 
immunofluorescence methods (see above). Motoneurons were counted in ChAT or 
SMI32-labeled slices as described before [29]. They were defined as ChAT- 
immunoreactive neurons in the ventrolateral parts of the slices or as large SMI32-
positive cell bodies in this region. In SMI32-labeled cultures also SMI32-
immunoreactive neurons in the dorsal horn or intermediate zone, representing a 
subset of spinal interneurons were counted [21]. In each experiment the numbers 
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of motoneurons and interneurons, were calibrated against the number of 
motoneurons and interneurons, respecively against control cultures. Results are 
presented as means ± SEM.  
 
 
2.3  Results 
 
2.3.1  Micro-injected 3-nitrotyrosine can be detected 
immunocytochemically in paraformaldehyde-fixed brain sections  
To be able to localize 3-nitrotyrosine after microinjection in the brain we have 
examined whether it could be labeled immunocytochemically using commercially 
available antibodies raised against nitrated-keyhole limpet hemocyanin (KLH) [28]. 
These antibodies have been shown to preferentially bind to 3-nitrotyrosine in 
peptides and proteins, but their immunoreactivity towards free 3-nitrotyrosine was 
not explored [28]. As shown in figures 1 and 2 intense immunostaining was 
obtained with a polyclonal antibody (Ab06-284, Upstate) in paraformaldehyde-fixed 
brain sections after microinjection of 3-nitrotyrosine (1 or 10 nmol diluted in 100 nl 
saline) in the striatum (Fig. 2a) or dorsal hippocampus and cortex (Fig. 1a). In 
contrast a monoclonal antibody (Mab1A6, Upstate) did not immunoreact with 
microinjected 3-nitrotyrosine (not shown). The staining obtained with Ab06-284 was 
specific for a 3-nitrotyrosine epitope, since it was inhibited by pre-adsorbing the 
antibody with 3-nitrotyrosine (Fig. 1d and e), or after treatment of the sections with 
sodium dithionite, which reduces 3-nitrotyrosine to amino-tyrosine (not shown). 
Importantly labeling of micro-injected 3-nitrotyrosine by Ab06-284 showed different 
properties as compared to 3-nitrotyrosine staining in non-injected brain.  First, 
staining of micro-injected 3-nitrotyrosine could be obtained with relatively high 
antibody dilutions as compared to the concentration required to obtain 
immunolabeling in non-injected brain (1:10.000 vs. 1:1.000; Fig. 1a-c). Second, 
immunostaining of microinjected 3-nitrotyrosine was inhibited by preabsorption with 
relatively low concentrations of 3-nitrotyrosine (100 µm; Fig.1d) while the staining 
of 3-nitrotyrosine in non-injected hemisphere could only be blocked by 
preadsorption with high concentration of 3-nitrotyrosine (10 mM; Fig. 1e). Together 
the data indicate that Ab06-284 recognizes free 3-nitrotyrosine in aldehyde-fixed 
brain sections.  
 
2.3.2 Micro-injected 3-nitrotyrosine is predominantly distributed in 
neurons and rapidly disappears 
Figures 1a and 2a show free 3-nitrotyrosine labeling in mice perfused with 
paraformaldehyde immediately after the micro-injection, i.e. within 3 min after the 
onset of microinjecton. Typically fixative reached the brain tissue within 60 s after 
onset of perfusion, i.e. within 4 min after the beginning of the injection. The volume 
of the region stained for microinjected 3-nitrotyrosine was 6.5 ± 1.7 (mean ± SD) 
mm3, indicating that within 4 min after the beginning of the injection 3-nitrotyrosine 
reached a relatively large area. Analysis of the cellular distribution of microinjected 
3-nitrotyrosine indicated a predominant neuronal distribution (Fig. 3). Analysis of 
brains perfused at different time points after injection, showed that the amount of 3- 
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Figure 2:  Micro-injected 3-nitrotyrosine 
disappears within 60 min. after injection. 
Brains were perfused at 4 min (A), 30 min (B) or 
60 min (C) after injection. Staining with the rabbit 
anti-nitrotyrosine antibody in a brain after 
unilateral intra-striatal micro-injection of 10 nmol 
3-nitrotyrosine (in 100 nl saline, pH 7.4) showed 
that the amount of 3-nitrotyrosine labeling was 
high minutes after injection (A), low 30 min after 
injection (B), and absent at 60 min after injection 
(C). Scale bar = 1 mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nitrotyrosine labeling was substantially reduced 15 min after injection, very low 30 
min after injection (Fig 2b), and absent at later time points (Fig. 2c). At all post-
injections times there was also no change in labeling with Mab1A6, which reacts 
with protein-bound 3-nitrotyrosine epitopes, but not with microinjected 3-
nitrotyrosine (see above). 
 
2.3.3 Chronic exposure to elevated levels of 3-nitrotyrosine does not 
cause neuronal degeneration in vivo in the striatum  
To examine whether 3-nitrotyrosine induced neuronal degeneration we have 
examined brain sections for neurodegenerative changes 1 and 2 days after 
injection using a silver staining procedure that selectively labels degenerating 
neurons and their processes [15] as well as a number of immunocytochemical 
markers that usually show altered expression after neuronal degeneration, i.e. glial 
acidic fibrillary protein (GFAP, a marker for reactive astrogliosis), MAP2 (a dendritic 
marker) and ATF3 (a marker for injured neurons) [15,21]. However, these methods  
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Figure 3: Microinjected 3-nitrotyrosine shows a predominant neuronal distribution. 
Confocal immunofluorescence of lamina V of the cortex in a section adjacent to the section shown in 
Fig. 2a double-labeled for phosphorylated neurofilament (SMI32, A) and micro-injected 3-nitrotyrosine 
(B). Note the co-localization of SMI32 and 3-nitrotyrosine labeling. Scale bar = 50 µm  
 
 
Figure 4:  Chronic intra-striatal delivery of 3-
nitrotyrosine does not cause neuronal 
degeneration. 
Polyclonal 3-nitrotyrosine (A, B) and tyrosine 
hydroxylase (C, D) immunoreactivity and 
acetylcholine esterase activity in the striatum 
after chronic (1 week) intrastriatal delivery of 3-
nitrotyrosine (A, C, E) or L-tyrosine (B, D, F) via 
an osmotic pump (Alzet 1007D) coupled to a 30 
G canula. Note that 3-nitrotyrosine treatment 
resulted in very high intraneuronal polyclonal 3-
nitrotyrosine labeling, but does not alter tyrosine 
hydroxylase and acetylcholine esterase staining.  
Scale bar = 25 µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
did not demonstrate any sign of neuronal degeneration after striatal or 
hippocampal 3-nitrotyrosine injections (not shown). 
In view of the rapid disappearance of microinjected 3-nitrotyrosine we examined 
the effect of prolonged delivery of 3-nitrotyrosine using Alzet osmotic minipumps 
coupled to intrastriatal cannulae. However, no signs of neuronal degeneration were 
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observed after 7 days of 3-nitrotyrosine infusion, although Ab06-284 staining 
confirmed the presence of high levels of 3-nitrotyrosine in the striatum (Fig. 4a and 
b). Furthermore we found no changes in other markers for the viability of nigral and 
striatal neurons, i.e. tyrosine hydroxylase immunoreactivity (Fig. 4c and d) and 
acetylcholine esterase histochemistry (Fig 4e and f).  
 
2.3.4 Chronic exposure to elevated levels of 3-nitrotyrosine does not cause 
neuronal degeneration in organotypic spinal cord cultures 
To further examine whether 3-nitrotyrosine may be neurotoxic, we have studied the 
effect of 3-nitrotyrosine on neuronal viability in organotypic spinal cord culture, 
which is a well established system to screen for factors that influence the viability of 
motoneurons and other spinal cord neurons [9,17,21,24]. Treatment of spinal cord 
cultures for 1 week with 50 or 100 µM 3-nitrotyrosine did not result in a change in 
the number of motoneurons as identified by non-phosphorylated neurofilament 
(SMI32) staining (Fig. 5i). Also the number of another population of spinal neurons, 
i.e. interneurons that were SMI-32 positive, was unchanged (Fig. 5i). Also in a 
second experiment increasing the 3-nitrotyrosine concentration up to 150 µM of 3-
nitrotyrosine and using another marker to label motoneurons (ChAT) there was no 
effect on the number of surviving motoneurons and their morphological 
appearance (Fig. 5j). Immunohistochemistry with Ab06-284 confirmed the 
presence of high-levels of 3-nitrotyrosine immunoreactivity in motoneurons from 3-
nitrotyrosine treated slices. Interestingly, 3-nitrotyrosine-treated slices also showed 
increased staining with Mab1A6, which does not immunoreact with free 3-
nitrotyrosine (see above), but specifically recognizes protein-bound 3-nitrotyrosine 
epitopes, indicating that 3-nitrotyrosine is incorporated into proteins. 
 
 
2.4 Discussion 
 
Because of a number of studies indicating that 3-nitrotyrosine may be neurotoxic 
we have examined the effect of acute and prolonged application of 3-nitrotyrosine 
in the brain and in organotypic spinal cord culture. Our data show that 3-
nitrotyrosine microinjected into cortical areas or striatum is predominantly localized 
in neurons. However, neither a single microinjection nor prolonged intrastriatal 
delivery of 3-nitrotyrosine by osmotic minipumps, nor prolonged treatment of 
organotypic cultures with 3-nitrotyrosine resulted in any evidence of neuronal 
degeneration.  
To localize microinjected 3-nitrotyrosine we used immunocytochemistry with a 
commercially available antibody raised against nitrated keyhole limpet hemocyanin 
[28]. Microinjection of 3-nitrotyrosine (1 or 10 nmol) in cortical areas resulted in 
very intense and a predominantly neuronal staining. Although the antibody has 
been shown to preferentially immunoreact with protein bound 3-nitrotyrosine [28], 
we hypothesize that the staining after microinjection represents free rather than 
protein bound 3-nitrotyrosine. First, immunostaining of microinjected 3-nitrotyrosine 
was inhibited after preadsorption of the antibody with relatively low concentrations  
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Figure 5:  Chronic exposure to elevated levels of 3-nitrotyrosine does not cause neuronal degeneration 
in organotypic spinal cord cultures 
A-H: Choline acetyltransferase (ChAT, A and D), polyclonal 3-nitrotyrosine (B, E) and monoclonal 3-
nitrotyrosine (G, H) labeling of organotypic spinal cord cultures that have been treated for 1 week with 3-
nitrotyrosine (50 µM diluted in saline, D-F, H) or saline (A-C, G). In 3-nitrotyrosine-treated slices strong 
polyclonal 3-nitrotyrosine-immunoreactivity is found in motoneurons (E). Notably, the slices treated with 
3-nitrotyrosine also show increased monoclonal 3-nitrotyrosine labeling (H). Scale bars = 50 µm. 
I: Counts of motoneurons stained with SMI32-antibody and of SMI32-positive interneurons in 
organotypic slices after treatment with saline, 50 or 100 µM 3-nitrotyrosine; no significant effects on 
survival of motoneurons or interneurons was found (I). Values represent means ± SEM of 20-35 
organotypic slices. The number of neurons is expressed as percentage of mean number of neurons in 
the control group. Mean numbers of motoneurons/slice and interneurons/slice in control group were 6.3 
and 170, respectively. 
J: Counts of motoneurons stained with ChAT in organotypic slices after treatment with saline, 100 or 
150 µM 3-nitrotyrosine; no significant effects on survival of motoneurons was found. Values represent 
means ± SEM of 10-15 organotypic slices. 
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of 3-nitrotyrosine (10 µM) as compared to concentrations needed to inhibit 
endogenous 3-nitrotyrosine labeling in the brain (i.e. 10 mM), which represents 
protein-bound 3-nitrotyrosine epitopes. Second, microinjected 3-nitrotyrosine was 
not labeled by a monoclonal antibody against protein-bound 3-nitrotyrosine 
epitopes. Endogenous free 3-nitrotyrosine may not be detected by the polyclonal 3-
nitrotyrosine antibody because its concentration in the CNS is much lower 
(nanomolar range [7,11]) than the concentrations of 3-nitrotyrosine shortly after 
micro-injections, which are likely to be in the low millimolar to high micromolar 
range (1 or 10 nmol spread over a volume of 6.5 µl, see results).  
3-Nitrotyrosine is considered to be a relatively stable a marker for damage left by 
nitric oxide-derived species, but our data showed that, although a large portion of 
3-nitrotyrosine injected in brain tissue entered neurons, most of it disappeared 
within 60 min after injection. One possibility is that 3-nitrotyrosine is metabolized 
within neurons. A half-life of 1-2 hours has been reported for free 3-nitrotyrosine in 
plasma and various tissues without any indication that it is build into proteins, but 
by what mechanism it is metabolized is not understood [11,26]. Denitrase- (or 
nitratase-) activities have been found in tissue-homogenates but no specific 
enzymes have yet been identified [13,19,20], and free 3-nitrotyrosine may not be a 
substrate for these denitrase activities [18]. An alternative possibility is that injected 
3-nitrotyrosine leaves the brain by diffusion. 
Mihm et al. [22] have reported degeneration of nigral dopaminergic neurons in mice 
after a single striatal 3-nitrotyrosine injection. In contrast to these findings we found 
no evidence for neurodegenerative changes in the striatum or the substantia nigra 
2 day after acute injections of 3-nitrotyrosine. More importantly, also chronic intra-
striatal administration of 3-nitrotyrosine via osmotic pumps did not result in any 
evidence of neurodegenerative changes in the nigro-striatal system, although this 
treatment resulted in prolonged elevation of intraneuronal 3-nitrotyrosine levels as 
visualized immunocytochemically. Differences in the experimental approaches may 
explain the differences in results, since Mihm et al. [22] injected higher doses of 3-
nitrotyrosine (32 nmol instead of 10 nmol) and a considerable larger injection 
volume (4 µl instead of 100 nl). Our data do not exclude the possibility that a single 
injection of a very high concentration of 3-nitrotyrosine causes neuronal 
degeneration in the nigrostriatal system. However, as suggested by our data, 
prolonged application of 3-nitrotyrosine in the micromolar range does not damage 
the nigro-striatal pathway.  
A recent study has indicated that also motoneurons are vulnerable to 3-
nitrotyrosine, since 50 to 100 µM of 3-nitrotyrosine induced apoptosis in the 
majority of neurons in isolated embryonic motoneuron culture [23]. This finding is 
relevant in view of evidence showing increased 3-nitrotyrosine levels in spinal cord 
of ALS patients and mouse models [2,11]. Increased levels of 3-nitrotyrosine also 
have been associated with excitotoxic degeneration of motoneurons [6,27]. Our 
data in organotypic slices, however, indicated no effect of 3-nitrotyrosine on the 
viability of motoneurons. The difference with the results of Peluffo et al. [23] al least 
in part can be explained by the use of different culture systems (purified 
motoneurons versus slice cultures that contain different populations and glia), 
developmental age of the neurons at the onset of culture (embryonic day 13 versus 
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postnatal day 7), and/or differences in culture media composition. In fact, the 
presence of glia or trophic factors attenuated the vulnerability of motoneurons 
towards 3-nitrotyrosine [23]. Hence, in 'in vivo-like conditions' as modeled in 
organotypic slices [9] motoneurons may be resistant to 3-nitrotyrosine at doses up 
to 100 µM. The absolute levels of 3-nitrotyrosine in control and diseased brain and 
spinal cord are not precisely known, but may be in the order of 1 or 2 µM or lower, 
since the tyrosine concentration in the CNS is below 100 µM, and the highest 
estimate of 3-nitrotyrosine concentration is 2% of total tyrosine. We therefore 
conclude that increased levels of free 3-nitrotyrosine as reported for amyotrophic 
lateral sclerosis and other neurodegenerative diseases [11,25] are unlikely to 
contribute to neuronal degeneration in these disorders.  
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3.1 Abstract 
Ubiquitinated inclusions are a constant feature of amyotrophic lateral sclerosis 
(ALS). It has been hypothesized that these inclusions reflect overload or failure of 
the ubiquitin-proteasome system, and that this failure contributes to the 
degeneration of motoneurons. 
In the present study we have examined the effect of low concentrations of 
proteasome inhibitors on protein aggregation and viability of neurons in 
organotypic spinal cord cultures. We found a dose-dependent degeneration of 
neurons after a one-week exposure to the proteasome inhibitors lactacystin and 
epoxomicin. Neuronal degeneration was associated with an increase in poly-
ubiquitination, consistent with failure of the ubiquitin-proteasome system. 
Proteasome inhibition caused degeneration of both motoneurons and interneurons, 
and no difference in survival between motoneurons and interneurons was 
observed.  
Since protein aggregation may particularly play a role in ALS-patients with 
superoxide dismutase 1 (SOD1) mutations, we have compared the effect of 
proteasome inhibition between spinal cord cultures from non-transgenic and G93A-
SOD1 transgenic mice. There was no difference between the viability of 
motoneurons from  transgenic and non-transgenic mice. 
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3.2 Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of 
motoneurons, resulting in a loss of spinal, bulbar and cortical motoneurons. ALS 
causes progressive paralysis that leads to death an average of 3 years after 
diagnosis. Approximately 10% of ALS cases are familial, with the majority of cases 
deemed to be sporadic (without known genetic linkage). About 20% of familial ALS 
(fALS) cases are associated with mutations in the Cu/Zn superoxide dismutase 
(SOD1) gene. More than 90 different mutations have been found in the SOD1-
gene that can cause fALS. The mutations are found in different parts of the SOD1 
protein, such as the dimer interface or the metal-binding sites. Some mutated 
proteins have full SOD1 function while other mutations disrupt the normal activity of 
SOD1 [19]. Despite these obvious different effects of mutations on the function of 
the protein, all these mutations cause a clinically similar disease. The cause of 
sporadic ALS (sALS) and the mechanism by which mutated SOD1 (mSOD1) 
causes ALS, remain still largely unknown. Hypotheses about the effect of SOD1-
mutations include decreased copper and zinc binding, enhanced peroxidase 
activity and enhancement of other oxidative reactions causing oxidative stress. A 
more recent hypothesis poses that the mutant protein may be sufficiently unstable 
that it precipitates to form aggregates. The formation of aggregates is a common 
feature of many neurodegenerative diseases. Although the presence of abnormal 
intracellular inclusions in ALS was described more than 40 years ago, it is only the 
last decade, that much attention has been given to the possibility that aggregation 
of proteins could be a cause of ALS. Misfolded or unfolded proteins can form small 
oligomers that arise from non-native protein-protein interactions. These oligomers 
are often poorly soluble and, if they are not degraded, they will form cytosolic 
aggregates. Inclusion bodies are defined as intracellular foci into which aggregated 
proteins are sequestered. There are two models for the formation of inclusion 
bodies. In the first model, single proteins or small oligomers diffuse to the site of 
the inclusion body forming a ‘giant aggregate’. In the second model, multiple 
aggregates are formed throughout the cell, and fuse into an ‘aggregate of 
aggregates’. A variant of the latter model suggests active retrograde transport of 
aggregates on microtubules forming an inclusion body, also called an ‘aggresome’ 
[10]. It has been shown that protein aggregation can impair the ubiquitin-
proteasome system, possibly caused by saturation of molecular chaperones 
involved in proteasomal function or by overloading of the proteasome by 
undegradable aggregates. This inhibition could lead to further aggregate formation, 
creating a positive-feedback system [1]. 
In ALS it is hypothesized that in Cu/Zn superoxide dismutase (SOD1)-related ALS, 
protein aggregation is the toxic gain of function of mutated SOD1 (mSOD1). 
Aggregates containing ubiquitin and SOD1 have been found in fALS patients [17], 
and mSOD1 transgenic mice [2,7], and it has been demonstrated that mutant 
SOD1 forms small aggregates in mSOD1 transgenic mice long before formation of 
large inclusion bodies or motoneuron dysfunction [7]. SOD1 has also been found in 
Lewy body-like inclusions of sporadic ALS patients [16]. A decrease in abundance 
of large aggregates after overexpression of HSP70, however, does not affect the 
survival of mSOD1 (G85R) transgenic mice [12]. This raises the question whether 
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these aggregates can be the cause of mSOD1 toxicity or are just a harmless by-
product of the disease, or if they even protect against damage by mutant SOD1. 
Degeneration of neurons in ALS is primarily restricted to motoneurons. This implies 
that, if aggregates are the cause of motoneuron degeneration, motoneurons are 
either more prone to aggregate formation or more sensitive to the harmful effects of 
aggregates. If the former is the case, it might be explained by the fact that 
motoneurons have a longer half-life and higher concentration than other cell-types, 
thus increasing the chances for oxidative modifications by reactive oxygen species. 
Oxidative damaged SOD1 is prone to form aggregates [14]. 
Protein degradation is mediated predominantly through the ubiquitin-proteasome 
pathway. Overload or failure of this system to degrade mSOD1 could lead to 
aggregation of ubiquitinated mSOD1 and other proteins and disruption of cellular 
homeostasis causing neuronal degeneration. This has been shown experimentally 
by short-term inhibition of the proteasome that causes accumulation of 
ubiquitinated proteins and apoptosis [13]. In the present study we used low 
concentrations of proteasome inhibitors for a relatively long period to study protein 
aggregation in organotypic spinal cord cultures of normal and G93A-SOD1 
transgenic mice. This culture system has also been used to study the effect of 
chronic mitochondrial inhibition on motoneurons [8]. We hypothesize that formation 
of aggregates in neurodegenerative diseases is caused by proteasome 
dysfunction. This implies that motoneurons with mSOD1 should be more sensitive 
to proteasome inhibition than motoneurons with normal SOD1 because the 
proteasome system is already stressed by high amounts of abnormal protein. It 
also implies that, since predominantly only motoneurons are degenerating in ALS, 
the motoneurons should be more sensitive to proteasome inhibition than spinal 
interneurons. 
 
 
3.3 Materials and Methods 
 
3.3.1 Organotypic slice cultures 
Experiments were performed in accordance with the "Principles of laboratory 
animal care"(NIH publication no.86-23, revised 1985) and the guidelines approved 
by the Erasmus University animal care committee (DEC, protocol nr 115-01-01 and 
115-00-09). SOD1G93A mice descendent from the Gurney G1L line were obtained 
from Jackson Laboratories (strain B6SJL-TgN (SOD1-G93A)1 Gur). In our animal 
facility, SOD1G93A mice were bred in FVB/N background by mating hemizygous 
transgenic animals with FVB/N females (Harlan, The Netherlands). Transgenic 
pups were identified by PCR of tail DNA with primers specific for human SOD1 [6].  
Organotypic spinal cord cultures were prepared from the lumbar spinal cord of 7-
day-old mouse pups similar to methods described previously [8]. In brief, lumbar 
spinal cords were dissected and sliced into 350 µm -thick sections. The slices were 
cultured on membrane inserts (Millicell-CM, Millipore, The Netherlands) with 5 
slices per insert. The inserts were placed in 35-mm culture dishes, containing 1 ml 
of culture medium and kept in a 5% CO2 incubator at 37°C. The medium consisted 
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Figure 1: Lactacystin causes a dose-dependent neuronal degeneration. Untreated slices showing ChAT 
specifically labels motoneurons (a, cc - central canal) while SMI32 labels motoneurons and a sub-
population of interneurons (b). (c-d) Slices treated with 1 µM of lactacystin (c) or 10 µM of lactacystin (d) 
show mild or severe damage respectively, in both the ventral and dorsal horn. (e) Relative amount of 
motoneurons (white bars) and interneurons (black bars) after treatment with lactacystin.  Data represent 
mean ± SEM based on analysis of more than 10 slices per treatment group. 
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 Figure 2:  (a) Epoxomicin 
causes dose-dependent 
degeneration of motoneurons and 
dorsal calretinin-immunoreactive 
neurons in organotypic spinal cord 
cultures after one week of 
treatment. In these experiments 
calretinin-immunoreactive (IR) 
interneurons were used to 
examine whether the effect of 
epoxomicin was cell-type specific. 
The effect of epoxomicin on 
survival is much more reliable 
than the effect of lactacystin. Data 
are mean ± SEM from 18-24 
slices per treatment group. * 
P<0.01 (b) Relative amount of 
motoneurons after 1-7 days of 
epoxomicin treatment. The effect 
of epoxomicin on survival is 
visible only after 3 days of 
treatment, indicating that 
epoxomicin is not acutely toxic. 
Data are mean ± SEM from 15-30 
slices. 
 
 
 
 
 
of Hanks' balanced salt solution (25%), horse serum (25%), minimal essential 
medium (50%), glucose (6.3 mg/ml), L-glutamine (2 mM), penicillin (100 IU/ml) and 
streptomycin (100 µg/ml). Culture medium was changed twice weekly.  
3.3.2 Treatment 
After 2 weeks in vitro, the cultures were treated with various doses of clasto-
lactacystin ß-lactone (Calbiochem, USA), epoxomicin (Affiniti, UK) or vehicle for 1 
week. Lactacystin was dissolved to a stock-concentration of 1 mM. Epoxomicin 
was dissolved in DMSO to a stock-concentration of 100 µM. A maximum of 10 µl 
was added to 1 ml of culture medium to obtain the final concentration.  
3.3.3 Immunohistochemistry 
At various time points after treatment, the cultures were fixed with 4% 
paraformaldehyde in 0.1 M phosphate buffer, and processed for fluorescent 
immunohistochemistry. The primary antibodies were diluted in PBS containing 2% 
normal horse serum and 0.3% Triton X-100: mouse anti-SMI31, mouse anti-SMI32 
(Sternberger monoclonals, USA), rabbit anti-ubiquitin (DAKO, Denmark), goat anti-
SOD1, rabbit anti-ATF3, goat anti-ChAT (Chemicon, UK). Fluorescently labeled 
and biotin-conjugated secondary antibodies were obtained from DAKO (Denmark). 
Immunofluorescent sections were analyzed with a Zeiss LSM 510 confocal 
microscope. Motoneurons were defined as large ChAT- and/or SMI32-positive cells 
in the ventral horn. Results are presented as means ± SEM. Ubiquitin- and  
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calretinin-immunoreactivity were determined using Scion Image Beta 4.0.2 
software (Scion Corporation, USA). 
 
 
3.4 Results 
 
Different types of neurons were present in the spinal cord cultures. Motoneurons 
were identified using ChAT or SMI32-staining (Figure 1a-b). Double-labelling 
experiments showed that almost 90% of motor neurons showed both ChAT and SMI32 
immunoreactivity, but to remove any existing doubts about SMI32 staining as a means 
to identify motor neurons we used either ChAT- or SMI32-staining in subsequent 
experiments. After 2-3 weeks in culture ± 10 motoneurons per slice were present. In 
the next weeks the number of motoneurons decreased slightly (approximately 7 
motoneurons per slice after 8 weeks in culture). culture). After 3 weeks in culture the 
number of SMI32-immunoreactive interneurons was approximately 250 while the 
number of calretinin immunoreactive neurons was about 215. In the proteasome 
inhibitor experiments we started the treatment after two weeks in culture and 
treated for one week. Initial experiments were carried out using lactacystin, an 
antibiotic derived from Streptomyces, that is currently the most often used 
proteasome inhibitor. Treatment with 0.1-10 µM lactacystin for one week resulted 
in a dose-dependent degeneration of motoneurons and interneurons (Figure 1) but 
only 10 mM had a consistent significant effect. Lactacystin also has inhibitory effects 
on some non-proteasomal proteases such as cathepsin A [11]. We therefore used 
epoxomicin in subsequent experiments. Epoxomicin is a more selective, 
irreversible proteasome inhibitor that does not inhibit non-proteasomal proteases 
such as trypsin, chymotrypsin and calpain [13]. As with lactacystin, a one-week 
treatment with epoxomicin (0.01-0.1 µM) resulted in a dose-dependent death of 
motoneurons (Figure 2a and 5b): 0.02 µM epoxomicin did not affect cell survival, 
whereas 0.03 µM and 0.04 µM epoxomicin caused 60% and 80% motoneuron 
death, respectively.  A decrease in the number of motoneurons was first visible 
after 3 days of epoxomicin (0.05 µM) treatment, indicating that epoxomicin had a 
chronic effect and was not acutely toxic (Figure 2b). The total immunoreactivity for  
 
Figure 3:  Optical density readings 
for the poly-ubiquitin 
immunoreactivity of the ventral 
horn of spinal cord slices. The 
increase in poly-ubiquitin 
immunoreactivity indicates that 
epoxomicin inhibits the 
proteasome in our culture system. 
Data are mean ± SEM from 5 
slices per treatment group 
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Figure 4: 
 Double-labeling confocal 
immunofluorescence 
showing ubiquitinated 
inclusions (middle panel, 
arrows) in motoneurons 
visualized with SMI32 
antibody (left panel). 
Inclusions can both be 
found near the cell 
membrane (a) or 
perinuclear (b). For 
original color pictures see 
[20]. 
 
 
 
 
 
poly-ubiquitin of the ventral horn of the spinal cord cultures increased significantly 
with the higher dosages of epoxomicin(Figure 3), showing that epoxomicin causes an 
elevation of the amount of ubiquitinated proteins in the cells. 
Motoneurons that received a sub-lethal dose of epoxomicin (0.02 µM) showed 
morphological changes that suggested degeneration (irregular cell shape, 
shortening of neurites). Aggregates were found in the cell body near the membrane 
or juxta-nuclear (Figure 4). Confocal microscopy using triple staining with 
antibodies against non-phosphorylated neurofilament (SMI32) and ubiquitin 
showed aggregates containing ubiquitin but not SOD1 in motoneurons (results not 
shown).  
To determine whether motoneurons were specifically vulnerable for the effects of 
proteasome inhibition we also looked at other populations of neurons. SMI32-
immunoreactive interneurons show no decreased vulnerability to epoxomicin 
(Figure 1e). Calretinin-immunoreactive interneurons seem to be more vulnerable to 
0.02 µM of epoxomicin, but with higher doses of epoxomicin there is no difference 
in the survival between motoneurons and small interneurons (Figure 2a).  
Neurons expressing mutant SOD1 spontaneously develop aggregates and 
inclusions. We found no spontaneous formation of aggregates in non-treated spinal 
cord cultures from SOD1G93A mice (results not shown).We subsequently looked at 
the effect epoxomicin in cultures from G93A-SOD1 mice.  We hypothesized that 
the high amount of mutant SOD1 in cultures from G93A-SOD1 spinal cord could 
make those cultures more vulnerable to proteasome inhibition. However, we did 
not find any significant differences in the survival of motoneurons and interneurons 
(Figure 5a), or in the number of aggregates between normal and G93A-SOD1 
spinal cord. There was no apparent difference in the survival of motoneurons 
between spinal cord slices from non-transgenic littermates and slices from G93A-
SOD1 mice after epoxomicin treatment (Figure 5b). 
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Figure 5:  (a) Slices from G93A-
SOD1 mice show the same 
number of motoneurons and 
calretinin immunoreactive dorsal 
interneurons as normal mice. This 
indicates that there is no decrease 
in the survival of neurons in 
G93A-SOD1 transgenic cultures. 
(b) Motoneurons from G93A-
SOD1 mice show the same 
survival after one week of 
treatment as control motoneurons. 
Which means that expression of 
G93A-SOD1 does not increase 
the vulnerability of neurons to 
proteasome inhibition. Data are 
mean ± SEM from 9-20 slices. 
 
 
 
 
 
 
 
 
 
 
 
 
3.5 Discussion 
Several lines of evidence indicate that accumulation of misfolded proteins is a 
central event in ALS and other neurodegenerative diseases. The main question is 
whether the formation of aggregates causes motoneuron degeneration or is just a 
harmless by-product of the disease. The current opinion, corroborated by findings 
in Parkinson's disease research, is that protein aggregates are formed by an 
overload of the proteasome and possibly also by overloading the chaperone 
system [3].  In agreement with this we also hypothesized that formation of 
aggregates in ALS is caused by proteasome dysfunction. If this hypothesis is 
correct, motoneurons with mutant SOD1 (mSOD1) should be more sensitive to 
proteasome inhibition than motoneurons with normal SOD1 because the 
proteasome system is already stressed by high amounts of abnormal protein. In 
our experiments with organotypic spinal cord cultures, however, we did not find a 
difference between neurons from normal mice and G93A-SOD1 mice. Although the 
mice we use are only 7 days old, they already have a high expression of G93A-
SOD1, excluding the possibility that a low expression of mSOD1 is the cause of the 
lack of difference between G93A-SOD1 cultures and control cultures. These data 
do not favor our hypothesis. 
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Inhibition of the proteasome causes an increase in posttranslationally modified 
proteins, probably by the loss or degradation of these proteins. The subsequent 
elevation of posttranslationally modified proteins produces cellular symptoms of 
oxidative stress and mitochondrial dysfunction [9]. Proteasome inhibition also 
causes an increase in levels of cell death factors [4]. Both effects of proteasome 
inhibition may cause cell death without formation of protein aggregates, explaining 
why we could find no difference in survival between normal and G93A-SOD1 
neurons. The opposite might happen after treating the slices with a low 
concentration (0.01 µM) of epoxomicin which caused a significant increase in the 
survival of motoneurons in organotypic slice cultures of non-transgenic mice. Other 
cases of increased survival of cells after treatment with proteasome inhibitors have 
been reported, including decreased apoptosis of growth factor-deprived 
sympathetic neurons [15,22]. In these cases the degradation of survival factors 
might be inhibited more than the degradation of death factors which cause 
apoptosis of motoneurons in culture. Both pro-apoptotic and antiapoptotic factors are 
known to be degraded by the ubiquitin-proteasome system][22], but how low-level 
proteasome inhibition can have other effects on apoptosis factors than high-level 
inhibition is not clear. A third possible explanation for cell death after proteasome 
inhibition is the unfolded protein response (UPR), which is a signal transduction 
pathway that is activated when misfolded or aggregated proteins accumulate in the 
endoplasmic reticulum. Although this reaction is meant to enhance protein folding 
capacity and increase survival, prolonged UPR-activation leads to programmed cell 
death [5]. 
We found no selective motoneuron degeneration. In contrast to our results, Kikuchi 
et al (2002) found that motoneurons are more susceptible to proteasome inhibition 
than other neurons. Unlike us, however, they used dissociated total spinal cord 
cultures and a different non-motoneuron population. Our choice of control 
population was based on earlier publication of different vulnerabilities found 
between motoneurons and calretinin-immunoreactive interneurons [8]. Other 
important differences between our experiments and those performed by Kickuchi et 
al (2002) are the dose and time-frame; they completed short-term high dose 
experiments while we performed relatively long-term, low dose experiments. Based 
on our results, we cannot conclude that motoneurons are more susceptible than all 
other types of neurons in the spinal cord. The selectivity of degeneration in ALS is 
either not proteasome dependent, or the inhibition of proteasomes in our 
experiments was too robust and the duration was insufficient to obtain the kind of 
aggregation that occurs in ALS.  
Since mSOD1 is abundant in slice cultures from G93A-SOD1 spinal cord, the lack 
of SOD1-immunoreactivity in aggregates is probably due to an antibody-binding 
defect and not to an absence of SOD1 in aggregates. In cultured cells expressing 
high levels of mSOD1, aggregates containing SOD1 haven been shown after 
proteasome inhibition [Hyun, 2003 #429]. The absence of SOD1 does not have to 
mean, however, that this model is not a suitable representation of ALS because 
little or no SOD1 has been found in ubiquitin-immunoreactive aggregates from 
sporadic ALS patients [16,21]. Possible factors leading to protein aggregation in 
sporadic ALS are lipid peroxidation and protein glycation caused by oxidative 
stress [18,19] and neurotoxic compounds. It is probable that aggregates containing 
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SOD1 are present in our experimental system, but that these aggregates are too small 
to be visible using lightmicroscopy. Aggregates containing mSOD1 have been found 
in vitro after proteasome inhibition but those cells probably had much higher mSOD1-
expression. 
Our findings that inclusions may be a side-product of ALS, rather than a disease-
causing event seem to support the findings of Liu et al. [Liu, 2001 #261] who found that 
a decrease in the number of large aggregates did not affect the survival of mSOD1 
transgenic mice. Since inclusions are also common in other neurodegenerative 
diseases it might be useful to further look at the toxicity of different types of inclusions 
in neurons in other neurodegenerative diseases. 
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4.1 Abstract 
 
We have investigated the expression of Hsp25, a heat shock protein constitutively 
expressed in motoneurons, in amyotrophic lateral sclerosis (ALS) mice that 
express G93A mutant SOD1 (G93A mice). Immunocytochemistry and Western 
blotting showed that a decrease of Hsp25 protein expression occurred in 
motoneurons of G93A mice prior to the onset of motoneuron death and muscle 
weakness. This decrease in Hsp25 expression also preceded the appearance of 
SOD1 aggregates as identified by cellulose acetate filtration and Western blot 
analysis. In contrast to Hsp25 protein levels, Hsp25 mRNA as determined by in situ 
hybridization and RTPCR, remained unchanged. This suggests that the decrease 
in Hsp25 protein levels occurs post-transcriptionally. In view of the cytoprotective 
properties of Hsp25 and the temporal relationship between decreased Hsp25 
expression and the onset of motoneuron death, it is feasible that reduced Hsp25 
concentration contributes to the degeneration of motoneurons in G93A mice. 
These data are consistent with the idea that mutant SOD1 may reduce the 
availability of the protein quality control machinery in motoneurons. 
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4.2 Introduction 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of 
motoneurons causing progressive paralysis. In a subset of ALS patients the 
disease is caused by mutations in the cytosolic CuZn superoxide dismutase 
(SOD1) gene [2], a small homodimeric metalloenzyme that catalyses the 
conversion of superoxide anion to hydrogen peroxide. More than 100 different 
SOD1 mutations have been identified that all cause a rather similar disease 
phenotype [2]. Mutant SOD1s display reduced conformational stability [49], 
abnormal metal binding [31], toxic oxidative catalytic activities [49], and an 
increased tendency to aggregate [10,13,23]. Several mechanisms have been put 
forward by which these properties could lead to the degeneration of motoneurons, 
which include (1) overload or disruption of the protein quality control machinery 
[23,36,43,48] and (2) disruption of vital intracellular processes (e.g. intracellular 
transport) by oligomeric SOD1 species [23,49] or by toxic oxidative reactions [29]. 
To prevent protein aggregation in the cell, molecular chaperones like heat shock 
proteins bind to unfolded and misfolded proteins. They regulate (re)folding and 
appropriate cellular compartmentalization, and target abnormal proteins for 
proteolysis [42]. Mutant but not wild-type SOD1 has been found to interact with 
several heat shock proteins, including Hsp70, Hsp40, αB-crystallin and Hsp27 
[36,43] and to reduce their availability [36]. It has been suggested that the selective 
vulnerability of motoneurons towards mutant SOD1 toxicity may depend on their 
relative inability to up regulate Hsp70 [4]. Indeed, increasing the level of Hsp70 
reduced formation of mutant SOD1 aggregates in cultured primary motor neurons 
and a neuronal cell line, and prolonged survival [6,45]. Insufficiency of chaperones 
would not only facilitate aggregation and precipitation of mutant protein, but also 
could affect other functions of chaperones. 
Motoneurons constitutively express Hsp27, a member of the small heat shock 
protein family [38]. Hsp27 has different functional properties that depend on its 
degree of oligomerization. Multimeric (16-meric to 32-meric) complexes of Hsp27 
may act as molecular chaperones by scavenging misfolded and denatured proteins 
through the formation of large (4000 kDa) complexes containing both Hsp27 and 
misfolded protein [12,41]. In a phosphorylated state Hsp27 forms small oligomeric 
(dimeric or tetrameric) complexes that interfere with specific cell death programs 
[7,32]. In addition, Hsp27 has been implicated in the regulation of actin dynamics 
and antioxidative enzymes [32]. Importantly, motoneurons are capable of up 
regulating Hsp27 expression after injurious stimuli such as axotomy, hyperthermia 
and hypoxia [8,34], and this response may be critical for their survival [5]. In the 
present study we have examined the expression of the mouse orthologue of 
Hsp27, Hsp25 in a line of transgenic mice that expresses G93A mutant SOD1 
(G93A mice) and that develops an ALS like disease [16]. Hsp25 and Hsp27 are 
orthologues but show differences in the number of phosphorylation sites and 
oligomeric configuration [41]. Therefore the murine protein is named Hsp25, 
whereas the rat and human variants are named Hsp27]. Rather than an up 
regulation of Hsp25 expression, the G93A mice show a marked decrease in Hsp25 
expression that precedes the onset of motoneuron death. 
CHAPTER 4 
 
 70 
4.3 Materials and methods 
4.3.1 Transgenic mice 
Mice were handled in accordance with the ‘Principles of laboratory animal care’ 
(NIH publication no. 86–23, revised 1985). Low-copy G93A mice descendent from 
the Gurney G1-line [16] were bred in an FVB background by mating transgenic 
males with nontransgenic FVB females (Harlan Netherlands), housed at a 12-h 
dark : 12-h light cycle, fed ad libitum with a standard diet (AM2-14–10, Hope farm, 
The Netherlands), and inspected twice a week for onset of paresis as previously 
described [20,21]. Our G93A mice develop weakness in one or more limbs from 
age 24–30 weeks, and reach endstage disease 2–10 weeks after onset of limb 
weakness [20,21]. For the immunocytochemical characterization of  
Hsp25 expression in G93A mice we analysed 14 age groups (6–8, 10, 12, 14, 16, 
18, 20, 22, 24, 26, 28, 30, 32 and > 32 weeks) with 2–6 animals per group. In most 
other experiments three groups of G93A mice were used: (1) early presymptomatic 
(age 10 weeks); at this age our G93A mice show swelling and mild vacuolization of 
a subset of mitochondria but no other pathological features [21] (Table 1). (2) Late 
presymptomatic (age 20 weeks); at this age our G93A mice in addition to 
mitochondrial abnormalities show several degenerative features in motoneurons 
(e.g. ubiquitination, induction of the ‘injury transcription factor’ ATF3 [51]) but no or 
minimal (< 10%) motoneuron loss (Table 1). (3) Symptomatic (age 30 weeks); this 
group consisted of G93A mice with moderate to severe muscle weakness in one 
 
 
Table 1: Time of appearance of selected clinical and pathological changes in G93A mice 
 
 Age (weeks) 
 5–9 10–14  15–19 20–24 25–29 > 30 
Clinical changes  
   Hind limb weakness 0 0 0 0 or + + ++ 
   Death 0 0 0 0 0 or + ++ 
Mutant SOD1 (whole spinal cord)  
   NP40-insolluble SOD1 + + ++ ++ ++ ++ 
   Cellulose-acetate filterable SOD1 0 0 0 + + ++ 
   High-molecular weight SOD1 0 0 0 + + ++ 
Motoneurons (in L4)  
   Mitochondrial vacuolization + ++ ++ ++ ++ ++ 
   Polyubiquitination, neuritis 0 0 or + + ++ ++ ++ 
   Decreased Hsp25 expression  0 0 + ++ + + 
   ATF3-expression  0 0 0 or + + + + 
   Polyubiquitination, somata  0 0 0 0 or + + + 
   Hsp70 expression  0 0 0 0 or + + + 
   Motoneuron loss  0 0 0 <20% 10-60% >20% 
Other neurons (in L4)  
   c-Jun ⁄ ATF3-expression  0 0 0 0 or + + ++ 
   Argyrophilic degeneration  0 0 0 0 or + + ++ 
Astrocytes (in L4)  
   Increased GFAP staining 0 0 0 or + + ++ ++ 
   Increased Hsp25 staining 0 0 0 0 or + ++ ++ 
   Polyubiquitination 0 0 0 0 + + 
Degree of change: 0, absent or no change; +, infrequent, moderate occurrence or moderate degree; 
++, frequent occurrence or severe degree. 
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or more limbs. Where indicated homozygous transgenic G93A mice were used. 
These G93A ⁄ G93A mice show an earlier disease onset and shorter survival 
similar to high-copy G93A mice [20]. Non-transgenic littermates and transgenic 
mice expressing wild-type hSOD1 (hSOD1 mice) derived from the Gurney N29 line 
and aged 10–100 weeks [20] were used as controls. 
4.3.2 Human tissue 
Paraffin sections from L3 lumbar spinal cord from four ALS patients (average age 
56 years; range 42–68 years), and three controls (average age 57 years; range 
45–65 years) were obtained from files of The Netherlands ALS tissue bank. Tissue 
was obtained and used in a manner compliant with the Declaration of Helsinki. 
Informed consent was obtained for the use of brain tissue. All autopsies were 
performed within 8 h after death of patients. The ALS cases were sporadic with 
either bulbar (n=2) or spinal onset (n=2). Average duration of disease after 
diagnosis was 33 months (range 20–72 months). Control cases died from 
myocardial infarct (n=1) or cancer (n=2). One control case showed mild 
Alzheimer’s pathology.  
4.3.3 Primary and secondary antibodies 
Primary antibodies reported in this study are: mouse anti-actin (Chemicon; Western 
blot (WB) 1 : 4000); rabbit anti-ATF3 (Santa Cruz; immunohistochemistry (IHC) and 
immunofluorescence (IF) 1 : 1000); mouse anti αB-crystallin (Santa Cruz; IHC and 
WB 1 : 1000); rabbit anti-CGRP (Calbiochem; IHC and IF, 1 : 10 000); goat anti-
ChAT (Chemicon; IHC and IF 1 : 500); rabbit anti-GFAP (DAKO; IHC 1 : 10 000; IF 
1 : 5000); rabbit anti-GluR2 ⁄ 3 (Chemicon; IHC 1 : 2000); rabbit anti-mouseHsp25 
(StressGen; IHC 1 : 10 000, IF and WB 1 : 5000); goat anti-humanHsp27 (Santa 
Cruz; IHC and WB 1 : 2000, IF 1 : 1000); sheep anti-phospho(ser15)- Hsp27 
(Upstate; IHC 1 : 2000); mouse anti-Hsp70 (SantaCruz; IF and WB 1 : 1000); rabbit 
anti-neurofilament-H (Chemicon; IHC 1 : 5000); mouse anti-neurofilament M 
(Sigma; IHC 1 : 50 000); mouse anti-neurofilament-L (Sigma; IHC 1 : 1000); rabbit 
antiperipherin (Chemicon; IHC 1 : 2000); rabbit anti-NMDA-R1 (Chemicon; IHC 1 : 
2000); mouse anti-MAP2 (Sigma; IHC 1 : 2000); goat anti-human SOD1 
(Calbiochem; IF 1 : 10 000); rabbit anti-murine SOD1 (SOD100, StressGen; WB 1 : 
8000); rabbit anti-SOD1 (SOD101, StressGen; WB 1 : 5000); goat anti-c-Ret (R & 
D systems; IF 1 : 200); and rabbit anti-ubiquitin (Dako; IHC and IF 1 : 2000); mouse 
anti-ubiquitin (clone FK2, Affiniti; IF 1 : 2000).  
For avidin-biotin-peroxidase immunocytochemistry biotinylated secondary 
antibodies from Vector Laboratories diluted 1 : 200 were used. FITC-, Cy3-, and 
Cy5-conjugated secondary antibodies raised in donkey (Jackson Immunoresearch, 
USA) diluted at 1 : 200 were used for confocal immunofluorescence. Horseradish 
peroxidase (HRP) conjugated secondary antibodies against mouse or rabbit IgG 
(DAKO) diluted 1 : 5000 were used for Western blot analysis and the filter trap 
assay. 
4.3.4 Immunocytochemistry 
For immunocytochemistry and immunofluorescence mice were anaesthetized with 
pentobarbital and perfused transcardially with 4% paraformaldehyde. The lumbar 
and cervical spinal cord were carefully dissected out and postfixed overnight in 4% 
paraformaldehyde. Unless otherwise stated, spinal cord tissue was embedded in 
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gelatine blocks [20], sectioned at 40 µm with a freezing microtome and sections 
were processed, free floating, employing a standard avidin-biotin-
immunoperoxidase complex method (ABC, Vector Laboratories, USA) with 
diaminobenzidine (0.05%) as the chromogen, for immunofluorescence [21]. 
Alternatively, tissue was embedded in paraffin, sectioned at 5 µm, deparaffinized 
and also processed for peroxidase-immunocytochemistry or immuno-fluorescence. 
Human paraffin sections were processed in the same way. Both gelatine and 
paraffin sections were usually pretreated with an antigen retrieval procedure 
consisting of a 30 min incubation in 40 mm sodium citrate (pH 8.5) at 80 °C [22]. 
Immunoperoxidase stained sections were analysed and photographed using a 
Leica DM-RB microscope and a Leica DC300 digital camera. Optical densities 
were determined with Scion Image for Windows Beta 4.0.2. Sections stained for 
immunofluorescence were analysed with a Zeiss LSM 510 confocal laser scanning 
microscope. 
4.3.5 mRNA in situ hybridization 
In situ hybridization was performed as previously described [9]. Mice were 
decapitated, the lumbar and cervical enlargements of their spinal cords quickly 
removed, rapidly frozen on powdered dry-ice and sectioned at 12-µm thick using a 
cryostat microtome (JUNG CM3000). Sections were thaw-mounted on charged 
glass slides (SuperFrost Plus), fixed in 4% paraformaldehyde, acetylated and 
hybridized overnight at 65 °C with digoxigeninlabelled probes, diluted at 20–100 ng 
⁄ mL (see Results). Sense and antisense digoxigenin-labelled cRNAs were 
transcribed from linearized pCMVsport6 plasmids containing full-length Hsp25 
cDNA (IMAGE clones 5097030 and 5327224) using a digoxigenin RNA labelling kit 
(Roche) according to the manufacturer’s instruction. The digoxigenin-labelled RNA-
RNA complex was detected immunocytochemically using alkaline phosphatase 
conjugated sheep-anti-digoxigenin (Roche) with 5-bromo-4-chloro-3-indolyl 
phosphate and nitro-blue tetrazoleum as substrate and chromagen, respectively. 
4.3.6 Western blot, gel filtration and filter trap 
The spinal cords of G93A mice and their non-transgenic littermates were 
homogenized in ten volumes of PBS with 1X protease inhibitors cocktail (Sigma, 
St. Louis, MO), centrifuged at 800 g for 5 min at 4 °C, and protein concentrations of 
the supernatants (S1) were determined using the BCA method (Pierce, Rockford, 
IL). Samples containing 2–10 µg protein were electrophoresed on 10% or 13% 
SDS-page gels and blotted on PVDF membranes (Millipore). For quantitative 
analysis of Hsp25-immunoreactivity recombinant Hsp25 protein (0.5–20 ng; 
StressGen) was electrophoresed and blotted together with the tissue samples. The 
membranes were blocked with 5% non-fat dry milk (BioRad) in PBS with 0.05% 
Tween20 (PBST), incubated in primary antibody, diluted in PBST with 1% dry milk 
followed by an incubation in secondary antibody, incubated in chemiluminescence 
reagent (ECL, Amersham), exposed to film or a Kodak Image station, and analysed 
with Kodak Image analysis and ImageQuant 2.2 software. To determine the 
molecular mass of Hsp25 complexes in spinal cord homogenates we used gel 
filtration with a Precision Column PC3.2 ⁄ 30 prepacked with Superdex 200 in a 
SMART system (Pharmacia) as previously described [46]. The optimal range for 
the separation of globular proteins in this column is 10–600 kDa, with an exclusion 
limit of 1300 kDa. Supernatants (S1, see above) of spinal cord homogenates were 
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centrifuged at 15 000 g for 5 min at 4 °C, and 100 µL of the supernatant (S2) was 
injected in the SMART system. Fractions (50 µL) were collected separately with a 
flow of 50 µL ⁄ min and analyzed by Western blot for the presence of Hsp25 and 
SOD1. The molecular size of the eluted fractions was determined in a separate run 
using protein markers [46]. For the filter trap assay spinal cord supernatants (S1, 
see above) were diluted to a final concentration of 2 µg protein ⁄ mL in PBS with 
0.1% or 1% SDS and filtered under vacuum through a 0.2-µm cellulose acetate 
membrane (Schleicher & Schuell) using a 96-well dot blot apparatus (Schleicher & 
Schuell) as described by Wang et al. (2002)[53]. Proteins trapped by the filter were 
detected on the membranes using the same procedure as for the Western blots.  
4.3.7 Preparation of detergent-soluble and detergent-insoluble protein 
extracts  
The spinal cords of G93A mice and their non-transgenic littermates were 
homogenized in ten volumes of PBS containing 0.5% Nonidet P-40 and 1 
protease inhibitors cocktail and centrifuged at 15 000 g for 15 min at 4 °C. After 
collection of supernatants, pellets were thoroughly washed five times with PBS-
0.5% Nonidet P-40 and then resuspended in sample buffer for SDS-page 
electrophoresis and Western-blotting. 
4.3.8 RT-PCR 
To examine the level of Hsp25 RNA total RNA was extracted from spinal cord 
tissue using Trizol, and treated with DNAse. The RNA (5 µg) was converted into 
cDNA using oligo(dT) primer and reverse transcriptase in a total reaction volume of 
20 µL (RT-reaction mixture). PCR was performed with 0.1 µL of the RT-reaction 
mixture in a reaction volume of 25 µL. Primers used for Hsp25 were:  
5’-GAGATCACTGGCAAGCACGAAG-3’ (forward) and 
5’-TGTTCAGACTTCCCAGCTTCTGG-3’ (backward). 
Primers for ChAT: 
5’–GCGAATCGTTGGTATGACAAGTC-3’ (forward), 
5’-TTGAAGTTTCTCTGCCGAGGAG-3’ (backward) and 
Primers for G6PDH: 
5’-CTTTGGACCCATCTGGAATCG-3’ (forward), 
5’-CACTTTGACCTTCTCATCACGGAC-3’ (backward). 
PCR cycles used were determined to be within the linear range of the reactions. To 
quantify the PCR products, they were electrophoresed on a 2% agarose gel, 
stained with ethidium bromide and scanned on a Molecular Dynamics Typhoon 
instrument. The relative expression level of Hsp25 mRNA was calculated using 
ChAT and G6PDH as a reference. 
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4.4 Results 
 
Immunocytochemistry showed that in non-transgenic mice Hsp25 immunoreactivity 
was present in motoneurons in all cranial nerve motor nuclei and the spinal motor 
columns (Figs 1–3). Labeling occurred throughout the soma, the dendritic arbors, 
and the axon, but not in the cell nuclei (Figs 3 and 4). Hsp25 immunoreactivity was 
present in approximately 60% of the motoneurons identified by choline 
acetyltransferase (ChAT) staining (Figs 2 and 3). Hsp25- immunonegative  
motoneurons were small (somal diameter 12– 20 µm). Apart from motoneurons, 
light or moderate Hsp25 staining occurred in sensory afferents in the dorsal horn, 
in astrocytes in the superficial part of the spinal white matter, and in endothelial 
cells. Next we examined the expression of Hsp25 immunoreactivity in the spinal 
cord of G93A mice, aged 8–40 weeks. Young adult G93A mice (age 8–14 weeks, 
early presymptomatic) showed the same Hsp25 labeling as controls (Fig. 1a and d, 
2a and b). However, as outlined below, older G93A mice developed marked 
differences.  
Figure 1: Late presymptomatic G93A mice show a decrease of Hsp25 expression in their spinal 
motor columns. Low magnification of C6 spinal cord sections of a non-transgenic mouse of 20 weeks 
(A), a wild-type hSOD1 transgenic mouse of 30 weeks (B), and G93A mice of 10 weeks (D), 20 weeks 
(E), 25 weeks (F) and 30 weeks (G) immunostained for Hsp25. Note the decrease of Hsp25 
immunoreactivity in the motor column (IX) of G93A mice of 20 weeks (E) as compared to controls (A 
and B) and G93A mice of 10 weeks. Also note the onset of astroglial Hsp25 expression in G93A mouse 
of 25 weeks (F) and dramatic astroglial Hsp25 expression in a G93A mouse of 30 weeks that showed 
severe muscle weakness (G). Calibration bar, 100 µm (A). (C) Optical density readings of Hsp25 
immunoreactivity in the motor columns (Rexed’s Lamina IX) and dorsal horn (Rexed’s Lamina II–III) of 
C6 spinal cord of non-transgenic, G93A and hSOD1 mice. Bars represent means ± SEM with five mice 
per group. Values for each mouse represent the mean of five serial C6 sections. *P < 0.01 compared 
with nontransgenic mice, and 10-week-old G93A mice (unpaired two-tailed Student t-test). 
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4.4.1 Decreased Hsp25 protein expression precedes motoneuron loss in 
G93A mice 
Late presymptomatic G93A mice, i.e. from 15 weeks to symptom onset (24–30 
weeks of age), showed a striking decrease of Hsp25 immunoreactivity in their 
spinal motor columns (Figs 1c and e, 2c and 3b). Densitometry showed that 
reduced Hsp25 labeling was specific for the motor columns and did not occur in the  
dorsal horn (Fig. 1c). Reduced Hsp25 labeling was never observed in non-
transgenic mice of 10–120 weeks (Fig. 1). Moreover, reduced Hsp25 labeling 
never occurred in age-matched (10–40 weeks) and old (120 weeks) transgenic 
mice that expressed wild-type hSOD1 (Fig. 1b). Homozygous G93A mice, which 
show an earlier disease onset and shorter survival as compared to hemizygous 
G93A mice [20], showed reduced motoneuronal Hsp25 staining at ten, but not at 
six weeks. 
 
 
Figure 2: Decreased Hsp25 expression precedes motoneuron loss. (A–L) High magnification of C6 
spinal cord sections of a non-transgenic mouse of 20 weeks (A, E and I) and G93A mice of 10 (B, F and 
J), 20 (C, G and K) and 30 weeks (D, H and L) immunostained for Hsp25 (A–D), ChAT (E–H), and 
ATF3 (I–M). Note that in presymptomatic (20 weeks) G93A mice Hsp25 staining in motoneurons is 
decreased (C), whereas the number and morphology of motoneurons identified by ChAT staining has 
not changed (G). Also note that the reduction of Hsp25 is associated with appearance of the injury 
marker ATF3 in a subset of motoneurons in late presymptomatic and symptomatic G93A mice (arrows 
in K and L, respectively). Bar in A, 50µm. (M) Quantification of the number of Hsp25, ChAT and CGRP 
immunoreactive motoneurons per C6 spinal cord section of non-transgenic and G93A mice. Values 
represent means ± SEM with 5 mice per group. Values are based on counting of five sections per 
animal. *P < 0.005 compared with non-transgenic mice, and 10 weeks old G93A mice (unpaired two-
tailed Student t test). N.D., not determined. 
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To examine whether decreased Hsp25 expression in presymptomatic G93A mice 
was specific for Hsp25 we have immunocytochemically screened the expression of 
a number of proteins that are expressed by motoneurons and that may show 
altered expression after injury, i.e. ChAT, calcitonin gene-related peptide (CGRP), 
AMPA and NMDA receptor subunits, peripherin, and neurofilament subunits [28]. 
None of these proteins showed altered expression in late presymptomatic G93A 
mice. Next, we have counted the number of motoneurons in serial sections 
immunostained for Hsp25, ChAT or CGRP, which like Hsp25 is preferentially 
localized in large motoneurons [3]. This analysis showed that late presymptomatic 
G93A mice (20 weeks), which showed a significant loss of Hsp25 labeled 
motoneurons, did not show a change in the number of ChAT or CGRP 
immunoreactive motoneurons (Fig. 2m). Motoneuron loss, as determined by ChAT 
immunocytochemistry occurred at a later time point (Figs 2h and m, and 3c). 
Therefore our data indicate that motoneurons of G93A mice show decreased 
Hsp25 immunoreactivity prior to the onset of motoneuron death. 
 
4.4.2 No correlation between Hsp25 and ATF3 expression in G93A mouse 
spinal cord 
The onset of reduced Hsp25 staining was in the same time window as the onset of 
expression of the stress transcription factor, ATF3, in a number of motoneurons in 
G93A mice, i.e. from 15 weeks (Fig. 2k and m, Table 1, see also Vlug et al., 2001 
[51]). As ATF3 has recently been identified as an activator of Hsp27 expression 
[35], we have examined Hsp25 expression in ATF3 positive motoneurons by 
double-labeling immunofluorescence. This analysis revealed no correlation 
between ATF3 and Hsp25 expression: of 100 ATF3 positive motoneurons analyzed 
in lumbar sections of late presymptomatic and symptomatic G93A mice 31 showed 
significant Hsp25 immunostaining, 46 showed light Hsp25 staining (arrow heads in 
Fig. 3e), and 23 showed no Hsp25 staining. The lack of a correlation between 
ATF3 and Hsp25 expression also follows from the fact that all Hsp25 expressing 
motoneurons in control mice and young G93A mice and most Hsp25 positive 
motoneurons in late presymptomatic and symptomatic G93A mice are negative for 
ATF3. Notably, a subset of motoneurons that show both a high level of ATF3 and 
Hsp25 expression showed an abnormal appearance (Fig. 3e; see below). 
 
4.4.3 Symptomatic G93A mice show induction of glial Hsp25 expression  
In contrast to the reduction in Hsp25 expression observed in presymptomatic mice, 
symptomatic G93A mice showed a dramatic increase of Hsp25-immunostaining as 
compared to controls (Figs 1c and g, and 2d). Double labeling confocal 
immunofluorescence showed that this increased Hsp25 immunoreactivity co-
distributed with the astroglial marker GFAP (glial fibrillary acidic protein, Fig. 4). 
Reactive astrogliosis, characterized by increased GFAP synthesis and astrocyte 
proliferation, is a well known phenomenon associated with neuronal degeneration. 
In our G93A mice a mild increase in GFAP staining occurred in late 
presymptomatic mice (Fig. 4d), whereas a high level of GFAP staining occurred in 
symptomatic mice (Fig. 4e and f). The onset of the induction of astroglial Hsp25 
expression was highly focal, starting with single or small groups of labeled 
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Figure 3: (A–C) Decreased Hsp25, but not ChAT expression in G93A mouse motoneurons. Double-
labelling confocal immunofluorescence of Hsp25 (A1–C1) with ChAT (A2–C2) in lumbar spinal cord 
sections of a control mouse of 20 weeks (A), and G93A mice of 20 weeks (B) and of 30 weeks (C). 
Merged images are shown in A3–C3. Hsp25 staining is reduced in motoneurons of presymptomatic 
G93A mice (B1), as compared to age-matched controls (A1), whereas the amount of ChAT staining is 
unchanged (A2 and B2). Symptomatic (30 weeks) G93A mice also show reduced Hsp25 staining in 
motoneurons (arrow in C), and show a dramatic up regulation of glial Hsp25 expression. Note that glial 
Hsp25 staining shows a patchy appearance (large arrows in C). Optical section, 4.6 µm. Scale bar, 100 
µm (A). (D and E) Hsp25 accumulate in ill-appearing ubiquitinated motoneurons. Double-labelling of 
Hsp25 (D1 and E1) with ubiquitin (D2) and ATF3 (E2) in lumbar spinal cord sections of a 30-week-old 
G93A mouse. A small number of motoneurons in late presymptomatic and symptomatic G93A mice is 
intensely immunoreactive for both Hsp25 and ubiquitin (double-headed arrow in D). These neurons 
usually show an ill appearance characterized by a flattened eccentric ATF3 immunoreactive nucleus, 
and abnormal cytosolic ATF3 labelling (double-headed arrow in E). Note that ATF3 expressing 
motoneurons do not necessarily express high levels of Hsp25 (arrow head in E). Optical sections, 4.6 
µm. Scale bars, 25 µm (D); 50 µm (E). For color photographs see published manuscript. 
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Figure 4: Symptomatic G93A mice show induction of glial Hsp25 expression. Double-labeling 
immunofluorescence of Hsp25 (A1–F1) and GFAP (A2–F2) in lumbar spinal cord sections of G93A mice 
of control (A) and G93A mice of 10 (C), 20 (D), 28 weeks (B and E) and 33 weeks (end stage disease, 
33 week, F). Merged images are shown A3–F3. Note the colocalization and age-related increase of 
Hsp25 and GFAP staining in G93A mouse spinal cord. Also note the ‘patchy’ distribution of Hsp25 
immunoreactivity in B1 (see also Figs 1f and 3c1). Arrow in D indicates an astroglial process with 
intense GFAP and weak Hsp25 staining. Arrow head in E shows the cell body of an astrocyte stained 
for both Hsp25 and GFAP. Optical sections, 4.6 µm (A and B) and 1 µm (C–F). Scale bars, 100 µm 
(A1); 25 µm (C3). For color photographs see published manuscript 
 
astrocytes in the motor columns (arrow in Fig. 1f), subsequently spreading to 
multiple foci (Fig. 4). In endstage G93A mice a very high level of glial Hsp25 
labeling occurs throughout the ventral horn and the intermediate zone of the spinal 
cord (Figs 1g, 2d and 4f). 
 
4.4.4 Hsp25 accumulate in the juxta-nuclear region of ill-appearing 
ubiquitinated motoneurons in late presymptomatic and symptomatic G93A 
mice 
A number of studies have indicated a stress-dependent redistribution of Hsp27 to 
the nucleus in several cellular systems [30,39], and a nuclear distribution of Hsp25 
in motoneurons of endstage G93A mice [50]. We have therefore extensively 
screened cervical and lumbar spinal cord sections of our G93A mice for 
motoneurons with nuclear Hsp25 expression. However, no nuclear Hsp25 
expression was observed. Instead, we identified a small number of motoneurons 
with a juxtanuclear accumulation of Hsp25 (Fig. 3d). These motoneurons in 
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addition showed a flattened eccentric nucleus, suggestive of ill health. The 
frequency of this type of abnormal motoneurons in L4 spinal cord varied from 0.1 to 
4%, with the highest number in early symptomatic mice (25–30 weeks of age). No 
juxta-nuclear Hsp25 expressing motoneurons were identified in G93A mice 
younger than 18 weeks. Double labelling showed that juxta-nuclear Hsp25 
expressing motoneurons also were immunoreactive for ubiquitin (Fig. 3e) and the 
injury transcription factor ATF3 (Fig. 3e). ATF3 usually shows a nuclear 
localization, but in juxta-nuclear Hsp25 expressing cells also occurred in the cell 
body and the dendrites (Fig. 3e). 
 
4.4.5 Decreased Hsp25 protein expression in late presymptomatic G93A 
mice is not associated with a change in Hsp25 mRNA expression 
Quantitative immuno-Western blot confirmed our immunohistochemical data that 
Hsp25 expression is decreased in late presymptomatic G93A mice and increased 
in symptomatic G93A mice (Fig. 5a and b). Hsp25 is a relatively abundant protein  
 
Figure 5:  Decreased Hsp25 protein 
expression is not associated with decreased 
Hsp25 mRNA expression in late presymptomatic 
G93A mice. Representative results (A) and 
quantification (B) of Western blot analysis of 
Hsp25 in crude total spinal cord homogenate (5 
µg) of non-transgenic and G93A mice. 
Recombinant Hsp25 was electrophoresed and 
blotted together with tissue samples. Values in B 
represent means ± SEM from 4 to 6 mice. The 
same results were obtained with calibration for 
the actin signal. Note decreased Hsp25 
concentration in G93A mice of 20 weeks, and 
increased Hsp25 concentration in older G93A 
mice. *P < 0.05 compared to non-transgenic 
mice and 10 weeks old G93A mice (unpaired 
two-tailed Student t-test). Representative results 
(C) and quantification (D) of RT-PCR analysis of 
the relative Hsp25, ChAT, and G6DPH mRNA 
concentration in total RNA samples isolated from 
control and G93A mouse spinal cord. Values in D 
represent semiquantitative estimates of Hsp25 
mRNA expressed as a percentage of the ChAT 
mRNA signal (means ± SEM from three mice). 
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in control crude spinal cord homogenate (0.49 ± 0.04 µg ⁄ mg, mean ± SEM). Its 
concentration in crude homogenates from 20-week-old G93A mice was decreased 
by 32% and 31% as compared to non-transgenic controls and young G93A mice, 
respectively.  
To examine whether decreased Hsp25 expression in presymptomatic G93A mice 
is associated with changes in Hsp25 mRNA levels we have used semiquantitative 
RT-PCR and in situ hybridization. Using RT-PCR no change in Hsp25 mRNA 
expression was observed in spinal cord of 20-week-old G93A mice as compared to 
controls and 10-week-old G93A mice (Fig. 5c and d). In situ hybridization, in 
accordance with the immunocytochemical data, showed that in control spinal cord 
Hsp25 mRNA was predominantly distributed in motoneurons (Fig. 6a and c). No 
change in Hsp25 mRNA expression occurred in presymptomatic G93A mice (Fig. 
6b), whereas symptomatic G93A mice showed astroglial induction of Hsp25 mRNA 
expression (Fig. 6). To enable semi-quantitative comparison of Hsp25 mRNA 
expression between 20-week-old G93A mice and controls, sections were incubated 
with different concentrations of labeled RNA probe. The number of labeled 
motoneurons depended on the probe concentration (Fig. 6f), which can be 
explained by the fact that at low probe concentrations (20 ng ⁄ mL) only cells 
expressing intermediate or high Hsp25 mRNA concentrations were stained, 
whereas at higher probe concentration (40–100 ng ⁄ mL) also cells expressing low 
levels of Hsp25 mRNA were stained. As shown in figure 6f, the number of labeled 
motoneurons was similar between 20-week-old G93A mice and controls, 
irrespective of the probe concentration, strongly suggesting similar levels of Hsp25 
mRNA.  
 
4.4.6 Decreased Hsp25 expression in late presymptomatic G93A mice is 
not associated with changes in its oligomeric configuration and solubility 
As the oligomeric configuration and solubility of Hsp25 and Hsp27 are controlled by 
various mechanisms [11,41], and may vary with the conditions of the cell 
[17,26,30,41], we have examined whether decreased Hsp25 expression in late 
presymptomatic G93A mice is associated with changes in its oligomerization and 
solubility. Both in the absence (not shown) and the presence of non-ionic detergent 
(0.5% Nonidet-P40) most of the Hsp25 is present in the soluble fraction (Fig. 7b, 
see below). Analysis of the soluble fraction by gel filtration chromatography showed 
a biphasic elution profile of Hsp25, indicating that approximately 50% of soluble 
Hsp25 is present in complexes of 50–250 kDa, whereas the other 50% occurs in 
complexes of approximately 500–800 kDa (Fig. 7a). This elution profile is similar to 
the elution profile of recombinant Hsp25 in vitro [41]. Spinal cord homogenates 
from 20-week-old G93A mice show the same elution profile as control mice (Fig. 
7a), indicating that decreased Hsp25 expression in presymptomatic G93A mice 
does not alter its oligomeric distribution. Accordingly, immunocytochemical analysis 
of phosphorylation of Hsp25, which controls its oligomerisation [41], indicated that 
Hsp25 with a phosphorylated ser15 residue occurs in all motoneurons expressing 
Hsp25, and that late presymptomatic G93A mice show a decrease in phospho-
Hsp25 (ser15) expression that is proportional to the decrease in total Hsp25 
expression.  
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To determine whether decreased Hsp25 expression in late presympromatic G93A 
mice is associated with a change in solubility we examined the relative amount of 
Hsp25 in the Nonidet-P40-soluble and insoluble fractions. As shown in Fig. 7b, 
young G93A mice showed the same amount of Hsp25 in the Nonidet-P40 insoluble 
fraction as controls, and late presymptomatic (20 weeks) mice showed a reduction 
of the insoluble Hsp25 concentration that is roughly proportional to the reduction of 
soluble and total Hsp25. This indicates that decreased Hsp25 expression in late 
presympromatic G93A mice is not associated with altered solubility. Also in 
symptomatic G93A mice, which show astroglial induction of Hsp25 expression, the 
concentration of insoluble Hsp25 was proportional to that of total Hsp25 (Fig. 7b). 
 
4.4.7 Hsp25-immunoreactivity co-distributes with mutant SOD1 in 
ubiquitinated dendrites 
Because of evidence indicating that Hsp25 may bind to mutant SOD1 in 
permanently transfected mouse neuroblastoma N2A cell lines [36], we used 
several methods to examine whether Hsp25 binds to mutant SOD1 in vivo in spinal 
cord of G93A mice. First, analysis of the fractions of the gel filtration experiments,  
Figure 6:  Late presymptomatic G93A mice show the same distribution of Hsp25 mRNA as controls. 
(A–E) In situ hybridization signal of antisense digoxigeninlabelled Hsp25 cRNA (100 ng ⁄ mL) on the 
ventral horn of C6 spinal cord sections from control (20 weeks, A), and presymptomatic (20 weeks, B) 
and symptomatic G93A mice (30 weeks, C). Dand E are magnifications of inserts in A and C, showing 
motoneuronal and glial Hsp25 mRNA labelling, respectively. Note the same Hsp25 mRNA staining in 
motoneurons of presymptomatic G93A and control mice. No staining was obtained with sense Hsp25 
probes (not shown). (F) Number of Hsp25 mRNA labelled motoneurons in C6 spinal cord sections of 
20-week-old G93A and control mice after incubation with different probe concentrations (20, 40 or 100 
ng ⁄ mL). The number of labelled motoneurons was dependent upon the probe concentration, and was 
the same in 20-week-old G93A and control mice. Bars represent means ± SEM with four mice per 
group. Values for each mouse represent the mean of eight serial C6 sections. All sections used to 
obtain this graph were processed into a single in situ hybridization run with sections from a control and 
G93A mice on the same slides. 
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showed that mutant SOD1 eluted in the same fraction as endogenous mouse 
SOD1, and did not elute with Hsp25 (Fig. 7a).This suggests that, at least in the 
soluble fraction, Hsp25 does not interact with mutant SOD1. Accordingly, using 
standard immunoprecipitation procedures [36,43] we did not succeed in co-
immunoprecipitating mutant hSOD1 with Hsp25 from cleared spinal cord 
homogenate (not shown). Furthermore, other immunoprecipitation methods that 
start with cross-linking of protein complexes in the whole homogenate to prevent 
premature dissociation of interacting proteins [55] also did not reveal an interaction 
with Hsp25 and mutant SOD1 (not shown). 
To further examine whether Hsp25 was associated with mutant SOD1 we have 
used a filter trap method that allows the detection of aggregated mutant SOD1 
species [53]. Detectable levels of filterable SOD1 complexes occurred in spinal 
cord of G93A mouse older than 20 weeks, but these mutant SOD1 filtrates were 
immunonegative for Hsp25 both in 1% and 0.1% SDS (Fig. 7d). The time of 
appearance of filterable SOD1 correlated with the time of appearance of high 
molecular weight forms of mutant SOD1 as detected by Western blot (Fig. 7c). 
Significantly, these abnormal SOD1 species predominantly appeared after the 
onset of reduced Hsp25 expression (compare Fig. 7b and c). 
Our gel filtration and immunoprecipitation experiments do not exclude the 
possibility that a small fraction of Hsp25 and mutant SOD1 interact in spinal 
motoneurons. To further study putative interactions between Hsp25 and mutant 
transgenic SOD1 we have examined colocalization of Hsp25 and mutant SOD1 
with double labeling immunofluorescense using SOD1 antibodies that specifically 
recognize transgenic human mutant SOD1, and do not immunoreact with sections 
of non-transgenic mice (Fig. 8a2). In G93A mice mutant SOD1 is expressed in all 
cells throughout the CNS [20,21]. In motoneurons mutant SOD1 like Hsp25 
showed a relatively homogeneous distribution throughout the cell body, the  
 
 
Figure 7:  Decreased Hsp25 expression in late presymptomatic G93A mice is not associated with 
changes in its oligomeric configuration and solubility. (A) Representative results (A1) and quantification 
(A2) of Western blot analysis of Hsp25 and SOD1 in fractions obtained after gel filtration 
chromatography of cleared spinal cord homogenate from control (non-TG) and G93A mice. Note that 
Hsp25 has a biphasic elution profile, and that this elution profile is not changed in G93A mice. Also note 
that endogenous mouse SOD1 (mSOD1) and transgenic mutant human SOD1 (hSOD1) eluted in the 
same fractions, and that SOD1 was not present in the same fractions as Hsp25. N.B. SOD1 is detected 
with SOD-101 antibody (StressGen), which preferentially binds to mSOD1, but since the concentration 
of transgenic hSOD1 is 4 to 5 fold the concentration of mSOD1 (Jaarsma et al., 2001) gives the same 
signal for mSOD1 and hSOD1. Values in A2 represent means ± SE from 2 non-TG and 3 G93A mice of 
the % of total Hsp25 in each fraction. B and C: Representative results (B1, C1) and quantification (B2, 
C2, C3) of Western blot analysis of Hsp25 (B) and SOD1 (C) expression in 0.5% Nonidet-P40-soluble 
and insoluble fractions of spinal cord homogenates of nontransgenic and G93A mice of different ages. 
Recombinant Hsp25 was electrophoresed and blotted together with tissue samples (not shown). Values 
represent means ± SEM from 3 mice. In B2 and C3, * = P < 0.01 compared to non-transgenic mice or 
10 weeks old G93A mice (unpaired two-tailed Student t-test). Note in B2 the differences in scaling of the 
vertical axes for soluble and insoluble Hsp25, respectively. Also note in C the absence of endogenous 
mouse SOD1 (mSOD1) and an age related increase of transgenic mutant human SOD1 (hSOD1) in the 
insoluble fraction. (D) Cellulose-acetate filter assay of spinal cord homogenate in buffer with 1% SDS to 
trap high molecular weight protein complexes, showing the appearance of SODI-immunoreactive 
complexes in G93A mice older than 20 weeks. Trapped protein complexes were immunonegative for 
Hsp25. The same results were obtained with homogenate diluted in 0.1% SDS which is less disruptive 
for protein-protein interactions. 
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Figure 8:  (A–G) Hsp25-immunoreactivity co-distributes with mutant SOD1 in ubiquitinated dendrites. 
Double-labelling confocal immunofluorescence of Hsp25 (A1–D1, F1 and G1), transgenic human SOD1 
(A1–E1 and G1) and ubiquitin (B1, F2 and G3) in lumbar spinal cord sections of a non-transgenic 
mouse (A), and G93A mice of 15 (B), 20 (C, E, F and G) and 28 weeks (D). Merged images are shown 
in A3–F3 and G4. Transgenic mutant hSOD1, visualized with an antibody that does not stain 
endogenous mouse SOD1 (A2), like Hsp25 shows a diffuse distribution throughout the somatodendritic 
domain of motoneurons (B and C), but, in addition, accumulate in vacuolated mitochondria (arrow 
heads in B, C, E, and G see also [Jaarsma, 2001 #254]) and in ubiquitinated dendrites (arrow in E). 
Hsp25 co-distributes with a subset of intensely hSOD1 immunoreactive structures (arrows in B–E) and 
with ubiquitinated profiles (F). Triple labeling shows co-distribution of Hsp25, hSOD1 and ubiquitin 
(arrow in G). Optical sections, 4.6 µm (A, C–E and G) and 1 µm (B and F). Scale bars, 25 µm (A1) (also 
for C–E); 15 µm (B1); 10 µm (F1); and, 25 µm (G1). (H and I) Light- (H) and electron photomicrograph 
(I) of consecutive semi-thin (0.5 µm, H) and ultra-thin (50 nm, I) sections of a lumbar section of an 18-
week-old G93A mouse immunoperoxidase stained for ubiquitin. The electron photomicrograph in I 
shows the labeled dendritic profile indicated by the arrow in H. Note that ubiquitin immunoreactivity is 
associated with amorphous and filamentous material in the core of dendritic profiles. Scale bars, 10 µm 
(I); 0.5 µm (B). For color photographs see published manuscript. 
 
dendrites and the axon, but, unlike Hsp25, also occurred in the nucleus (Fig. 8b). 
As previously reported [20,21] with ageing motoneurons of G93A mice showed the 
accumulation of mutant SOD1 into two pathological structures, i.e. (1) in the 
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intermembrane space of swollen and vacuolated mitochondria, which represent an 
early (from 4 weeks) pathological feature of G93A mice; and (2) in cytosolic 
aggregates, which appear at a later time point (from 12 to 15 weeks) in the 
proximal dendrites of motoneurons, and occur at a relatively low frequency as 
compared to vacuolated mitochondria [21]. Intramitochondrial SOD1 ‘accumulates’, 
which can be detected light-microscopically as intensely SOD1-immunoreactive dot 
or ring-like structures (arrow heads in Fig. 8b and c; see also Jaarsma et al., 2001 
[21]) were not immunoreactive for Hsp25 (Fig. 8b and c). Cytosolic SOD1 
aggregates can be distinguished from intramitochondrial SOD1 accumulates 
because of their immunoreactivity for ubiquitin (Fig. 8e, h and i). Double labeling for 
Hsp25-hSOD1 (Fig. 8b–d) and Hsp25-ubiquitin (Fig. 8f) and triple labeling (Fig. 8g) 
showed that these dendritic ubiquitinated SOD1 aggregates were strongly 
immunoreactive for Hsp25. In late presymptomatic and symptomatic G93A mice, 
i.e. several weeks after the appearance of dendritic ubiquitinated SOD1 
aggregates, ubiquitin immunoreactivity also occurred in cell bodies of motoneurons 
and in glia [19,44]. Ubiquitinated motoneurons (see above; Fig. 3d) and astrocytes 
(not shown) usually were immunoreactive for Hsp25, whereas ubiquitinated 
structures in oligodendrocytes were not stained for Hsp25 (not shown).  
 
4.4.8 Human control and ALS motoneurons express Hsp27 
Although Western blot analysis has revealed the constitutive presence of Hsp27 in 
human spinal cord, immunohistochemical studies have failed to detect Hsp27 in 
human motoneurons [38]. Therefore we have re-examined the distribution of 
Hsp27 immunoreactivity in human spinal cord, and studied the distribution of 
Hsp27 in ALS tissue. As shown in figure 9 intense Hsp27 immunostaining was 
present throughout the cell body, dendritic arbours, and the axon of human 
motoneurons (Fig. 9). Hsp27 did not occur in neurons in the dorsal horn and the 
intermediate zone. Comparison of Hsp27 staining with haematoxylin and eosin 
staining indicated that approximately 80–90% of the neurons in the motor column 
were stained for Hsp27. Also motoneurons in ALS spinal cord were stained for 
Hsp27, but the overall staining in the motor columns was reduced as compared to 
controls (Fig. 9b and d). Also the number of Hsp27 immunoreactive motoneurons 
was reduced (Fig. 9). However, the relative amount of Hsp27 stained vs. unlabelled 
motoneurons was not changed (Fig. 9). Unlike the G93A mice, ALS spinal cord did 
not show an increase in astroglial Hsp27 expression (Fig. 9) 
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Figure 9: Hsp27 is expressed in control and ALS human motoneurons. Low (A and B) and high (B–
H) magnification of a control (A, C, E and G) and ALS (B, D, Fand H) human L3 spinal cord section (A–
F) and ventral roots (G and H) stained for Hsp25. Note in D, Hsp27 immunoreactivity in surviving 
motoneurons and reduced Hsp27 immunoreactivity throughout the neuropil of that human ALS spinal 
cord. Some Hsp27 positive astrocytes are seen in white matter of ALS spinal cord (F). Calibration bars, 
500 µm (A); 50 µm (C); 25 µm (E) (also for F–H). (I and J) Absolute (I) and relative (J) number of 
Hsp27-immunoreactive neurons in the motor column (Rexed’s lamina IX). In ALS patients the number of 
Hsp27 labelled neurons is decreased, but the relative amount, as compared to the total number of 
motoneurons, is not changed. 
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4.5 Discussion 
 
Hsp27 and its murine orthologue Hsp25 are multifunctional proteins that are 
constitutively expressed by motoneurons, and show increased expression in 
motoneurons after injury [8,33]. In this study we find a decreased expression of 
Hsp25 protein in motoneurons of a transgenic mouse model for ALS that express 
G93A mutant SOD1. Decreased Hsp25 expression occurred several weeks prior to 
the onset of motoneuron death (Table 1). Hsp25 so far is the only motoneuronal 
protein investigated in our laboratory that shows a decreased expression in this 
time window. Although the function of Hsp25 in motoneurons is not known, it has 
several properties that may protect motoneurons against toxic properties of mutant 
SOD1, including its ability to scavenge misfolded proteins [12,41] and its ability to 
inhibit certain programmed cell death pathways [5,7]. In view of these properties 
and the temporal relationship between decreased Hsp25 expression and the onset 
of motoneuron death, it is feasible that reduced Hsp25 concentration contributes to 
the degeneration of motoneurons in G93A mice. For instance, reducing the Hsp25 
concentration may facilitate the accumulation and aggregation of mutant SOD1. 
Accordingly, we found that the accumulation of high molecular weight SOD1 
species in the G93A mice occurs after the onset of reduced Hsp25 expression 
(Table 1). Reducing Hsp25 also may cause the dysinhibition of the mitochondrial 
cytochrome c- dependent cell death pathway. There is evidence for the activation 
of this pathway in G93A mice [15], but it may not be executed in motoneurons 
unless the Hsp25 concentration is decreased.  
What causes decreased motoneuronal Hsp25 protein expression in G93A mice? 
Our data point to a post-translational mechanism, as decreased Hsp25 expression 
was not associated with a change in Hsp25 mRNA levels. Interestingly, a reduction 
of Hsp27 protein, but not mRNA expression also has been observed in cells 
expressing mutant ataxin-3 [54], which indicates that a posttranscriptional reduction 
of Hsp27 protein levels can be induced by the presence of mutant protein.  
Hsp27 and Hsp25 have the ability to bind to misfolded and denatured proteins 
resulting in large (4000 kDa) precipitable complexes [12,41,52]. Accordingly, in 
permanently mutant SOD1 transfected mouse neuroblastoma N2A cell lines Hsp25 
binds to mutant SOD1, which causes a redistribution to a non-ionic detergent-
insoluble fraction and decreased expression of Hsp25 [36]. On the basis of these 
data we hypothesized that mutant SOD1 causes a similar redistribution of Hsp25 in 
motoneurons of G93A mice and that this redistribution underlies reduced Hsp25 
expression. However, we found no evidence for altered oligomerization and 
solubility of Hsp25 in G93A mice, i.e. the fraction of insoluble Hsp25 was the same 
in either control, young and late presymptomatic G93A mice, in spite of the 
accumulation of insoluble mutant SOD1 in the G93A mice. Gel filtration indicated 
that Hsp25 did not bind to mutant SOD1 in the soluble fraction, but we can not 
exclude the possibility of such an interaction in the insoluble fraction, which 
contains approximately one-third of total Hsp25. Hence, our data leave open the 
possibility that a fraction of Hsp25 binds to mutant SOD1 and redistributes to the 
insoluble fraction without changing the ratio between soluble and insoluble Hsp25. 
For instance, an interaction between Hsp25 and mutant SOD1 may occur in 
cytosolic SOD1 aggregates, which appear in the proximal dendrites of 
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motoneurons in late presymptomatic G93A mice and are immunoreactive for 
Hsp25.  
The concentration of Hsp25 in control and young G93A mouse spinal cord is 
approximately 0.5 µg ⁄ mg protein, but, as Hsp25 is expressed in only a subset of 
structures in the spinal cord, the actual concentration in motoneurons is likely to be 
higher. Hsp25 levels therefore may be of the same order of magnitude as the 
concentration of mutant SOD1, which is 5–10 µg ⁄ mg protein [21]. Together our 
data indicate that Hsp25 and mutant SOD1 are expressed in the same cellular 
compartment in motoneurons at approximately equal and abundant levels, but 
show little or no interaction. This can be explained by the fact G93A mutant SOD1 
is relatively stable and shares many properties with wild-type SOD1, and only after 
secondary phenomena like (auto)oxidation, disulphide reduction, or heat shock 
[47,49], or in a metal-free configuration immediately after its synthesis [14], may be 
sufficiently abnormal to bind to Hsp25. A recent study with ALS patients and 
transgenic mice expressing mutant SOD1 with the G127insTGGG mutation, in fact 
showed that only minute quantities of mutant SOD1 (below 0.5% of control SOD1 
levels) accumulate in the spinal cord of these patients and mice, indicating that a 
small amount of abnormal SOD1 protein is sufficient to cause the disease [24]. 
Recently, two studies on the distribution of Hsp25 in SOD1-ALS mice have been 
reported, but unlike our study no changes in motoneuronal Hsp25 expression were 
observed [4,50]. This discrepancy might be explained by the fact that the time 
between the onset of decreased motoneuronal Hsp25 expression and astroglial 
Hsp25 induction is short. In accordance with the previous studies, however, we 
found a large increase of Hsp25 immunoreactivity in astrocytes of symptomatic 
G93A mice. Astroglial Hsp27 induction has been reported for different pathological 
conditions, including ischemia [25], excitotoxicity [27,37], and Alzheimer’s disease 
[40] and therefore seems to be a common characteristic of very different types of 
brain pathology [18]. It is surprising in this context that astroglial Hsp27 induction 
did not occur in postmortem human ALS spinal cord, despite a large increase in 
GFAP expression. 
Increasing the expression of Hsp27 has been shown to protect neonatal 
motoneurons from dying after axotomy [5] and other neurons against excitotoxic 
injury [1]. It remains to be determined whether viral or transgenic delivery of Hsp27 
or Hsp25 is neuroprotective in G93A mice. Another question is whether reduced 
Hsp27 expression precedes the degeneration of motoneurons in human ALS 
patients. Data from the present study indicate that Hsp27 expression is decreased 
in motor columns in sporadic ALS cases, but this may be consequence of the 
degeneration of motoneurons. 
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5.1 Abstract 
 
We have examined the expression of N-terminal phosphorylated c-Jun and the 
'stress transcription factor' ATF3 in amyotrophic lateral sclerosis (ALS) mice that 
express G93A-mutant SOD1 (SOD1-G93A mice). Immunocytochemistry and in situ 
hybridization showed that a subset of motoneurons express both ATF3 and 
phosphorylated c-Jun starting from a relatively early phase of disease before the 
onset of active caspase 3 expression and motoneuron loss. The onset of 
phosphorylated c-Jun and ATF3 expression correlated with the onset of dendritic 
ubiquitination. The highest number of ATF3 and phosphorylated c-Jun expressing 
motoneurons occurred at symptom onset. At symptom onset phosphorylated c-Jun 
and ATF3 activation also occurred in spinal interneurons. Confocal-double labeling 
immunofluorescence showed that phosphorylated c-Jun and ATF3 expression in 
motoneurons correlated with Golgi fragmentation. A subset of ATF3 and 
phosphorylated c-Jun immunoreactive motoneurons showed an ill appearance 
characterized by number of distinctive abnormalities, including an eccentric 
flattened nucleus, perinuclear accumulation of the Golgi apparatus and the ER, 
perikaryal accumulation of ubiquitin immunoreactivity and intense Hsp70 
immunoreactivity. These abnormal cells were not immunoreactive for active 
caspase 3. A partially overlapping population of phosphorylated c-Jun and ATF3 
immunoreactive motoneurons showed the expression of CHOP, a potential target 
gene of ATF3. We conclude that motoneurons in SOD1-ALS mice prior to their 
death show a prolonged phase in which they are compromised and express the 
injury transcription factors ATF3 and phosphorylated c-Jun. This compromised 
state is being characterized by an increasing amount of ubiquitinated material that 
first fills the neurites and subsequently the cell body.   
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5.2 Introduction 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of 
motoneurons causing progressive paralysis. In a subset of ALS patients the 
disease is caused by mutations in the cytosolic Cu/Zn superoxide dismutase 
(SOD1) gene [1], coding for a small homodimeric metalloenzyme that catalyses the 
conversion of superoxide anion to hydrogen peroxide. More than 100 different 
SOD1 mutations have been identified that all cause a relatively similar disease 
phenotype [1]. Mutant SOD1s display reduced conformational stability, 
susceptibility to disulfide reduction, abnormal metal binding, toxic oxidative catalytic 
activities, and an increased tendency to oligomerise and aggregate [33,41,58,60]. 
Recent studies with spinal cord tissue from ALS patients and transgenic mice 
expressing SOD1 with the G127insTGGG mutations have shown that minute 
quantities of mutant SOD1 (below 0.5% of control SOD1 levels) are sufficient to 
cause ALS [34], and that the toxicity of mutant SOD1 may be represented by a 
disulfide-reduced hydrophobic fraction [54]. When exposed to the cellular 
environment these abnormal SOD1 species may interact with a wide range of 
cellular targets to elicit cellular toxicity [53]. 
Transgenic mice expressing ALS-related mutant SOD1s develop an ALS-like 
motoneuron disease and have provided a powerful tool to examine the cellular 
mechanism by which mutant SOD1 causes the selective degeneration of 
motoneurons [9]. Biochemical and pathological studies in these mice have 
revealed several abnormalities in motoneurons prior to their death, including 
mitochondrial abnormalities [14,31,37,40,65], slowing of axonal transport 
[6,16,64,66], appearance of ubiquitinated structures [8,34,56,63], Golgi 
fragmentation [45], loss of neuromuscular synapses [17,18], and activation of 
programmed cell death pathways [21]. The association of mutant SOD1 with 
motoneuronal mitochondria is an early and progressive phenomenon in SOD1-ALS 
mice [31,40] that also has been identified in post-mortem spinal cord tissue from 
SOD1-ALS patients [40], suggesting that mitochondria may be an early and direct 
target of mutant SOD1. However, it is not understood how, if indeed, these 
mitochondrial abnormalities are linked to the functional deterioration and death of 
motoneurons and to the other abnormalities identified in SOD1-ALS mice. This lack 
of knowledge is partially due to a poor understanding of the dynamics of the 
disease process. Next to that, the morphological and molecular correlates of 
motoneuron degeneration in SOD1-ALS mice are still poorly documented [21]. 
Neurons including motoneurons respond to injurious stimuli such as axotomy, 
excessive excitation and survival factor withdrawal by increased expression and 
phosphorylation of the AP-1 transcription factor c-Jun [26] and by expression of 
ATF3, a member of the ATF/CREB family of transcription factors [23,59]. These 
factors play an important role in the control of survival and repair programs, but 
under specific conditions also may trigger cell death [5,23,25,27,46,52]. Since 
phosphorylated c-Jun and ATF3 are selectively associated with injured neurons, 
they might serve as early markers of degenerating motoneurons. Therefore, in this 
study we have studied their expression in a line of SOD1-ALS mice expressing 
G93A-mutant SOD1. Our data indicate that ATF3 and phosphorylated c-Jun are 
expressed in motoneurons in these mice from a relatively early stage of disease, 
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and that their expression in motoneurons closely correlates with Golgi 
fragmentation and dendritic ubiquitination. We conclude that ATF3 and phospho-c-
Jun mark motoneurons throughout an ill phase that precedes their rapid death and 
disappearance in SOD1-ALS mice. 
 
 
5.3 Materials & Methods 
 
5.3.1 Transgenic mice 
Experiments were performed in accordance with the "Principles of laboratory 
animal care" (NIH publication No. 86-23) and the guidelines approved by the 
Erasmus University animal care committee (DEC; protocol No. 115-97-01 and 115-
99-03 ). G93A-SOD1 mice descendent from the Gurney G1del-line that carry about 
8 transgene copy numbers per haploid genome [22] were maintained in a FVB/N 
background. Our G93A-SOD1 mice develop weakness in one or more limbs 
starting at age 24-30 weeks, and reach end stage disease 2–10 weeks after onset 
of limb weakness [29,31]. Pathologically the mice develop swelling and 
vacuolization of a subset of mitochondria from early age long before the onset of 
motoneuron loss and gliosis, which starts from 20 weeks of age [42]. For the 
immunocytochemical characterization of ATF3 and phospho-c-jun expression in 
G93A-SOD1 mice we analyzed 7 groups: 1) 10 weeks (at this age the mice show 
swelling and mild vacuolization of a subset of mitochondria but no other 
pathological features [31]); 2) 15 weeks); 3) 20 weeks (at this age the mice, in 
addition to mitochondrial abnormalities, show several degenerative features in 
motoneurons (e.g. ubiquitination, Golgi fragmentation), but no or minimal (<10 %) 
motoneuron loss [42]); 4) 25 weeks; 5) symptom onset (29-32 weeks: mild muscle 
weakness in one or more of the hind limbs); 6) 2 weeks post-symptom onset (29-
32 weeks: moderate to severe muscle weakness in one or more of the hind limbs); 
7) 5 weeks post-symptom onset (32 weeks: severe muscle weakness of the hind 
limbs). Non-transgenic littermates and transgenic mice expressing wild-type 
hSOD1 (hSOD1 mice) derived from the Gurney N29 line and aged 10-100 weeks 
[29] were used as controls. 
5.3.2 Antibodies 
Primary antibodies (supplier, applications {IHC, immunohistochemistry; IF, 
immunofluorescence} and dilutions) reported in this study are: rabbit anti-ATF3 
(Santa Cruz; IHC and IF 1:1.000); rabbit anti-calreticulin (Affinity BioReagents, IHC 
and IF 1:5.000), rabbit anti-cleaved caspase 3 (Asp175, Cell Signalling, IHC 
1:1.000); rabbit anti-CGRP (Calbiochem, IHC and IF, 1:10.000); goat anti-ChAT 
(Chemicon, IHC and IF 1:500); rabbit anti-CHOP (SantaCruz, IHC and IF 1:2.000); 
rabbit anti-c-fos (Ab5; Oncogene IHC, IF 1:20.000); rat anti-CR3 receptor (clone 
5C6; Serotec, IHC 1:500); rabbit anti-GFAP (DAKO, IHC 1:10.000, IF 1:5.000); 
mouse anti-GM130 (Golgi matrix protein of 130 KDa associated with the cis-
compartment; Transduction Laboratories, IF 1:1.000); rabbit anti-Hsp25 (Stessgen, 
IF 1:2.000); mouse anti-Hsp70 (SantaCruz, IHC and IF 1:500); rabbit anti-c-Jun 
(ab1; Oncogene, IHC 1:10.000 and IF 1:2.000); rabbit anti-phospho-c-Jun (Ser73; 
Upstate Biotechnology, IHC 1:2.000, IF 1:500); rabbit anti-phospho-c-Jun (Ser63; 
Cell Signalling, IHC 1:2.000, IF 1:500); mouse anti-phospho-c-Jun (Ser63; Santa 
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Cruz, IHC 1:2.000, IF 1:500); rabbit anti-Krox24 (Santa Cruz, IHC 1:5.000); goat 
anti-c-Ret (R&D systems, IF 1:200); goat anti-human SOD1 (Calbiochem, IF 
1:10.000); rabbit anti-SOD1 (1:5.000); rabbit anti-STAT3 (Santa Cruz, IHC 1:2000); 
rabbit anti-phospho-STAT3 (Tyr705; Cell Signalling, IHC 1:2.000); rabbit anti-
ubiquitin (Dako, IHC and IF 1:2.000); mouse anti-ubiquitin (clone FK2; Affiniti, IF 
1:2.000). 
Secondary antibodies: For avidin-biotin-peroxidase immunocytochemistry 
biotinylated secondary antibodies from Vector Laboratories diluted 1:200 were 
used. FITC-, Cy3-, and Cy5-conjugated secondary antibodies raised in donkey 
(Jackson Immunoresearch, USA) diluted at 1:200 were used for confocal 
immunofluorescence. Cy3-conjugated donkey anti-rabbit Fab fragments (Jackson 
Immunoresearch, USA) were used in double-labeling experiments with two rabbit 
primary antibodies.  
5.3.3 Immunocytochemical and histochemical analyses 
For immunocytochemistry and immunofluorescence mice were anaesthetized with 
pentobarbital and perfused transcardially with 4% paraformaldehyde with or without 
glutaraldehyde (0.1 or 0.5%). The lumbar and cervical spinal cord were carefully 
dissected out and post-fixed overnight in 4% paraformaldehyde. Unless otherwise 
stated, spinal cord tissue was embedded in gelatin blocks [29], sectioned at 40 µm 
with a freezing microtome and sections were processed, free floating, employing a 
standard avidin-biotin-immunoperoxidase complex method (ABC, Vector 
Laboratories, USA) with diaminobenzidine (0.05%) as the chromogen, or single, 
double- and triple-labelling immunofluorescence [29,31]. In addition, a selected 
number of frozen sections were processed for a silver staining procedure that 
selectively labels dying neurons and their processes [29]. 
Some spinal cord specimens were sectioned with a vibratome (50-60 µm thick). 
These sections were used for pre-embedding immunoperoxidase electron 
microscopy as described [31], or for light-microscopic double-labeling experiments, 
in which sections were sequentially processed for 2 different primary antibodies 
using the ABC method for both. To label the first antibody CoCl2 was included in 
the diaminobenzidine solution to yield a dark-blue precipitate. The second antibody 
was visualized with diaminobenzidine alone. Following the immunostaining 
procedure these sections were dehydrated, embedded in Durcupan, sectioned at 1 
µm and counterstained with methylene blue. 
For double-labeling immunofluorescence with two rabbit antibodies Cy3-conjugated 
donkey anti-rabbit Fab fragments were used to label and sterically cover the first 
antibody as described by the manufacturer (Jackson Immunoresearch, USA). Then 
the sections were incubated with the second primary antibody which consecutively 
was labeled with FITC-donkey ant-rabbit IgG. Single-labeling experiments were 
always performed in parallel to these double-labeling experiments to evaluate the 
specificity of the staining. 
Immunoperoxidase-stained sections were analyzed and photographed using a 
Leica DM-RB microscope and a Leica DC300 digital camera. Quantitative analyses 
were performed with 20 consecutive L4 lumbar spinal cord sections/mouse that 
were serially immunoperoxidase-labeled for ATF3, ChAT, CGRP and cleaved 
caspase 3, respectively (e.g. sections 1, 6, 11, and 16 were labeled for ATF3,  
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Figure 1: Phospho-c-Jun and ATF3 expression are induced first in motoneurons and subsequently in 
interneurons in spinal cord of G93A-SOD1 mice 
(A-C) Distribution of phospho-c-Jun-immunoreactivity in the ventral horn (vh) and intermediate zone (iz) 
of the L4-spinal cord of G93A-SOD1 mice of 10 weeks (A), 20 weeks (B) and 30 weeks (C) of age. Note 
phospho-c-Jun labelled motoneurons in the 20 and 30 weeks old G93A-SOD1 mice (arrows in B and 
C), and phospho-c-Jun labelled interneurons in the 30 weeks old G93A-SOD1 mouse. (D-L) Distribution 
of ATF3 immunoreactivity (D-I) and mRNA (J-L) in L4-spinal cord of G93A-SOD1 mice of 10 weeks (D, 
J), 20 weeks (E, G, H, K) and 30 weeks (F, I, L) of age. Note in high-magnification images of ATF3 
immunoreactive motoneurons (G-I) that ATF3-immunoreactivity although primarily localised in the nuclei 
also occurs in the somato-dendritic cytoplasm. Also note the ATF3-immunoreactive motoneuron with an 
flattened eccentric nucleus  (arrow in H). Calibration bars: C and L, 100 µm; G (also for H), 10 µm; and 
H, 20 µm.  
(B) Neurolucida plots of representative consecutive L4 spinal cord sections of G93A-SOD1 mice of 
different ages showing motoneurons (filled circles) and non-motoneurons (open circles) stained for 
phosphorylated(ser73)-c-Jun and ATF3, resepectively. 
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sections 2, 7, 12, 17 for ChAT etc.). The remaining sections were stained for 
phospho-c-Jun and ubiquitin, respectively. A selected number of sections stained 
for phospho-c-Jun, ATF3, cleaved caspase 3 and ubiquitin were plotted using an 
Olympus microscope fitted with a LucividTM miniature monitor and NeurolucidaTM 
software (MicroBrightField, Colchester, VT, USA). Statistical analysis was done 
with Graphpad Prism software (San Diego, USA). 
Sections stained for immunofluorescence were analyzed with a Zeiss LSM 510 
confocal laser scanning microscope. For quantitative analysis of co-localization of 
ATF3 with other markers (active caspase 3, CGRP, c-Jun, phospho-c-Jun, 
Gadd153, GM130, Hsp70, ubiquitin) in motoneurons 50 ATF3-labeled 
motoneurons were randomly selected in L4 sections of 20, 25 and 30 weeks old 
G93A-SOD1 mice using 20x or 63x objectives. All motoneurons in a field of 150 x 
150 µm surrounding the labeled cell were scored for single or double labeling. In 
the same way 25-50 phospho-c-Jun, Gadd153, Hsp70 or ubiquitin immunoreactive 
motoneurons were randomly selected and analyzed for co-localization with ATF3. 
Ultra thin sections for electron microscopy were and analyzed in a Phillips CM100 
electron microscope operated at 80 kV [31]. 
5.3.4 mRNA in situ hybridisation 
In situ hybridization was performed on 12 µm thick cryostat sections using standard 
methods with digoxigenin-labeled cRNA probes [42]. Sense and anti-sense 
digoxigenin-labelled cRNAs were transcribed from liberalized plasmids containing 
full-length ATF3 cDNA (NCBI acc.no. BF166234), c-Jun cDNA (NCBI acc.no. 
BE283254). 
 
 
5.4 Results 
 
5.4.1 Phospho-c-Jun and ATF3 expression is induced first in motoneurons 
and subsequently in interneurons 
Non-transgenic mice show constitutive expression of c-Jun in a subset of 
motoneurons [26,30]. However, motoneurons in non-transgenic mice were not 
immunoreactive for N-terminal (ser73) phosphorylated c-Jun (phospho-c-Jun) [29]. 
Also motoneurons of young adult G93A-SOD1 mice (age 10 weeks) were not 
immunoreactive for phospho-c-Jun (Figs 1a and 2b). In contrast G93A-SOD1 mice 
older than 15 weeks showed an increasing number of intensely phospho-c-Jun 
immunoreactive motoneurons (Figs 1b, and c and 2). From 20 weeks-of-age 
phospho-c-Jun also occurred in neurons in the intermediate zone (Rexed's laminae 
V-VIII and X) of the spinal cord (Figs 1c and 2b). The number of phospho-c-Jun 
labeled interneurons varied between G93A-SOD1 mice of the same age, and 
positively correlated with the duration of symptoms (Fig. 2). G93A-SOD1 mice with 
severe paresis or at end-stage disease showed phospho-c-Jun immunoreactive 
neurons throughout all laminae of the spinal cord including the dorsal horn (Fig. 2). 
Immunocytochemistry and in situ hybridization showed that ATF3 is not expressed 
in control spinal cord, but has the same spatio-temporal distribution as phospho-c-
Jun in the spinal cord of G93A-SOD1 mice (Figs 1 and 2). Other inducible 
transcription factors, i.e. c-fos and krox24, did not show altered expression in  
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Figure 2: Phospho-c-Jun and ATF3 expression precedes motoneuron loss in G93A-SOD1 mice. 
(A) Bar graphs showing the number of ChAT, CGRP and ATF3-labeled motoneurons and ATF3-labeled 
interneurons in L4-spinal cord sections of non-transgenic and G93A-SOD1 mice of different age (see 
materials and methods. Dashed line in ChAT and CGRP graphs represent the mean number of ChAT 
and CGRP-labeled motoneurons, respectively, of 20 and 30 weeks old control mice.c 
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G93A-SOD1 mice (not shown). Double-labeling confocal immunofluorescence 
confirmed that ATF3 and phospho-c-Jun were expressed in the same population of 
motoneurons (Fig. 5e), i.e.  48 of 50 randomly selected ATF3 labeled motoneurons 
were positive for phospho-c-Jun, and, vice versa, 50 of 50 randomly selected 
phospho-c-Jun immunoreactive motoneurons were also immunoreactive for ATF3 
(see material and methods). Accordingly, all ATF3 motoneurons also were 
immunoreactive for c-Jun. ATF3 also co-localized with phospho-c-Jun and c-Jun in 
interneurons of G93A-SOD1 mice (not shown). In contrast with phospho-c-Jun 
which was exclusively localized in the nucleus, ATF3 immunoreactivity was also 
found in the cytoplasm of a subset of neurons in G93A-SOD1 mice (Fig 1e and f). 
As discussed in paragraph 5.4.3, extra-nuclear ATF3 co-localized with ubiquitin 
immunoreactivity. 
ATF3 and phospho-c-Jun labeling did not occur in non-neuronal cells in the spinal 
cord of control, presymptomatic and early symptomatic G93A-SOD1 mice. 
However, in a late phase of disease clusters of small cells that showed moderate 
ATF3 and phospho-c-Jun labeling occurred in areas with severe neuronal 
pathology (not shown). 
 
5.4.2 Phospho-c-Jun and ATF3 expression precede the activation of 
caspase 3 and motoneuron death 
To determine the relationship between ATF3 and phospho-c-Jun expression on the 
one hand and motoneuron degeneration on the other hand, we have counted 
motoneurons in serial sections immunostained for choline acetyltransferase (ChAT) 
or CGRP, respectively. No or very little loss of ChAT-labeled motoneurons 
occurred at 20 weeks of age, no to moderate (0-20%) loss at 25 weeks of age, and 
moderate to severe loss (10-60%) at 29-32 weeks of age, depending on the 
severity of the symptoms as determined by a hind limb extension test  (Fig. 2a) 
[42].  The same dynamics of motoneuron loss was observed with CGRP (Fig. 2a), 
a peptide that is preferentially localized in large motoneurons [3]. In accordance 
with previous studies showing that large motoneurons are selectively afflicted in 
G93A-SOD1 mice [43], we found that a relatively large percentage (50-95%) of 
CGRP-immunoreactive motoneurons were lost in symptomatic G93A-SOD1 mice. 
However, no or little loss of CGRP-labeled motoneurons was observed up to 25 
weeks of age (Figs 2a and 6a-c). Since ATF3 and phospho-c-Jun could be 
identified in motoneurons in G93A-SOD1 mice from 15 weeks of age, it can be 
concluded that ATF3 and phospho-c-Jun expression precede the onset of 
motoneuron loss.  
To further analyze the relation between ATF3 and phospho-c-Jun expression and 
motoneuron death we have compared their expression with the expression of 
caspase 3, an executioner caspase in neurons that has been identified in the 
spinal cord at the onset of motoneuron death in various lines of SOD1-ALS 
mice[51]. Immunocytochemistry with an antibody specific for active caspase 3 
showed that active caspase 3 was not present in lumbar L4 sections of our G93A-
SOD1 mice at 10 and 15 weeks of age, but was present in a minority (2 of 8) of 
mice at 20 weeks, a majority (6 of 8) of mice at 25 weeks, and all mice (18 of 18) 
sacrificed at29-32 weeks. In line with previous studies [51] active-caspase 3- 
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Figure 3: Active caspase 3 
shows a different spatio-
temporal distribution as 
ATF3 in G93A-SOD1 mice. 
(A) Neurolucida plots of 
representative consecutive 
L4 spinal cord sections from 
a symptomatic 30 weeks old 
G93A-SOD1 mouse 
showing motoneurons (filled 
circles) and non-
motoneurons (open circles) 
stained for active caspase 3 
(Casp3) and ATF3, 
respectively. Note the 
relatively low number of 
active caspase 3-stained 
neurons. (B-D) Low (B) and 
high-magnification (C and 
D) photomicrographs of 
active caspase 3 staining in 
the spinal cord of 
G93ASOD1 mice. Note in 
(B) that staining is more 
abundant in the intermediate 
zone as compared to the 
motor column (i.e. left part 
of the grey matter). In the 
motorcolumns labeling is 
usually associated with 
unidentifiable structures 
(arrow head). Labeled 
motoneurons as shown in 
(C) are very infrequent. 
Labeled neurons usually 
were interneurons (arrows in 
B; D). Calibration bars: B, 
50 µm; C, 15 µm; and D, 10 
µm. 
 
immunoreactivity was most frequently associated with irregular structures, 1-5 µm 
in diameter, in the ventral horn and intermediate zone (Fig. 3b). These structures 
putatively reflect debris of dead cells. The frequency of these structures, which was 
about 3 per transverse lumbar section in symptomatic G93A-SOD1 mice, did not 
correlate with the severity of symptoms. Less frequently, active caspase 3 was 
found in cells that could be identified either as neurons (less than 0.5 per L4 
section, Fig. 3a-c) or astrocytes (not shown). In these cells active caspase 3-
labeling was concentrated in the nucleus (Fig. 3a-c). Active-caspase 3-labeled 
neurons were predominantly found in the intermediate zone (Fig. 3a and b) and the 
dorsal horn (Fig. 3d), and very infrequently (4 cells in over 100 L4 sections 
examined) in motor columns (Rexed's lamina IX, Fig. 3c). This very low number of 
active-caspase 3-immunoreactive motoneurons is consistent with our data 
obtained with a silver degeneration method that stains dying neurons and their 
processes, which revealed a very low number of argyrophilic motoneurons in our 
G93A-SOD1 mice (not shown). In sum, compared to ATF3 and phospho-c-Jun, 
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active caspase 3 is expressed at a later time point and in a considerably lower 
number of neurons (Fig. 3a). 
Analysis of ATF3 and active caspase 3 co-expression by double-labeling confocal 
immunofluorescence, showed that all ATF3-immunoreactive motoneurons (50 of 
50), including motoneurons with an abnormal appearance (see 5.4.4), were 
immunonegative for active caspase 3. Further analysis of ATF3 and phospho-c-Jun 
immunoreactivity in semi-thin (1 µm) plastic sections double-stained for ATF3 or 
phospho-c-Jun and the complement 3 receptor (CR3, a marker of microglia [29]), 
showed that although ATF3 and phospho-c-Jun expressing motoneurons often 
were surrounded by microglial processes these cells did not show classical 
apoptotic changes such as cell shrinkage and chromatin condensation (Fig. 5a). 
On the other hand in the same material we have identified cells with apoptotic 
morphology and surrounded by microglial processes that were negative for ATF3 
and phosphorylated c-Jun (Fig. 5a). In sum, our data indicate that ATF3 and 
phosphorylated c-Jun are not associated with cells undergoing apoptosis. 
 
5.4.3 Phospho-c-Jun and ATF3 expression in motoneurons correlates with 
ubiquitination and Golgi fragmentation 
The earliest neuropathological feature in our G93A-SOD1 mice is mitochondrial 
swelling and vacuolization. These mitochondrial abnormalities appear as early as 4 
weeks postnatal [31], and hence precede the appearance of phospho-c-Jun and 
ATF3 immunoreactive motoneurons by several weeks. The second abnormality in 
time is the appearance of ubiquitinated neurites, i.e. neuronal processes that are 
stained by antibodies raised against polyubiquitinated epitopes. Ubiquitinated 
neurites were present in 1 of 5 G93A-SOD1 mice of 10 weeks old, and in all mice 
of 15 weeks and older (Fig. 4c and e). Double-labeling confocal 
immunofluorescence with ChAT and immuno-electron microscopy showed that this 
ubiquitin immunoreactivity is localized in dendrites (and occasionally the axon) of 
motoneurons and co-distributes with mutant SOD1 [31,42]. In some instances 
ubiquitin-immunoreactivity could be 'traced back' to the cell body of motoneurons 
(e.g. Fig. 5d). Ultrastructurally, dendritic ubiquitination was characterized by a 
disorganized ensemble of filamentous and amorphous material and, in many 
occasions, small vesicles (Fig. 5f). These ubiquitinated ensembles were 
surrounded by normal appearing mitochondria and cytoplasm (Fig. 5f), and were 
never found in proximity of swollen and vacuolated mitochondria in the same 
dendrite. The frequency of ubiquitinated neurites increased with aging. In addition 
with aging ubiquitin immunoreactivity also accumulated in other structures, i.e. in 
the somata of motoneurons (from 20 weeks of age), in spinal interneurons (from 25 
weeks), and in glia (from 20-25 weeks). 
The time of appearance and relative density of ubiquitinated structures grossly 
correlated with the time of appearance and density of phospho-c-Jun and ATF3 
positive neurons (Fig. 4a and b). Since in most instances it was not possible to 
identify the cell bodies of ubiquitinated neurites, analysis of the relation between 
dendritic ubiquitination and ATF3 or phospho-c-Jun expression was not possible. 
Indirect evidence from systematic analysis of serial L4 lumbar sections of 10-, 15- 
and 20-week-old G93A-SOD1 mice suggested that the appearance of ubiquitinated 
neurites preceded the appearance of ATF3 and phospho-c-Jun immunoreactivity,  
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Figure 4: The onset of phospho-c-
Jun and ATF3 expression correlate 
with dendritic ubiquitination. 
(A, B) Neurolucida plots of 
representative consecutive L4 
spinal cord sections from a 20 
weeks (A) and 30 weeks (B) old 
G93A-SOD1 mouse showing 
motoneurons (filled circles) and 
non-motoneurons (open circles) 
stained for phosphorylated(Ser73)-
c-Jun and ubiquitin-
immunoreactive structures, 
respectively. Note that both the 
amount of phospho-c-Jun and 
ubiquitin labeling increased with 
aging  progressive 
increaserelatively low number of 
active caspase 3 stained neurons. 
(C-F)  Low (C, D) and high-
magnification (E) light-microscopic 
photomicrographs, and electron 
photomicrograph (F) of ubiquitin-
immunoperoxidase labeling  in the 
L4 spinal cord 15 weeks (C), 20 
weeks (E and F) and a 30 weeks 
(D) old G93A-SOD1 mouse. In 15 
and 20 weeks old G93A-SOD1 
mice ubiquitin labeling is 
selectively associated with neurites 
in the motor columns (arrows in C 
and E). Ultrastructurally, this 
neuritic labeling is associated with 
core of motoneuron dendrites 
(area indicated by arrows in F). 
Note that cytoplasm en 
mitochondria surrounding the 
ubiquitinated area have a normal 
appearance (see also Fig. 8h and i 
of Chapter 4). In 30 weeks old 
G93A ubiquitinated structures are 
associated with both neuronal and 
glial profiles (not shown) and fill 
the entire ventral and intermediate 
gray matter (B and D). Calibration 
bars: C (also for D), 50 µm; E, 25 
µm; and F, 500 nm. 
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because 1) dendritic ubiquitin immunoreactivity occurred in one 10-week-old G93A-
SOD1 mouse in the absence of ATF3 and/or phosphorylated c-Jun labeled 
motoneurons; and 2) the number and distribution of ubiquitinated dendrites per L4 
section in 15-week-old G93A-SOD1 mice suggested that multiple motoneurons per 
L4 section had ubiquitinated dendrites (Fig. 4a and c), whereas the mean 
frequency of ATF3 immunoreactive motoneurons was 0.55 or 1.3 per L4 section at 
15 and 20 weeks, respectively.  Further analysis using double-labeling confocal 
immunofluorescence of ubiquitin and ATF3 showed that 1) all motoneurons 
showing focal (Fig. f1) or diffuse (Fig. f2) perikaryal ubiquitin immunoreactivity (20 
of 20) also stained for ATF3 (Fig. f1 and f2); 2) the majority of ATF3-
immunoreactive motoneurons (37 of 50) did not show perikaryal ubiquitin 
immunoreactivity in the cell body; and 3) ATF3 immunoreactivity co-distributed with 
ubiquitin in motoneurons with perikaryal ubiquitin immunoreactivity (Fig. f1 and f2) 
and in a subset of ubiquitinated neurites (Fig. f2). These confocal data indicate that 
ATF3 expression precedes perikaryal ubiquitination. 
Fragmentation of the Golgi apparatus, i.e. the transformation of the Golgi 
apparatus from a network of linear profiles to dispersed smaller elements (e.g. see 
Fig. 5d and 5g1), has been identified as a constant feature in a subset of 
motoneurons of ALS patients [55] and SOD1-ALS mice [45,56]. To study the 
relationship between Golgi fragmentation and ATF3 or phospho-c-Jun expression 
we have used two markers to stain the Golgi apparatus, i.e. the cis-Golgi matrix 
protein GM130 [47]; and CGRP, a peptide selectively expressed in large 
motoneurons (see above) and that is localized in the trans-Golgi, multivesicular 
bodies, and secretory granules [10]. Motoneurons with fragmented Golgi were 
identified in our G93A-SOD1 mice from 15 weeks. Double labeling confocal 
immunofluorescence showed that GM130 and CGRP in motoneurons with 
fragmented Golgi maintain their adjoining slightly overlapping localization 
consistent with their distribution in the cis- and trans-Golgi, respectively (Fig. 5g1). 
In some motoneurons we noted the redistribution of the fragmented Golgi to a 
subregion of the cell, usually in close proximity of the nucleus (Fig. 5g1-g4, see 
below). In addition, we noted that motoneurons with fragmented Golgi labeled for 
CGRP showed the accumulation of CGRP in the dendrites (Figs 5g4 and 6a-f) and 
sometimes the soma (Figs. 5g1 and 6c). This dendritic CGRP did not co-distribute 
with GM130 indicating that it reflects a non-Golgi fraction of CGRP (not shown). 
Interestingly, at least a portion of dendritic CGRP-immunoreactivity co-distributed 
with ubiquitin (Fig. 5g4). 
Double labeling of ATF3 with GM130 indicated that nearly all ATF3 labeled 
motoneurons (49 of 50) showed a fragmented Golgi (Fig. 5c and 5g2) and that all 
of the ATF3-negative motoneurons identified in the same fields (84 of 84) displayed 
a normal Golgi. Accordingly, all ATF3 motoneurons that were also positive for 
CGRP (17 of 17) showed an abnormal Golgi, and inversely all CGRP 
immunoreactive motoneurons with an abnormal Golgi (20 of 20) were 
immunoreactive for ATF3 (Fig. 5g3). Analysis of phospho-c-Jun and GM130 
labeled sections also showed a close relationship between phospho-c-Jun and 
Golgi fragmentation. Although not systematically studied, Golgi fragmentation also 
was frequently observed in phospho-c-Jun of ATF3-labeled intermediate zone  
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Figure 5: Phospho-c-Jun and ATF3 expression correlates with Golgi fragmentation and ubiquitination. 
(A) High magnification of semi-thin (0.5 µm thick) section showing a motoneuron with phospho-c-Jun 
(dark-brown) labeled nucleus surrounded by CR3-labeled microglial processes (light-brown). Note that 
the phospho-c-Jun labeled nucleus has a healthy appearance. Also note that the cell with the pyknotic 
nucleus (arrow) is not phospho-c-Jun labeled. (B) Semi-thin ATF3 stained section showing a 
motoneuron with intense nuclear and cytosolic ATF3 labeling. Note that part of the cell is ATF3-negative 
(arrow heads). (C-J) Double-labeling confocal immunofluorescence of ATF3 with phospho-c-Jun (E1 
and E2), ubiquitin (F1 and F2), the cis-Golgi protein GM130 (C and G2), CGRP (G3), Hsp70 (H1) and 
CHOP (J); or of ubiquitin with GM130 (D), CGRP (G4), Hsp70 (H2) and calreticulin (I). 
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neurons (not shown). In sum our data indicate that ATF3 and phospho-c-Jun 
expression occur in the same motoneurons that show Golgi fragmentation.  
 
5.4.4 A subset of phospho-c-Jun and ATF3 positive motoneurons show 
signs of degeneration 
As indicated in paragraph 5.4.3 a subset of ATF3 and phospho-c-Jun positive 
motoneurons showed the accumulation of the fragmented Golgi apparatus in a 
subregion of the cell. These cells showed an ill appearance in most instances 
characterized by a flattened eccentric nucleus. The juxta-nuclear area 'left over' by 
the flattened nucleus was occupied by the Golgi apparatus (Fig. 5f2, 5g2 and 5g4). 
Further analysis demonstrated that these cells showed moderate to intense 
ubiquitin and ATF3 labeling throughout most of the perikaryon. Significantly, the 
region occupied by the Golgi apparatus shows little ubiquitin and ATF3 
immunoreactivity (Fig. 5f2, 5g2, 5g3, 5g4 and 5h2). In contrast, calreticulin, an ER 
protein, also was preferentially distributed in the perinuclear region (Fig. 5i). The ill-
appearing cells also were selectively labeled for the heat shock protein Hsp70 
(Figs 6h and i). Hsp70, like the Golgi apparatus and ER, was preferentially 
distributed in the perinuclear region not occupied by ubiquitin (Figs 5h1 and h2). 
The ill-appearing motoneurons in some cases showed resemblance with active 
caspase 3 immunoreactive motoneurons (e.g. compare Figs 3c and f2), but 
double-labeling showed that these cells did not stain for active caspase 3. 
In sum, ill-appearing motoneurons in G93A-SOD1 mice showed the accumulation 
of ubiquitinated structures throughout most of the perikaryon, resulting in the 
accumulation of organelles in a small usually perinuclear portion of the cell. In spite 
of these morphological and neurochemical features of ill health, these cells did not 
(yet) show the activation of the caspase 3. 
 
5.4.5 ATF3 and phospho-c-Jun positive motoneurons do not show signs 
associated with axonal injury.  
Phospho-c-Jun and ATF3 expression are part of a coordinated program induced in 
motoneurons following axon transection [44,52,59]. To examine to what extend 
phospho-c-Jun and ATF3 expressing motoneurons are in the process of executing 
an 'axotomy response' we have examined the expression of a number of proteins 
known to be upregulated in axotomized motoneurons, including Hsp27, CGRP and 
phospho-STAT3 [3,13,39]. Previously, we have reported a poor correlation 
between ATF3 and Hsp27 expression [42]: the onset of ATF3 expression in 
motoneurons was associated with a global decrease in Hsp27 protein levels, and 
furthermore ATF3 labeled motoneurons frequently were immunonegative for 
Hsp27. In the same way we identified a poor correlation between ATF3 and CGRP 
expression: Thus only a subset of randomly selected ATF3 immunoreactive 
motoneurons (17 of 25) was immunoreactive for CGRP, and the onset of ATF3 
expression was not associated with an increase in CGRP labeling of motoneurons. 
Finally, we did not identify phospho-STAT3 or nuclear translocation of STAT3 in 
our G93A-SOD1 mice at any age (not shown). In sum, ATF3/phospho-c-jun 
immunoreactive motoneurons in G93A-SOD1 mice do not show the gene 
expression profile of axotomized motoneurons. 
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Figure 6: Subsets of motoneurons in G93A-SOD1 mice show dendritic accumulation of CGRP and 
Hsp70 expression. 
 (A-F)  Low (A-C) and high-magnification (D-F) of CGRP immunoperoxidase labeling  in the L4 spinal 
cord of 20 weeks old non-transgenic (A, D) and G93A-SOD1 mice (B, E, F) and a 30 weeks old G93A-
SOD1 mouse (C). In all control and most 20 weeks old G93A-SOD1 motoneurons CGRP was 
distributed in elongated linear profiles (A, B, D). However, a subset of motoneurons in G93A-SOD1 
mice showed a granular labeling pattern, consistent with Golgi fragmentation, and furthermore showed 
abnormal dendritic CGRP labeling (arrows in B, C, E, F). 
(G-I)  Low (G-H) and high-magnification (I) of Hsp70-immunoperoreactive motoneurons in the L4 spinal 
cord of 30 weeks old non-transgenic (G) and G93A-SOD1 mice (H and I). Hsp70-immunoreactivity is 
associated with a small number of ill-appearing motoneurons. Note the flattened nucleus in the Hsp70 
immunoreactive neuron. Calibration bars: A and C, 100 µm; I, 15 µm. 
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5.4.6 A subset of ATF3 and phospho-c-Jun positive motoneurons is 
immunoreactive for CHOP/Gadd153 
The C/EBP homologous protein CHOP, also named Gadd153, is a stress 
transcription factor [50] whose expression depends on the presence of ATF3 after 
specific stress stimuli [23,32]. Double-labeling immunofluorescence showed that a 
subset of ATF3 labeled motoneurons (15 of 50) also was immunoreactive for 
CHOP (Fig. 5j). Vice versa, random selection of CHOP-labeled cells showed that 
nearly all (24 of 25) CHOP-labeled motoneurons were positive for ATF3. The 
majority of ATF3/CHOP double-labeled motoneurons (11 of 15) showed an ill 
appearance (Fig. 5j). However, a number of ill-appearing motoneurons were not 
immunoreactive for CHOP. 
 
 
5.5 Discussion 
 
The availability of transgenic SOD1-ALS mice that develop an ALS-like 
motoneuron disease enables the detailed characterization of the morphological 
and molecular correlates of motoneuron degeneration in ALS. Several studies 
have uncovered the recruitment of programmed cell death pathways in these mice 
[21,28,35], but the precise morphological and molecular correlates preceding the 
death of motoneurons are still incompletely understood. In this study we have used 
phosphorylated c-Jun and ATF3 to label motoneurons in an early phase of their 
degeneration in a line of SOD1-ALS mice carrying the G93A mutations. We found 
that 1) ATF3 and phospho-c-Jun are expressed in a subset of motoneurons 
starting from several weeks prior to the onset of their death. 2) The number of 
phospho-c-Jun/ATF3-labeled motoneurons increased with aging and was highest 
at symptom onset. 3) The morphology of phospho-c-Jun/ATF3 labeled 
motoneurons varied from normal appearing cells to cells with an ill morphology, but 
none of the phospho-c-Jun/ATF3 labeled motoneurons showed the expression of 
active caspase 3, a major neuronal executioner caspase. 4) All phospho-c-
Jun/ATF3-labeled motoneurons showed a fragmented Golgi apparatus. 5) The 
onset of phospho-c-Jun and ATF3 expression in motoneurons did not correlate 
with the onset of mitochondrial swelling and vacuolization which is the earliest 
pathological feature in G93A-SOD1 mice, but correlated with the appearance of 
ubiquitin immunoreactivity in dendrites and perikarya of motoneurons. 6) Phospho-
c-Jun and ATF3 are also expressed in spinal interneurons, but in a later phase of 
disease compared to motoneurons. 
 
Do ATF3 and phospho-c-Jun have an effect on the viability of motoneurons? ATF3 
and phospho-c-Jun are well known for their activation after injurious stimuli, and 
both have been linked to either survival or death. The effect of their activation is 
variable and depends on the promotor and cellular contexts [23,24,26]. C-Jun is a 
component of the heterodimeric AP-1 transcription factor and has been identified 
as an important factor in inducing neuronal degeneration after trophic factor 
deprivation [25,52]. However, its role in adult neurons is ambiguous [7,27]. The 
ATF3 homodimer acts as a transcriptional repressor, but the ATF3 heterodimer 
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with c-Jun (or JunD) functions as a transcriptional activator of specific promoters 
containing CRE sites. Other bZip proteins that dimerize with ATF3 include ATF2, 
JunB, and CHOP (also named Gadd153)[23,24]. Recently, it has been shown that 
ATF3 rescues PC12 cells and superior ganglion cells from c-Jun-activated cell 
death by promoting Hsp27 expression, and that Hsp27 is a target gene of c-
Jun/ATF3 heterodimers [46]. However, there is a poor correlation between 
phospho-c-Jun/ATF3 and Hsp27 expression in motoneurons of G93A-SOD1 mice 
[42]. ATF3 under specific conditions may contribute to the induction of the 
expression of CHOP [32], a stress transcription factor that has been predominantly 
linked to ER stress and that may promote cell death [50]. We have found that a 
subset of phospho-c-Jun and ATF3 immunoreactive motoneurons also expresses 
CHOP, and that the CHOP-positive cells predominantly showed a rather ill 
appearance. These data raise the possibility that the effect of ATF3 and phospho-
c-Jun in motoneurons changes throughout the degeneration process of an 
individual motoneuron as a consequence of changes in the cellular context 
throughout this process. In other words the effect may shift from a beneficial role in 
relatively healthy motoneurons to a cell death promoting role in ill cells. Systematic 
analysis of the expression of interacting transcription factors and potential target 
genes is needed to support this possibility. In addition, crossing G93A-SOD1 mice 
in mice deficient in specific transcription factors may help to clarify the role of 
phospho-c-Jun and ATF3. 
What induces phosphorylated c-Jun and ATF3 expression in motoneurons in 
G93A-SOD1 mice? The transcriptional activity of c-Jun is controlled by the c-Jun-
N-terminal kinase (JNK) pathways, a subgroup of mitogen activated protein 
kinases (MAPKs) that integrate various intra- and extracellular signals [15,27]. 
Once activated, c-Jun may positively autoregulate its expression. The c-Jun/JNK- 
pathway also may trigger ATF3 expression since many of the insults that activate 
the c-Jun/JNK pathways also induce ATF3, and the ATF3 promotor contains 
potential AP1 binding sites for c-Jun [24]. Our data indicate that the motoneurons 
that express phospho-c-Jun and ATF3 represent the same population of cells that 
show Golgi fragmentation i.e. the transformation of the Golgi apparatus from a 
network of linear profiles to dispersed smaller elements forming ministacks. This 
indicates that ATF3 and phospho-c-Jun expression are linked to Golgi 
fragmentation. Golgi fragmentation has been previously identified in a subset of 
motoneurons and Betz cells of patients with ALS and other motoneuron disorders 
[55] and in motoneurons in SOD1-ALS mice [45], but also occurs in some neurons 
in other neurodegenerative diseases [19]. The mechanism underlying Golgi 
fragmentation is not yet understood. It differs from Golgi fragmentation as observed 
after blocking the secretory pathway by brefeldin, but shows similarity with Golgi 
fragmentation induced by microtubule destabilization [45]. One hypothesis is that 
Golgi fragmentation is caused by abnormalities in trafficking between Golgi and 
other membrane compartments  [45,56], possibly because of the presence of 
aggregated protein complexes that may impair dynein trafficking [20,33]. Abnormal 
trafficking also may explain our observation that motoneurons with fragmented 
Golgi show an abnormal dendritic accumulation of CGRP. 
Our data also indicate that induction of phospho-c-Jun and ATF3 (and Golgi 
fragmentation) is shortly preceded by the appearance of ubiquitin immunoreactivity 
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in the proximal dendrites. This is consistent with previous studies showing a 
correlation between fragmented Golgi apparatus and deposits of ubiquitinated 
protein in motoneurons of ALS patients [55] and SOD1-ALS mice [56]. These data 
indicate that Golgi fragmentation and ATF3 and phospho-c-Jun expression are 
downstream of the accumulation of ubiquitin immunoreactivity. Ubiquitin is a small 
polypeptide that is enzymatically conjugated to misfolded and denatured proteins 
to target them for degradation by the proteasome proteolytic complex (see chapter 
1, box1). The accumulation of ubiquitin immunoreactivity in neurons has been 
linked to the presence of aggregates of misfolded protein that can not be effectively 
degraded by the proteasome [38]. Accordingly, the ubiquitinated structures in 
SOD1-ALS mice were strongly immunoreactive for mutant SOD1 indicating that 
they represent ensembles of aggregated SOD1 [8,42,56]. However, ubiquitination 
may not exclusively represent SOD1 aggregates, because a study in chimeric 
SOD1-ALS mice that expressed mutant SOD1 in a subset of their motoneurons, 
showed that accumulation of ubiquitin immunoreactivity also occurred in 
motoneurons that did not express mutant SOD1 [12]. Hence, ubiquitination may 
represent a feature associated with degeneration of motoneurons, putatively 
representing a mix of denatured proteins derived from the collapsing cytoplasm. 
This may explain our ultrastructural data showing that dendritic ubiquitination is 
associated with heterogeneous ensembles of filamentous, amorphous and 
vesicular material, rather than with a single type of aggregate. Our data also show 
that the accumulation of ubiquitinated material is a progressive process that 
gradually fills the entire cell and eventually 'pushes away' the Golgi and the ER into 
a small, usually juxtanuclear portion of the cell. This accumulation of ubiquitinated 
material in the end also seems to lead to impaired proteasome function, because 
the motoneurons that were entirely filled with ubiquitin also expressed Hsp70, 
which in motoneurons has been found to be selectively upregulated after 
proteasome inhibition and not after other injurious stimuli [4]. Significantly, recently 
it has been shown that the level of phospho-c-Jun depends on ubiquitination and 
degradation by the proteasome [48]. Also, ATF3 has been shown to be strongly up 
regulated after proteasome inhibition [67], raising the possibility that ATF3 and 
phospho-c-Jun expression result from impaired proteasome function. However, this 
scenario is not consistent with our observation that Hsp70 is only expressed in a 
subset of ATF3 and phospho-c-Jun positive motoneurons, indicating that impaired 
proteasome function occurs after the onset of ATF3 and phospho-c-Jun 
expression. 
 
How do motoneurons in G93A-SOD1 mice die? Our data are consistent with 
previous reports suggesting that the motoneurons ultimately die through the 
activation of programmed cell death pathways [21,28,35]. However, the activation 
of caspase 3 (a dominant final executioner caspase in neurons) within a single 
motoneuron is delayed until they reach a very ill appearance. These ill 
motoneurons are large in size, have an eccentric flattened nucleus, and have a 
perikaryon filled with ubiquitinated material, with the exception of a small 
juxtanuclear area containing the Golgi and the ER. This morphology differs from 
the morphology of motoneurons in acute in vivo models of apoptotic and non-
apoptotic motoneuron death [36,49,57]. It seems unlikely that these ill 
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motoneurons are still functional. Whether the ill motoneurons are irreversibly 
damaged or still can be rescued is an open question. 
In conclusion, the present study provides a description of a series of changes in 
motoneuron death preceding their death and disappearance in a line of SOD1-ALS 
mice. The data provide a framework to further examine the mechanisms underlying 
the degeneration of motoneurons in ALS. Importantly, we show that ATF3 and 
phospho-c-Jun are effective markers to identify motoneurons in an early phase of 
their degeneration. Questions raised by our data include: 1) How are early 
mitochondrial abnormalities in motoneurons of SOD1-ALS mice [14,31,37,40,65] 
related to the further degeneration of motoneurons? Significantly, our data show 
that mitochondria surrounding ubiquitinated areas in dendrites are normal, whereas 
swollen and vacuolated mitochondria occur more distally and in the axon. One 
possibility is that ubiquitination follows from collapse of distal dendrites due to 
mitochondrial pathology. 2) What mechanism causes dendritic and somatic 
ubiquitination? 3) How are the neurodegenerative changes in the somato-dendritic 
domain, as depicted in the present study, related to the functional deterioration and 
degeneration of the axon? A number of studies have suggested that the axon is 
the primary target of mutant SOD1 since transport abnormalities and degeneration 
of the axon and its terminals are early phenomena in SOD1-ALS mice [6,16-
18,64,66]. Preliminary analysis of muscle denervation in our G93A-SOD1 mice 
showed no signs of denervation at 15 weeks of age, and mild denervation at 20 
weeks of age, indicating that denervation coincides with or occurs after the onset of 
ubiquitination and ATF3/phospho-c-jun expression. Significantly, the ‘axon first'-
hypothesis of mutant SOD1-mediated motoneuron degeneration has been 
challenged by the recent demonstration that expression of Wlds, which is an axon-
protective protein which attenuates the course of disease in axon-first motoneuron 
diseases [2], does not influence motoneuron loss in SOD1-ALS mice [61]. 4) How 
are changes in c-Jun and ATF3 signaling related to other signaling events 
identified in motoneurons and surrounding glia in SOD1-ALS mice [9]? 5) To what 
extend is the sequence of events identified in our study reproduced in human ALS 
motoneurons? In accord with our data c-Jun activation has been identified in post-
mortem ALS spinal cord specimen [62]. However, unfortunately, so far we have 
been unsuccessful in obtaining reliable phospho-c-Jun and ATF3 staining in 
human tissue. 
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6.1 Discussion 
 
The overall aim of the studies in this thesis was to obtain greater understanding 
about the pathogenesis of ALS focusing on the role of oxidative and misfolded 
protein stress. A dominant approach has been the detailed analysis of what 
happens in the spinal cord of SOD1-ALS mice prior and during the development of 
muscle weakness. This approach, which might be termed molecular 
neuropathology, is an invaluable complement of interventional approaches 
enabling the proper interpretation of these data. As discussed in this chapter the 
main conclusions from the studies of this thesis are the following: 
• Nitro-oxidative damage of protein bound or free tyrosine residues does not 
contribute to the pathogenesis of SOD1-linked ALS (chapter 2). 
• Motoneurons in SOD1-ALS mice may experience a deficient proteasome 
function in a late phase of their degeneration (chapter 5). The selective 
vulnerability of motoneurons towards mutant SOD1 can not be explained by an 
increased sensitivity to proteasome inhibition (chapter 3). 
• Mutant SOD1 decreases the availability of a major heat shock protein in 
motoneurons of SOD1-ALS mice (chapter 4). 
• Degeneration of motoneurons of SOD1-ALS mice is characterized by an 
ordered sequence of events that starts with activation of the injury transcription 
factors ATF3 and c-Jun (chapter 5). 
 
Figure 1: Summary of potential events contributing to motoneuron degeneration caused by mutant 
SOD1. (UPS, ubiquitin-proteasome system)  
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• Execution of programmed cell death by caspase 3 is a very late event that only 
operates in very sick ghost-like motoneurons (chapter 5). 
• The mechanism by which mutant SOD1 triggers the functional deterioration and 
degeneration of motoneurons remains to be determined. Potential contributing 
events are summarized in Fig. 1. 
 
 
6.1  The role of oxidative stress in ALS: what is the evidence? 
 
The accumulation of oxidative stress mediated damage has been implicated in 
multiple age-related disorders. Accordingly, it has long been suspected that 
oxidative stress contributes to the lesions of ALS. However, precise knowledge 
about which toxic reactive oxygen (ROS) or nitrogen (RNS) species are involved, 
their source, their target molecules, and why they selectively afflict motoneurons 
has been lacking [19,33,54 ,85] (chapter 1). The source of ROS and RNS has 
been attributed to leakage from the electron-transport chain of mitochondria, and 
more recently to activated microglia, that can generate large numbers of 
superoxide ions on their external membranes, from which they are released into 
the surrounding area. Other, less abundant sources of free radicals are cytosolic 
enzymes like xanthine oxidase and nitric oxide synthase [19,33,54 ,85]. 
The identification of SOD1 mutations has stimulated oxidative stress hypotheses of 
ALS, since it enabled to formulate specific routes of ROS and RNS production. 
Multiple gained catalytic copper-mediated toxic activities yielding highly toxic ROS 
and RNS species have been reported for mutant SOD1, which, since SOD1 is an 
abundant protein, may have an significant impact on the cell [18,34,54,91]. These 
gained catalytic properties result from improper shielding of the catalytic copper 
because of conformational changes and altered zinc binding. To explain the 
selective vulnerability of motoneurons, the 'gain of toxic oxidative function' 
hypotheses have zoomed in on specific target molecules such as the glial 
glutamate transporter, cytoskeletal proteins, and mitochondrial membranes 
[18,34,54,91]. However the idea of a toxic oxidative action of mutant SOD1 as a 
primary disease mechanism has been controversial for several reasons. First, any 
specific gained catalytic activity is difficult to reconcile with the great structural and 
functional diversity of SOD1 mutants (see chapter 1). Second, studies in SOD1-
ALS mice have shown that mutant SOD1 toxicity is not influenced by copper 
loading (see chapter 1). Third, antioxidant drugs like vitamin E, vitamin C, N-
acetylcysteine, and selegeline so far have been found to be not or marginally 
effective in influencing the disease course in SOD1-ALS mice (Table 1) [13,56]. 
Similarly, anti-oxidant drugs also seem to be ineffective in sporadic and familial 
ALS patients [27,85]. However, this lack of effect has been attributed to the inability 
of the tested antioxidants to cope with local overloads of free radicals [19,33,54 
,85] and does not conclusively disqualify oxidative stress hypotheses. In addition to 
a direct toxic oxidative role of mutant SOD1, several alternative schemes involving 
oxidative stress mediated toxic activities in ALS pathogenesis have been put 
forward. For instance, oxidative stress may operate as a secondary phenomenon 
following microglia activation or after mitochondrial degeneration [19,33,54 ,85]. 
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Evidence supporting a role of oxidative stress in ALS also came from various 
pathological studies, showing increased levels of molecular markers of free-radical 
attack in ALS spinal cord [19,33,54,85]. Increased expression in ALS tissue has 
been reported for 3-nitrotyrosine, a marker for damage left by nitric oxide-derived 
species, advanced glycation end products (AGEs) and a receptor for AGE, as well 
as for 4-hydroxy-2-nonenal-histidine and crotonaldehyde- lysine, two markers of 
lipid peroxidation, and pentosidine, a marker of protein glycooxidation 
[19,30,33,42,54 ,85]. 
 
6.1.1 Immunocytochemical detection of 3-nitrotyrosine in ALS: free or 
protein-bound? 
Since cumulative damage left by nitric oxide-derived reactive species, in particular 
peroxynitrite (ONOO–), was strongly suspected to play a role in both mutant SOD1-
linked and sporadic ALS, we have examined the distribution of 3-nitrotyrosine-
immunoreactivity in the spinal cord of our G93A mice. 3-Nitrotyrosine is formed by 
a reaction between nitric oxide-derived reactive species and tyrosine, and has 
been widely used in neuropathological studies as a marker for damage left by nitric 
oxide-derived species [6,42]. More importantly, nitration of protein has been 
identified as a potential cause of aggregate formation. For instance, intracellular 
filamentous pathology in Parkinson’s disease and Alzheimer's disease neurons 
contains nitrated α-synuclein and tau, respectively [40,50]. Recent studies have 
suggested that nitration of proteins may play a role in the formation of protein 
aggregates in the presence of mutant SOD1, and that SOD1 is a target for nitration 
itself [51]. Hence, the original aim of our analyses was to determine whether 3-
nitrotyrosine immunoreactivity was associated with early subcellular abnormalities 
in our G93A-SOD1 mice that contain high levels of mutant SOD1, i.e. the swollen 
mitochondria and ubiquitinated dendrites [57]. The following results emerged from 
these investigations: 
 1) The staining pattern obtained with two commonly used and commercially 
available 3-nitrotyrosine antibodies strongly depends on the type of fixation, and 
which antibody is used. These differences could, be explained, at least in part by 
their differential immunoreactivity with free (non-protein-bound) 3-nitrotyrosine in 
aldehyde fixed tissue. Both antibodies have been raised against nitrated-keyhole 
limpet hemocyanin (KLH) and have been shown to selectively bind to 3-
nitrotyrosine in peptides and proteins [102]. Their specificity for 3-nitrotyrosine 
epitopes in tissue sections was firmly established, since the antibodies did not 
produce staining in sections in which 3-nitrotyrosine epitopes were chemically 
disrupted (see chapter 2). However, as explained in chapter 2 we noted that one of 
the antibodies (Ab06-284) immunoreacted with free 3-nitrotyrosine microinjected 
into the brain. This labeling strongly depended on aldehyde fixation suggesting that 
the antibody recognized 3-nitrotyrosine that is chemically cross-linked to proteins. 
The concentration of 3-nitrotyrosine recognized by the antibody is in the mid-
nanomolar range, which is in the order of magnitude of the concentration of free 3-
nitrotyrosine in murine CNS [42]. Since, the other antibody (Mab1A6) did not 
immunoreact with microinjected 3-nitrotyrosine, this antibody may be specific for 
protein-bound 3-nitrotyrosine epitopes. The differential affinity of Mab1A6 and 
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Ab06-284 for aldehyde-fixed free 3-nitrotyrosine may, at least in part, explain the 
multiple disagreements in the literature on the distribution of 3-nitrotyrosine-
immunoreactivity in normal and diseased brain [42].  
2) 3-Nitrotyrosine immunostaining patterns in control and G93A mouse spinal cord 
were different for Mab1A6 and Ab06-284: a diffuse increase in 3-nitrotyrosine 
immunoreactivity was observed with Ab06-284, whereas no changes as compared 
to control were observed with Mab1A6 (Fig. 2). Surprisingly, increased Ab06-284 
labeling was only observed in pre-symptomatic G93A mice, and no consistent 
changes were observed in symptomatic mice (Fig. 2). Since Ab06-284 labels free 
3-nitrotyrosine and Mab1A6 does not, a possible explanation for these results is 
that increased staining observed with Ab06-284 represents an increase in free 3-
nitrotyrosine in presympromatic G93A mice. This would be consistent with 
neurochemical studies reporting increased free 3-nitrotyrosine in two lines of 
SOD1-ALS mice [11,37], but no change in protein-bound 3-nitrotyrosine levels 
have been consistently reported [11]. However, the data disagree with other  
Figure 2: The pattern of 3-nitrotyrosine immunostaining in spinal cord of G93A-SOD1 mouse depends 
on which 3-nitrotyrosine antibody is used.  
Photomicrographs of representative L4-spinal cord sections showing 3-nitrotyrosine labeled with 
Mab1A6 (A-C) or with Ab06-284 (D-F) in presymptomatic (18 weeks old; B, E) and symptomatic (32 
weeks old; C, F) G93A-SOD1 mice and 34 weeks old non-transgenic mouse (A, D). Note, a diffuse 
elevation in 3-nitrotyrosine-immunostaining in the spinal cord of 18 week-old G93A-SOD1 mice stained 
with Ab06-284 (E) but not with Mab1A6 (B, H).No change in 3-nitrotyrosine labeling occurred in the 
spinal cord of symptomatic G93A-SOD1 mice. Scale bar in F = 200 µm. 
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studies using the same antibodies reporting increased 3-nitrotyrosine 
immunoreactivity in the spinal cord of symptomatic SOD1-ALS mice [14,37,60,92]. 
Remarkably, the latter studies disagreed on the cellular distribution of increased 3-
nitrotyrosine labeling, in that increased labeling was found in glia [14], in neurons 
[60], or in both [37,92] independent of which of the two antibodies was used. The 
source of this variability is not clear, but it is unlikely that it results from non-specific 
staining since the specificity of 3-nitrotyrosine immunostaining can be reliably 
determined (see above). In conclusion, data on the distribution of 3-nitrotyrosine in 
spinal cord SOD1-ALS mice are remarkably variable. Our data indicate that G93A-
SOD1 mice may experience a diffuse increase in free 3-nitrotyrosine concentration. 
3) The light-microscopic data indicated that 3-nitrotyrosine immunoreactivity was 
not associated with abnormal mitochondria and ubiquitinated dendrites. The same 
results emerged from post-embedding immunogold immunocytochemistry. This 
method showed that 3-nitrotyrosine immunoreactivity in normal brain has a 
ubiquitous distribution, although the highest level of labeling consistently occurred 
in mitochondria (Fig. 3A, B). Swollen and vacuolated mitochondria showed a low 
level of 3-nitrotyrosine immunoreactivity (Fig. 3C) despite high levels of mutant 
Fig.3. Vacuolated mitochondria in the spinal cord of G93A mice do not show increased 3-nitrotyrosine 
immunoreactivity. 
Post-embedding immunogold immunoelectron microscopy of 3-nitrotyrosine labeling in the spinal cord 
ventral horn of 20 weeks old control (A, B) and G93A mice (C). In control spinal cord 3-nitrotyrosine 
labeling occurs in all structures but a higher labeling density can be seen in the mitochondria (A, B). 3-
nitrotyrosine has the same subcellular distribution in G93A mouse spinal cord. Vacuolated mitochondria 
which are characterized by a high level of SOD1 immunoreactivity (D) do not show increased 3-
nitrotyrosine labeling (C). Scale bars, 500 nm. 
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SOD1 ((Fig. 3D). In the same way ubiquitinated dendrites showed a low level of 3-
nitrotyrosine immunoreactivity (not shown). This indicates that protein nitration is 
not a critical factor in the formation of these pathological structures. Accordingly, no 
increased 3-nitrotyrosine labeling did occur in ubiquitinated inclusions in another 
line of SOD1-ALS mice that carry the G85R mutation, and in Lewy body-like 
inclusions in familial ALS patients [63]. 
6.1.2 Is free 3-Nitrotyrosine neurotoxic? 
Nitration of protein-linked tyrosine residues can disturb the function of proteins, 
because 3-nitrotyrosine is bulkier and more hydrophilic than tyrosine [42,94], and in 
addition may facilitate the aggregation of proteins  [40,50]. It has been proposed 
that also free 3-nitrotyrosine may affect the function of some proteins. For instance, 
it can be post-translationaly incorporated in α-tubulin and hence affect microtubule 
dynamics [31]. Recent data have suggested that free 3-nitrotyrosine may cause 
neuronal degeneration in vitro and in vivo [79,88]. Mihm et al. [79] have reported 
degeneration of nigral dopaminergic neurons 1 week after striatal 3-nitrotyrosine 
injections. However as discussed in chapter 2 we found no evidence for 
neurodegenerative changes in the striatum or the substantia nigra using a similar 
procedure. More importantly, also chronic intra-striatal administration of 3-
nitrotyrosine via osmotic pumps did not result in any evidence of 
neurodegenerative changes in the nigro-striatal system. Peluffo et al. [88] showed 
that also motoneurons are vulnerable to 3-nitrotyrosine, since 50 to 100 µM of 3-
nitrotyrosine induced apoptosis in the majority of neurons in isolated embryonic 
motoneuron culture [88]. Furthermore, increased levels of 3-nitrotyrosine also have 
been associated with excitotoxic motoneuronal degeneration [28,100]. However, 
we identified no effect of 3-nitrotyrosine on the viability of motoneurons in 
organotypic spinal cord culture (see chapter 2). The mismatch between our data 
and the results of Peluffo et al. [88] can at least in part be explained by the 
absence of glia in their culture system, which increases their vulnerability to 
multiple factors (see chapter 2). As discussed in chapter 2, our data enabled us to 
conclude that even at very high unphysiological doses (100-150 µM), 3-
nitrotyrosine is not neurotoxic, and that mild increases in 3-nitrotyrosine 
concentration as observed in SOD1-ALS mouse spinal cord are unlikely to 
contribute to the disease.  
 
6.2 The role of misfolded protein stress and protein aggregation in ALS: 
what can we learn from the SOD1-ALS mouse model? 
 
The excessive formation and aggregation of misfolded proteins is regarded as 
dominant pathogenic factor in neurodegenerative diseases including ALS (see 
chapter 1). In ALS evidence supporting for protein aggregation predominantly 
came from the neuropathological identification of ubiquitinated inclusions in ALS 
motoneurons and glia. These inclusions, although diverse in structure are specific 
for ALS, and therefore have linked to its pathogenesis (chapter 1). The term 
‘inclusion bodies’ has been applied to the intracellular foci into which aggregated 
proteins are sequestered in such amounts that they are visible by light microscopy, 
and usually are considered giant aggregates. There has been a recent awareness 
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that these giant aggregates usually are relatively harm-less to the cell, and may 
represent a protective response of the cell to sequester toxic stable oligomers of 
misfolded protein, also termed protoaggregates  [4,15,69]. These macroaggregates 
appear in cells after transfection with mutant aggregate prone proteins or inhibition 
of the proteasome, and have been termed aggresomes [69]. Aggresomes are 
defined as inclusions located near the centrosome, predominantly containing 
aggregated (and usually ubiquitinated) proteins and surrounded by intermediate 
filaments [69]. The aggresomes serve as a temporary storage of aggregated 
proteins that are further disposed by an autophagosomal and lysosomal 
mechanisms [38,108]. The formation of aggresomes depends on dynein-dynactin 
dependent trafficking [69]. Recently, a histone deacetylase, HDAC6, has been 
identified as a protein that links polyubiquitinated protein complexes to dynactin 
[64]. 
It is now well established that SOD1 mutants under specific conditions represent 
aggregate prone proteins that form stable oligomeric complexes and aggregates ex 
vivo, in transfected cells, in SOD1-ALS mice and in ALS patients (see chapter 4) 
[32,58,59,96,101]. In cultured cells mutant SOD1 may accumulate in aggresomes 
and this process is accelerated after proteasome inhibition [58]. Interestingly, a 
high throughput analysis aimed at finding drugs that prevented the accumulation of 
mutant SOD1 into aggregates, yielded two histone deacetylase inhibitors that 
strongly inhibited HDAC6 function. Closer inspection showed that treatment with 
these inhibitors prevented aggresome formation and resulted in dispersed mini-
aggregates [20]. This indicates that ubiquitinated SOD1 aggregates or 
protoaggregates may be recognized by HDAC6 and transported to the centrosome 
in healthy cells. 
 
6.2.1  Aggregates: the role of insufficient proteasome function 
Although there is substantial evidence suggesting that mutant SOD1 may afflict 
motoneurons via oligomerisation or aggregation, it is not known how, if indeed, it 
does so. It has been shown that protein aggregates can impair the ubiquitin-
proteasome system by overloading the proteasome by undegradable aggregates, 
or because of saturation of molecular chaperones involved in proteasomal function. 
This inhibition could lead to further aggregate formation, creating a positive-
feedback system [7]. Insufficient proteasome function has been identified as an 
important factor in Parkinson's disease, either because of an overload of misfolded 
protein trough oxidation or mutation, or because of genetic defects in components 
of the ubiquitin-proteasome system [16,77]. Accordingly, Lewy body inclusions, a 
frequent pathological feature in Parkinson's disease brain, have many features in 
common with aggresomes [78]. 
Is inhibition of the proteasome a mechanism that contributes to mutant SOD1 
toxicity? Studies in cell lines showed that mutant SOD1s mildly decreased 
proteasome activity [2,51]. We have examined whether the expression of mutant 
SOD1 increased the vulnerability of motoneurons to prolonged proteasome 
inhibition. This study indicated that motoneurons expressing mutant SOD1 show 
the same sensitivity to proteasome inhibition as control motoneurons (chapter 3). 
These studies also showed that motoneurons were as sensitive to proteasome 
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inhibition as other spinal neurons. Hence, the selective vulnerability of 
motoneurons towards mutant SOD1 can not be explained by an increased 
sensitivity to proteasome inhibition (chapter 3). 
A mild dysfunction of the proteasome also was found in the spinal cord of SOD1-
ALS mice [61]. However, in this study it could not be determined whether impaired 
proteasome function Since Hsp70 expression is a signs of impaired proteasome 
function in motoneurons [5] we studied Hsp70 expression in our G93A mice. This 
study showed that Hsp70 is only expressed in a small subset of sick-appearing 
motoneurons, indicating that insufficient proteasome is a late event in the process 
of motoneuron degeneration (chapter 5). 
 
6.2.2 What happens with chaperones in SOD1-ALS mice? 
Molecular chaperones like heat shock proteins are an important part of the protein 
quality control machinery. They bind to unfolded, misfolded or denatured proteins 
and either help them refold or direct them to the ubiquitin-proteasome system [95].  
It has been proposed that one way by which misfolded protein stress may affect 
the function of the cell is through overloading the capacity of the chaperone 
system, which on the one hand would facilitate aggregation of misfolded protein 
and on the other hand compromise normal function of the chaperones [95]. The 
inducible heat shock protein Hsp70 is one the main chaperones involved in 
protecting cells after denaturing conditions [95]. Accordingly, overexpression of 
Hsp70 has been found to be neuroprotective in various in vitro and in vivo models 
of neuronal degeneration [24,104,106], Pathological studies have not reported 
changes of Hsp70 expression in motoneurons of ALS patients [39]. This may be 
explained by the fact that motoneurons have a relative inability to induce Hsp70 
expression [5], which has been put forward as one of the factors to explain the 
selective vulnerability of motoneurons towards mutant SOD1. It has been shown 
that Hsp70 and some other heat shock proteins (i.e. Hsp40, αB-crystallin and 
Hsp27) bind to mutant SOD1, but not to wild-type SOD1 [96], [83], which results in 
their reduced availability [83]. Increasing the level of Hsp70 reduced formation of 
mutant SOD1 aggregates and prolonged survival in cultured primary motor 
neurons and a neuronal cell line [10,99]. However, in vivo overexpression of Hsp70 
in SOD1-ALS mice by crossing these mice with Hsp70 transgenic mice did not 
influence the disease progression and survival [107]. Importantly, crossing the 
same Hsp70 mice in a mouse model carrying a mutant androgen receptor that 
develops an early onset motoneuron disease [1], showed that in these mice Hsp70 
attenuated motoneuron degeneration. Hence, together the data indicate that 
although Hsp70 interacts with mutant SOD1 and prevents its aggregation, it does 
not protect motoneurons against mutant SOD1 in SOD1-ALS mice. This implies 
that insufficient Hsp70 is not a factor contributing to the pathogenesis in SOD1-ALS 
mice. 
In a recent study, heat shock protein expression has been pharmacologically up 
regulated in the spinal cord of a line of SOD1-ALS mice (G1H-G93A) with 
arimoclomol [65]. This treatment which resulted in increased expression of Hsp70 
and Hsp90, putatively via activation of Heat shock protein-inducing factor (HSF1), 
resulted in considerable prolonged life span, even though treatment was started 
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after disease onset [65]. Direct proof that arimoclomol is beneficial via the 
activation of heat shock proteins is still lacking, and other modes of actions cannot 
yet be excluded. 
We have performed a detailed analysis of heat shock protein expression in our 
G93A mice. First, a high throughput gene expression analysis with Affymetrix Gene 
chips (MG-U74Av2), which enables the mRNA expression profiling of 
approximately 10.000 murine genes (www.affymetrix.com), did not show any 
changes in mRNA levels of 150 genes encoding for molecular chaperones in the 
spinal cord of presymptomatic G93A mice as compared to controls (Fig 4). Also 
using immuno(cyto)chemical methods no change in Hsp70, Hsp60, Hsp40 and the 
small heat shock proteins, Hsp27 and α-B-crystallin, were observed in young G93A 
mice. However, a number of changes in the expression of specific heat shock 
proteins occurred in mid-late presymptomatic and symptomatic G93A mice 
(Chapters 4 and 5). In order of time of appearance these changes consisted of 1) a 
decreased expression of Hsp27 in motoneurons starting from mid-late 
presymptomatic stages of disease, i.e. several weeks before the onset of 
motoneuron loss (chapter 4). 2) Induction of Hsp27 expression in astrocytes in late 
presymptomatic and symptomatic mice (chapter 4). 3) Increased α-B-crystallin in 
oligodendrocytes in late presymptomatic and symptomatic mice (in preparation), 
and 4) Induction of Hsp70 expression in of a subset of sick-appearing motoneurons 
in late presymptomatic and symptomatic mice (chapter 5). 
 
Fig. 4. Affymetrix Genechip analysis shows that the relative mRNA expression of molecular chaperones 
in the spinal cord of 12-weeks-old G93A mice is not altered as compared to non-transgenic mice 
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Hsp27 (also called Hsp25 in mice or HspB1) is a multifunctional protein that is 
constitutively expressed by α-motoneurons. Like Hsp70 it has many 
neuroprotective properties, including the ability to inhibit misfolded protein 
aggregation [111]. As discussed in chapter 4, decreased Hsp27 expression prior to 
the onset of motoneuron death can contribute to the degeneration of motoneurons 
in several ways, including the facilitation of SOD1 aggregation, facilitation of 
caspase 3 activation, and troubling of cytoskeletal proteins homeostasis. 
Importantly, missense mutations in Hsp27 [35] and another small heat shock 
protein, Hsp22 [53] have been linked to peripheral distal motor and sensory 
axonopathies. The mutations impair the chaperone function of Hsp27 [35], further 
supporting the notion that loss of Hsp27 function may be deleterious for 
motoneurons. Hence, a decreased availability of Hsp27 may be one of the 
mechanisms that contribute to the toxicity of mutant SOD1. A question that remains 
to be resolved is what causes decreased motoneuronal Hsp27 protein expression 
in G93A-SOD1 mice. Our data point to a post-translational mechanism, putatively 
through an interaction with mutant SOD1, but this hypothesis needs further support 
(see chapter 4). 
Astroglial Hsp27 induction as identified in our symptomatic G93A mice (see 
chapter 4) has been reported for different pathological conditions, including 
ischemia, excitotoxicity, and Alzheimer’s disease and, therefore, seems to be a 
common characteristic of very different types of brain pathology [55]. In contrast, 
increased expression of α-B-crystallin may be more directly linked to mutant SOD1 
toxicity since all astro- and oligodendroglial ubiquitinated structures are strongly 
immunoreactive for α-B-crystallin (in preparation). 
The sick Hsp70-immunoreactive cells showed a characteristic set of abnormalities 
including a strong immunoreactivity for ubiquitin (chapter 5), which together with 
other data indicate that these cells have an impaired proteasome function (see 
above). Notably, other cells in G93A mice that contained high levels of ubiquitin, 
i.e. astrocytes, oligodendrocytes and spinal interneurons, did not show increased 
Hsp70 expression. This again challenges the idea that the selective vulnerability of 
motoneurons, is caused by a relative inability to induce Hsp70 expression.  
 
6.2.3 The identity of ubiquitinated structures in SOD1-ALS mice: 
aggregates, aggresomes or something else? 
The advantage of SOD1-ALS mice is that aggregates and ubiquitinated structures 
can be examined in early phases of disease, and furthermore the temporal 
relationship between aggregate formation and other signs of neuronal 
degeneration can be determined. As discussed in chapter 4, the accumulation of 
oligomeric and aggregated mutant SOD1 species at a level that can be detected by 
immunochemical methods is a relatively late event, occurring at the onset of the 
death and disappearance of motoneuron death. In earlier stages of disease 
accumulation of mutant SOD1 suggestive of aggregates could be detected in 
mitochondria and dendritic cytosolic ensembles of filamentous and granular 
material (chapters 4 and 5; [57]). As described by others in a later phase of disease 
SOD1 aggregates also appear in oligo- and astroglia [12,98]. Together the data 
indicate that SOD1 aggregation happens independently in different cell types. The 
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time of appearance suggests that glial SOD1 aggregation occurs secondarily to the 
degeneration of motoneurons, putatively in association with a stress response 
induced in these cells by the death of motoneuron. 
Mitochondrial SOD1 aggregates were not ubiquitinated (chapter 4) which can be 
explained by the fact that the ubiquitination machinery does not operate in 
mitochondria. Accordingly, all neuronal and glial cytosolic SOD1 aggregates were 
ubiquitinated. In chapter 5 we have focused on the identity of the dendritic cytosolic 
SOD1 aggregates, since their time of appearance precede the further degeneration 
of motoneurons (chapter 5). These dendritic cytosolic SOD1 aggregates are not 
Lewy body-like inclusions or aggresome-like structure, because unlike these 
structures they are not located at the centrosome. In contrast, they show some 
resemblance with skeins, i.e. the irregular loosely arranged bundles of filamentous-
appearing material which represent a constant feature in ALS motoneurons. The 
precise identity of ubiquitinated cytosolic remains to be established (chapter 5). A 
preliminary hypothesis proposes that they represent SOD1 aggregates together 
with material from collapsing microtubule network.  
 
 
6.3 How do motoneurons die in ALS? 
 
The mechanisms by which motoneurons die and disappear in ALS has remained an 
unresolved issue [13,44]. Initially the discussion has been centered on the question 
whether the death was apoptotic or necrotic. However, this discussion may not be 
fruitful, since in neurodegenerative disorders a diverse array of degenerative 
pathways, either apoptotic, necrotic or autophagic may operate sequentially or in 
parallel to yield degradation and death of neurons that differs from classical 
apoptosis or necrosis [113]. Hence more important questions are: which death 
pathways are involved and do they represent targets for therapeutic intervention? 
Studies in post-mortem human ALS spinal cord and motor cortex have provided 
evidence favoring a role for apoptotic programmed cell death pathways [93]. An 
instrumental role for apoptotic programmed cell death pathways also has been 
suggested for SOD1-ALS mice (see below). The roles of necrotic and 
autophagolytic programs have not yet been investigated.  
 
6.3.1  The recruitment of programmed cell death pathways in SOD1-ALS mice 
The recruitment of molecular pathways in SOD1-ALS mice has been extensively 
reviewed [44]. Programmed cell death is a complex multi-step process involving 
many factors that grossly can be grouped into sensors, initiators, modulators and 
effectors. The two main pathways are the 'death receptor' (extrinsic) and the 
'mitochondrial' (intrinsic) pathways that result in the activation of members of the 
caspase family of proteases, caspases 8 and 9, respectively (Fig. 5) [25,41]. This 
activation consists of oligomerisation of procaspase 8 and 9, respectively, which 
results in cleavage and activation of these caspases. This in turn through cleavage 
cause the activation of downstream caspases that coordinate the proteolytic 
breakdown of the cell [90,97]. Also the endoplasmatic reticulum (ER) has been  
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Figure 5: diagram of the main caspase-dependent apoptosis pathways. Both extrinsic pathways are 
mainly started up by extracellular signals, while the ER-stress pathway is activated specifically when 
ER-stress occurs. The mitochondrial pathway can be initiated by many kinds of cellular stress causing 
Bax translocation to mitochondria. 
 
involved in the initiation of programmed cell death operating through the activation of 
caspase 12 in rodents and putatively caspase 4 in man, who does not produce a 
functional caspase 12 [49]. The final common pathway of most programmed cell 
death pathways is the activation of executioner caspases, like caspase 3 (Fig. 5) 
Several studies have reported the activation of caspase 3 in the spinal cord of SOD1-
ALS mice, strongly supporting a role for programmed cell death in the pathogenesis 
[44,87]. This was further supported by the finding that the irreversible broad-
caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone 
attenuates mutant SOD1–mediated cell death and mildly prolongs survival in 
transgenic G93A-SOD1 mice [71]. Whether the beneficial effect of caspase 
inhibition operates through delaying the death of motoneurons is not clear. Our 
data, as reported in chapter 5, indicate that activated caspase 3 predominantly 
occurs in interneurons, glial cells, and debris of motoneurons, and further suggest 
that motoneurons show active caspase 3 only in a very late irreversible phase of 
their degeneration (see chapter 5). Caspase inhibition has been shown to be 
ineffective in rescuing sick neurons [84]. Hence, inhibition of caspases may 
predominantly have its beneficial effect via inhibition of interneuron and glia cell 
death, which indirectly may be beneficial for motoneurons [17]. 
What mechanism activates caspase 3 in SOD1-ALS mice? Some studies have 
suggested a role for caspase 1, which is thought to play a role in cytokine maturation 
rather than programmed cell death [71,87]. However, the role of caspase 1 has 
been questioned [62]. Most studies point to the activation of a mitochondrial cell 
death pathway. This pathway is modulated by proteins of the Bcl-2 family that in part 
may operate by controlling the permeability of the mitochondrial outer membrane, 
and, hence, control the release of cytochrome c which triggers caspase 9 activation 
[41]. An early study showed that overexpression of Bcl-2, an anti-apoptotic member 
of the Bcl-2 family prolongs survival of G93A mice [70]. Subsequently it was found in 
various lines of SOD1-ALS mice that Bcl-2 levels were decreased and levels of the 
pro-apoptotic Bcl-2 family members Bax and Bak were increased in the spinal cord 
[44]. Furthermore caspase 9 activation was shown to occur at about the same time 
as Bax-translocation to mitochondria and mitochondrial cytochrome c release [45]. 
Also inhibition of caspase 9 attenuates disease progression in G93A mice [52]. 
More recently, a direct interaction between mutant SOD1 and Bcl-2 has been 
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reported, and aggregates containing both mutant SOD1 and Bcl-2 have been 
found in mitochondria of the spinal cord but not the liver of SOD1-ALS mice 
suggesting that mutant SOD1 may trap Bcl-2 and hence inhibit its anti-apoptotic 
property [86]. It is not clear how the latter finding is related to the early 
accumulation of mutant SOD1 in the mitochondrial intermembrane space and outer 
membrane [57,72]. Furthermore the specific entrapment of Bcl-2 is difficult to 
reconcile with the selective vulnerability of motoneurons since both Bcl2 and SOD1 
are ubiquitously expressed. Another problem that needs to be resolved is the poor 
temporal correlation between mitochondrial pathology which occurs in an early 
phase of disease [57] and active caspase 3 expression. Yet another problem is 
that swollen and vacuolated mitochondria are morphologically distinct from 
apoptotic mitochondria, and that mitochondria in sick motoneurons have a normal 
appearance. 
 
6.3.2 The role of stress transcription factors 
In addition to the activation of cell death programs, intracellular damage also may 
activate survival, repair and regenerations programs. An example of the activation 
of such a program can be observed in adult motoneurons after axotomy. This event 
results in a sequence of morphological and genetic rearrangements, such as 
synaptic stripping, activation of adjacent glial cells, downregulation of glutamate 
receptors, upregulation of tubulin and many neuropeptides, upregulation of trophic 
factor signaling, and up-regulation of growth associated proteins [9,48,80]. Several 
signaling pathways have been implicated in this response. One component is the 
c-Jun N-terminal kinase (JNK)-stress signaling pathway that activates the AP1 
transcription factor c-Jun through phosphorylation (Fig. 6) [48,89]. Importantly, the 
beneficial effect of c-Jun in axotomized motoneurons strongly depends on the 
transcriptional context, since under specific conditions activated c-Jun also acts as 
an activator of neuronal degeneration [103,109]. One factor influencing c-Jun 
transcriptional activity is its hetero-dimerization partner, which can be other 
members of the AP-1 family or members of other bZIP motif-containing families like 
the ATF/CREB, Maf, and C/EBP families. Another stress transcription factor is 
ATF3, a member of the ATF/CREB family [47]. Like c-Jun, ATF3 is expressed in 
axotomized motoneurons, and shows both survival and death promoting properties 
depending on the cellular context [47]. The presence of ATF3 strongly influences 
the effect of c-Jun. For instance, in trophic factor-deprived neurons it can turn c-Jun 
from a cell death promoting factor into a factor that promotes neurite outgrowth 
[81]. 
 
Figure 6: The JNK/c-Jun signaling pathway. The MAP kinase kinases MKK 4 and 7 can activate c-Jun 
N-terminal kinases (JNK), which can activate multiple transcription factors including c-Jun, ATF2 and 
p53. 
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In Chapter 5 we have shown that both phosphorylated c-Jun and ATF3 are 
expressed in a subset of motoneurons in G93A mice starting from an early phase 
of disease prior to the onset of motoneuron death. These phosphorylated c-Jun 
and ATF3 expressing motoneurons showed a variable morphology varying from 
normal to sick-appearing cells. Importantly, these sick motoneurons were not (yet) 
immunoreactive for active caspase, and showed a unique morphology that differed 
from the morphology of dying motoneurons reported in the literature (see chapter 
5).  We concluded that ATF3 and phosphorylated c-Jun are expressed by 
motoneurons throughout their degeneration process starting from a relatively early 
phase until a very sick phase shortly before dying. The activation of c-Jun and 
ATF3 initially may represent a survival response since there is no activation of 
programmed cell death pathways in these cells. However, it is possible that the 
transcriptional context within ATF3/phosphorylated c-Jun expressing motoneurons 
changes as the cell deteriorates. Accordingly, a subset of (frequently ill-appearing) 
ATF3/phosphorylated c-Jun expressing motoneurons showed the expression of 
CHOP (Gadd153), which influences the transcriptional activity of ATF3 [47]. We 
also concluded that ATF3 and phosphorylated c-Jun are excellent markers to 
pinpoint motoneurons in an early phase of their degeneration, and may serve as a 
reference to study the role of other signaling pathways in motoneuron 
degeneration. 
 
 
6.4 Is there a future ALS-research in SOD1-ALS mice? 
 
Research on SOD1 mutations has dominated the ALS field in the past decade. Did 
this research increase our understanding of the pathogenesis of ALS? In case of 
ALS caused by SOD1 mutations the answer is obviously 'yes'. Although we do not 
yet fully understand how mutant SOD1 causes the degeneration of motoneurons, a 
lot has been learned about potential mechanisms (e.g. see this chapter and 
chapter 1). In terms of therapeutic approaches, data so far have indicated that 
down-regulating mutant SOD1 expression or preventing its aggregation may be 
most effective. Although technically challenging, recent studies have shown that 
this may be achieved using RNAi-approaches [76,112]. In view of the linear 
relationship between the level of mutant SOD1 expression and the time of onset 
and severity of disease, even down-regulating mutant SOD1 expression by 10-20% 
may have a large effect on survival. Thus also drugs that 'slow down' the 
metabolism of SOD1 in motoneurons may be beneficial. Accordingly, 'unexpected 
results' obtained in SOD1-ALS mice, such as the dramatic beneficial effect of 
altering neurofilament expression on survival of SOD1-ALS mice, may be 
explained by a mechanism affecting the global metabolism of motoneurons and 
consequently reducing mutant SOD1 expression. Both overexpression of 
neurofilament H [21], or either deletion or overexpression of neurofilament L in 
SOD1-ALS mice were found to increase their lifespan [68,110]. These results were 
counterintuitive since alterations in neurofilament levels cause neurofilament 
aggregates or reduces axon caliber [73], and hence by themselves are deleterious 
to motoneurons. However, the results with the neurofilament mice can be easily 
explained, if motoneurons compromised by altered neurofilament status would 
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produce 20% less mutant SOD1, which in view of their altered health is 
conceivable. This illustrates the importance of evaluating the effect of a drug on 
motoneuron morphology and overall mutant SOD1 expression in every drug trial. 
Alternative approaches in SOD1-linked ALS may be directed at preventing protein 
aggregation, for instance by up regulating heat shock protein expression [65]. Also 
drugs that interfere with specific neuroprotective signaling pathways may be 
helpful, but prior of considering such an approach a further molecular dissection of 
signaling pathways that operate in injured motoneurons is needed. Yet another 
approach in delaying ALS caused by mutant SOD1 may be the attenuation of 
inflammatory response. This is suggested by recent findings that prolonged 
systemic inflammation causes an earlier onset of disease in SOD1-ALS mice [82]. 
The latter approaches are likely to be also relevant for sporadic ALS, and hence 
illustrate the importance of SOD1-ALS mice as an ALS research tool. Thus, 
although the primary disease causing factors may differ, phenomena such as 
inflammation, protein aggregation, neuron-glia signaling, and perhaps excitotoxicity 
may play a role (and represent a target for therapeutic approach) in all forms of 
ALS.  
 
 
Table 1: A selection of preclinical and clinical drug trials.  
Substance mechanism Age at start 
(days) 
Onset 
delay 
(days) 
Death 
delay 
(days) 
Human 
effect 
ref 
riluzole Anti-excitotoxicity 50 not sign 13 2-3 
months 
[8] 
[46]  
Topiramate Anti-excitotoxicity 30 nd not sign none [22] [75]  
vitamin E Anti-oxidant 50 13 not sign none [26] [46]  
NAC Anti-oxidant 120 * not sign not sign nd [56] 
  28-35 7 8  [3] 
GDNF Growth factor 63  
adenoviral vector
13 17 nd [105] 
  35 wks ** 
intramuscular 
injection 
not sign nd  [74] 
AR-R 17477 nNOS inhibitor 40 nd 13 nd [36] 
L-NAME NOS inhibitor 30 nd not sign nd [36] 
creatine Energy 
supplementation 
70 nd 25 none [43] [66]  
celecoxib Anti-inflammatory 28 16 28 none [23] [29]  
creatine + 
celecoxib 
 30 nd 36 nd [67] 
* G1L-G93A mice ** G93A mice with extra low transgenic copy number 
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Hundreds of potential drugs now have been tested in SOD1-ALS mice (e.g. see 
[13]). A selection of tested drugs is shown in table 1. In general results obtained in 
the SOD1-ALS mice have a relevant predictive value for what will happen in 
patients as illustrated with drugs like Riluzole and topiramate and anti-oxidants 
(see table 1). However, the mouse studies also have yielded 'false positives' like, 
for instance, creatine which had a large beneficial effect in G93A mice [66], but no 
effect in patients [43]. There are many possible explanations for this type of 
discrepancies, such as 'a mouse is not a man' or 'creatine may be only beneficial in 
SOD1-linked ALS cases'. However, another possibility is that false positives, such 
as creatine, arise from the use of high copy G93A mice that show a number of 
pathological features that do not occur in other lines of SOD1-ALS mice. Hence, 
one way of minimizing 'false hopes' is by performing drug trials in multiple lines of 
SOD1-ALS mice, including low-copy mice which may more realistically model ALS 
in man. 
In sum, the SOD1-ALS mice represent a highly important (and still the only) mouse 
model for ALS, although as with any model data should be interpreted with care. 
The neuropathological investigations as presented in this thesis have provided a 
frame work for future studies with these mice. The future of ALS research will 
continue to be a multidisciplinary fishing expedition focusing on the following 
approaches: 1) The identification of new mutations linked to familial forms of ALS. 
2) Screening and identification of the mode of action of potential drugs and 
therapeutic approaches in SOD1-ALS mice. 3) Further characterization of the cell 
biology of motoneurons. In view of recent data emerging from ALS genetics these 
studies should focus on trafficking and logistics. 4) Further characterization of 
motoneurons and surrounding glia in SOD1-ALS mice (and, eventually, novel 
mouse models of adult onset motoneuron degeneration) to identify novel targets 
for therapeutic approaches.  
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Summary 
Neurons are large post-mitotic cells with a high metabolic activity and a highly 
complex morphology characterized by a dendritic tree that consists of a network of 
processes, and an axon that can have length of up to 104 times the diameter of the 
cell body. Because of this complexity the maintenance of the functional and 
structural integrity of neurons throughout life is a complex task that requires 
sophisticated transport, damage control and repair machineries. Hence, it is not 
surprising that aging is associated with structural and functional deterioration of the 
central nervous system and that neurodegenerative diseases (diseases that cause 
the premature loss of neurons) are among the dominant disorders associated with 
aging. The knowledge on processes involved in normal aging and neuronal death 
in neurodegerative diseases is increasing, but far from complete. Intervention in 
these processes is therefore not yet possible. 
Amyotrophic lateral sclerosis (ALS) is a fatal disease in which motoneurons in the 
spinal cord, brain stem and motor cortex degenerate. This disease has an 
incidence of 2-3 per 100.000 people, meaning that 300-450 people are diagnosed 
with the disease each year. The survival of ALS-patients is on average 3 years 
after diagnosis. The first symptoms are usually fatigue, muscle cramps, and 
weakness in the muscles of one of the limbs, progressing to paralysis and 
spreading to other parts of the body, eventually causing total body paralysis. In 
most patients (about 90%) no apparent genetic cause for their disease has been 
found, in those cases the disease is called sporadic ALS. In the other 10% a 
hereditary pattern has been found; familial ALS. In 1993 a mutation was found in 
the gene for superoxide dismutase 1 (SOD1) which causes ALS in some familial 
ALS families. By now more than 110 different mutations in the SOD1-gene have 
been linked to familial ALS and more recently mutations in 5 other genes have 
been found to cause familial ALS. 
The discovery of SOD1-mutations has enabled the production of transgenic 
mutant-SOD1 expressing mice that develop an ALS-like motoneuron disease. 
These SOD1-mutant mice develop a disease strongly resembling human ALS. 
These transgenic mice offer the possibility to study all stages of motoneuron death. 
In this thesis different aspects of ALS in the transgenic mouse model and in 
cultured motoneurons are studied and discussed. 
 
In chapter 2 the possible toxicity of 3-nitrotyrosine is studied. 3-Nitrotyrosine is a 
modified amino acid that is formed by a reaction between nitric oxide-derived 
reactive species and tyrosine. Because of a number of studies indicating that 3-
nitrotyrosine may be neurotoxic to particular populations of neurons, we have 
examined the effect of acute and prolonged application of 3-nitrotyrosine in the 
brain of mice and in murine organotypic spinal cord cultures. Using an antibody 
that labels 3-nitrotyrosine injected into the brain, we showed that after a single 
microinjection into the cortex, striatum or hippocampus, 3-nitrotyrosine is 
predominantly distributed in neurons, but subsequently disappears within 60 min. 
Neither single microinjections nor prolonged intra-striatal delivery of 3-nitrotyrosine 
via osmotic minipumps resulted in any evidence for neuronal degeneration. Also 
prolonged exposure of organotypic spinal cord cultures to high doses of 3-
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nitrotyrosine did not influence neuronal viability. From these results we conclude 
that although increased levels of free 3-nitrotyrosine are reported for various 
neurodegenerative diseases, free 3-nitrotyrosine is unlikely to contribute to 
neuronal degeneration. 
 
Defects in protein repair and degradation can lead to protein aggregation and 
inclusion formation. The proteasome is a complex of enzymes responsible for an 
important part of the degradation of proteins. In chapter 3 we studied the effect of 
mild inhibition of the proteasome on inclusion body-formation in (moto)neurons in 
organotypic spinal cord cultures. We found a dose-dependent degeneration of 
neurons after a one-week exposure to proteasome inhibitors. This degeneration 
was associated with an increase in poly-ubiquitination, consistent with failure of the 
ubiquitin-proteasome system. No difference in survival between motoneurons and 
interneurons was observed. Because of our interest in ALS we repeated these 
experiments with spinal cord cultures from G93A-SOD1 mice, which showed that 
neurons whit high expression of mutant SOD1 are not more vulnerable to death 
caused by proteasome inhibition than normal neurons. These results indicate that 
inclusion formation is not directly caused by a combination of proteasome inhibition 
and mutant SOD1, but that mutant SOD1 possibly causes formation of inclusion 
bodies via another mechanism. Whether inclusion bodies are a primary cause of 
neurodegeneration is discussed in more detail in chapter 6. 
We also looked for alterations in the protein repair system. Molecular chaperones 
are proteins that assist new proteins to fold or that can assist damaged, (partially) 
unfolded proteins to refold.  Heat shock protein 25 (Hsp25) is a molecular 
chaperone which is constitutively expressed in murine motoneurons. Chapter 4 
describes a decrease in the amount of Hsp25 protein prior to the onset of 
motoneuron death. This decrease is post-translational since the amount of Hsp25-
mRNA is unchanged. In view of the cytoprotective properties of Hsp25 and the 
temporal relationship between decreased Hsp25 expression and the onset of 
motoneuron death, it is feasible that reduced Hsp25 concentration contributes to 
the degeneration of motoneurons in G93A mice. These data are consistent with the 
idea that mutant SOD1 may reduce the availability of the protein quality control 
machinery in motoneurons. 
 
If a cell is damaged beyond repair, a process called programmed cell death is 
started. Apoptosis is a common form of programmed cell death. In chapter 5 we 
studied the phosphorylation of c-Jun and ATF3, two factors that play a role in the 
final phases of survival. Immunocytochemistry and in situ hybridization showed that 
a subset of motoneurons express both ATF3 and phosphorylated c-Jun starting 
from a relatively early phase of disease before the onset of active caspase 3 
expression and motoneuron loss. The onset of phosphorylated c-Jun and ATF3 
expression correlated with the onset of dendritic ubiquitination. Confocal-double 
labeling immunofluorescence showed that phosphorylated c-Jun and ATF3 
expression in motoneurons correlated with Golgi fragmentation. A subset of ATF3 
and phosphorylated c-Jun immunoreactive motoneurons showed an ill appearance 
characterized by number of distinctive abnormalities, including an eccentric 
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flattened nucleus, perinuclear accumulation of the Golgi apparatus and the ER, 
perikaryal accumulation of ubiquitin immunoreactivity and intense Hsp70 
immunoreactivity. These abnormal cells were not immunoreactive for active 
caspase 3. We conclude that motoneurons in SOD1-ALS mice prior to their death 
show a prolonged phase in which they are compromised and express the injury 
transcription factors ATF3 and phosphorylated c-Jun. This compromised state is 
being characterized by an increasing amount of ubiquitinated material that first fills 
the neurites and subsequently the cell body.  
 
In chapter 6 a number of subjects from the previous chapters are discussed more 
comprehensively. We conclude that mutated SOD1 causes a complex pathology 
involving protein-repair and –degradation mechanisms, mitochondria and multiple 
other systems, finally leading to programmed cell death. 
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Samenvatting 
Zenuwcellen worden gekenmerkt door zeer uitgebreide morfologie met enerzijds 
een dendrietboom met vele uitlopers en anderzijds een axon met een lengte tot 
10.000 keer de doorsnede van het cellichaam. Sommige delen van de cel liggen 
hierdoor zeer ver van het controle centrum van de cel, waardoor het vervangen 
van onderdelen een complex proces is. Daarnaast worden zenuwcellen in 
tegenstelling tot de meeste andere cellen in het lichaam niet vervangen gedurende 
het leven. Om zichzelf in stand te houden zijn zenuwcellen daarom afhankelijk van 
efficiënte transport-, en reparatiesystemen. Falen van deze systemen gedurende 
veroudering of door ziekte leidt tot het disfunctioneren en eventueel afsterven van 
de zenuwcellen. De kennis over veroudering en sterfte van zenuwcellen is zeer 
onvolledig, en er zijn nog geen effectieve medicijnen die dit proces tegengaan.  
Dit proefschrift richt zich op een ouderdomsziekte van de zenuwcellen die de 
spieren aansturen, de motoneuronen. Deze ziekte, amyotrofische lateral sclerose 
(ALS), begint meestal tussen de 40 en 60 jaar met vermoeidheid, kramp en/of 
spierzwakte in één van de ledematen. De spierzwakte wordt steeds ernstiger, 
uiteindelijk leidend tot volledige verlamming en vervolgens de dood van de patiënt. 
Per jaar wordt in Nederland de ziekte bij 300-450 personen vastgesteld. De 
patiënten overlijden gemiddeld 3 jaar na diagnose. Uit genetisch onderzoek blijkt 
dat de ziekte bij 10% van de patiënten wordt veroorzaakt door een erfelijke 
afwijking. In 1993 is het eerste ALS-gen ontdekt. Mutaties in dit gen, het 
superoxide dismutase 1 (SOD1)-gen, veroorzaken ongeveer 20% van de erfelijke 
ALS. De ontdekking van SOD1-mutaties heeft geleid tot een diermodel waarbij 
gemuteerd SOD1 als transgen in een muizenlijn is ingebracht. Deze muizen 
ontwikkelen een ziektebeeld dat nagenoeg identiek is aan menselijke ALS, en 
vormen daarom een zeer goed proefdiermodel voor de ziekte. In hoofdstuk 1 
wordt een overzicht gegeven van de stand van zaken van het genetisch en 
experimenteel onderzoek naar de pathogenese van ALS, en worden daarnaast de 
belangrijkste eigenschappen van de SOD1-ALS muizen besproken. 
Een groot voordeel van een muizenmodel is dat men niet alleen systematisch 
onderzoek kan doen naar mogelijke behandelingen, maar ook zeer vroege stadia 
van het ziekteproces kan bestuderen; iets wat bij de mens onmogelijk is. Het 
grootste deel van het onderzoek in dit proefschrift richt zich op het nauwkeurig in 
kaart brengen van vroege veranderingen die optreden in motoneuronen van 
SOD1-ALS muizen. Op grond van de resultaten hebben we van een aantal 
factoren kunnen vaststellen of ze wel, dan wel niet een rol spelen bij het 
ziekteproces. De resultaten bevestigen het idee dat het degeneratieproces van de 
motoneuronen samenhangt met opeenhoping en klontering van misvormd SOD1 
eiwit. Een dergelijk proces speelt waarschijnlijk ook bij andere ouderdomsziekten 
van de hersenen, zoals de ziekte van Alzheimer (gekenmerkt door klontering van 
het tau- en het β-amyloid eiwit), of de ziekte van Parkinson (klontering van 
synucleine), een centrale rol. Vragen die een dergelijk ziektemechanisme 
oproepen zijn: 1) Wat veroorzaakt de ophoping en klontering van abnormaal eiwit? 
2) Waarom gebeurt dit alleen in een specifiek soort zenuwcellen (zoals 
bijvoorbeeld de motoneuronen bij ALS)? 3) Hoe veroorzaakt de ophoping en 
klontering van eiwitten het verval en de dood van zenuwcellen? Het onderzoek in 
dit proefschrift heeft betrekking op het beantwoorden van deze vragen. Voor geen 
 van de vragen is er echter nog een eenduidig antwoord. Dit wordt besproken in 
hoofdstuk 6. Hieronder volgt een korte beschrijving van het onderzoek in de 
hoofdstukken 2 - 5. 
 
Er zijn verschillende oorzaken voor het ontstaan van misvormde eiwitten. In de 
eerste plaats veroorzaken mutaties vaak ernstige misvorming van het eiwit. Ook 
niet gemuteerde eiwitten kunnen een foute structuur krijgen, ofwel omdat tijdens 
het in elkaar vouwen van het eiwit iets mis is gegaan, ofwel door beschadiging van 
een eiwit door bijvoorbeeld vrije radicalen. Voor veel SOD1 mutaties is 
aangetoond, dat het eiwit door mutaties in die mate misvormd is dat het 'plakkerig' 
wordt en kan gaan klonteren. Bij een aantal mutaties heeft het eiwit echter een 
relatief normale structuur. Een ander mechanisme dat kan bijdragen aan misvormd 
SOD1 is vrije radicaal schade. De normale functie van SOD1 is het onschadelijk 
maken van vrije zuurstof radicalen, maar van gemuteerd SOD1 is aangetoond dat 
het in plaats daarvan bepaalde vrije radicalen genereert, zoals bepaalde 
schadelijke stikstofoxide verbindingen die onder andere het SOD1 zelf kunnen 
aantasten. Het onderzoek in hoofdstuk 2 vloeit voort uit ons onderzoek naar de rol 
van reactieve stikstofoxide verbindingen in het degeneratie proces bij de SOD1-
ALS muis. Stikstofoxide radicalen kunnen o.a. bepaalde aminozuren veranderen. 
Eén van deze veranderde aminozuren, 3-nitrotyrosine, wordt gebruikt als 
vingerafdruk voor de aanwezigheid van schade door stikstofoxide radicalen. 
Bovendien wordt verhoogd 3-nitrotyrosine in verband gebracht de eiwitklontering in 
zenuwcellen van ALS patiënten. In de SOD1-ALS muis bleek echter geen 3-
nitrotyrosine aanwezig te zijn in SOD1-eiwit klonten (deze resultaten worden 
beschreven aan het begin van hoofdstuk 6). Onze (en andere) studies wijzen 
echter wel op een diffuse verhoging van de concentratie van vrij 3-nitrotyrosine 
(dus niet gebonden aan een eiwit) in de SOD1-ALS muis. Omdat in studies in de 
literatuur de suggestie werd gewekt dat ook vrij 3-nitrotyrosine schadelijk kan zijn, 
hebben we dit in hoofdstuk 2 systematisch onderzocht. Uit onze studies resultaten 
bleek echter dat 3-nitrotyrosine niet schadelijk was voor zenuwcellen. 
De aanwezigheid van gemuteerd plakkerig SOD1, kan op zichzelf het ontstaan van 
eiwitklonten in de motoneuronen van SOD1-ALS muizen verklaren, maar de vraag 
blijft dan waarom dit alleen in motoneuronen gebeurd terwijl SOD1 in alle cellen 
aanwezig is. Een mogelijke verklaring is dat bij motoneuronen de eiwitten en 
enzymcomplexen die misvormde eiwitten wegvangen en afbreken, relatief minder 
goed werken. Een belangrijke schakel in het afbreken van misvormde eiwitten is 
het ubiquitine-proteasoom systeem, waarbij misvormde eiwitten een 'label' krijgen 
in de vorm van een ketentje van een klein eiwit, ubiquitine, en vervolgens worden 
afgebroken door een groot eiwitcomplex, het proteasoom. Er zijn aanwijzingen dat 
mutant SOD1 het proteasoom complex kan overbelasten, en dat remming van het 
proteasoom leidt tot de vorming van grote microscopisch zichtbare SOD1-eiwit 
klonten. In hoofdstuk 3 hebben we gekeken naar het effect van milde remming 
van het proteasoom op de overleving van motoneuronen in ruggenmergkweken. 
Uit deze studies bleek dat milde proteasoomremming op de lange duur kan leiden 
tot het afsterven van motoneuronen. Dit effect werd echter niet beïnvloed door de 
aanwezigheid van mutant SOD1. Bovendien hadden andere typen zenuwcellen 
dezelfde gevoeligheid voor proteasoomremming. Deze gegevens pleiten tegen het 
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idee dat het proteasoom systeem een zwakke schakel is in motoneuronen. Dit 
wordt ook bevestigd door gegevens uit onze neuropathologische studie 
beschreven in hoofdstuk 5, die erop wijzen dat motoneuronen pas in een zeer late 
fase van hun degeneratieproces vlak voordat ze sterven, over onvoldoende 
proteasoomfunctie beschikken. 
Een andere schakel in het defensiemechanisme van de cel tegen misvormde 
eiwitten zijn de 'chaperon eiwitten', die verkeerd-gevouwen of beschadigde eiwitten 
omringen en zodoende onschadelijk maken. Omdat er aanwijzingen waren dat 
gemuteerd SOD1 ook bepaalde chaperon eiwitten kon overbelasten, hebben we in 
hoofdstuk 4 onderzocht wat er met één van deze chaperons, Hsp25 (bij de mens 
Hsp27 genoemd), gebeurt in de SOD1-ALS muis. Deze studie toont aan dat de 
hoeveelheid Hsp25 aanzienlijk is verlaagd in motoneuronen van SOD1-ALS 
muizen. Dit gebeurt op het moment dat ook andere degeneratieverschijnselen 
optreden. Het optreden van deze degeneratieverschijnselen kan verklaard worden 
uit de afname van de hoeveelheid Hsp25, omdat Hsp25 enkele belangrijke 
beschermende functies heeft in motoneuronen. Hoe de aanwezigheid van 
gemuteerd SOD1, leidt tot een verlaging van de Hsp25 concentratie is nog niet 
bekend. 
 
Om inzicht te krijgen in hoe de stapeling en klontering van gemuteerd SOD1, leidt 
tot het afsterven van de motoneuronen, hebben we in hoofdstuk 5 het 
degeneratieproces van motoneuronen in de SOD1-ALS muis nauwkeurig in kaart 
gebracht. Om 'zieke' motoneuronen te kunnen identificeren hebben we gebruik 
gemaakt van twee eiwitten, ATF3 en c-Jun, die vaak worden aangemaakt in 
beschadigde cellen. ATF3 en c-Jun zijn transcriptie factoren, d.w.z. eiwitten die 
expressie van bepaalde genen kunnen sturen. De belangrijkste conclusies van 
hoofdstuk 5 zijn (1) dat ATF3 en c-Jun relatief vroeg in het ziekteproces in een deel 
van de motoneuronen tot expressie komen. Dit hangt samen met het verschijnen 
van geklonterd SOD1 in de dendrieten van de motoneuronen. (2) De morfologie 
van ATF3/c-Jun-positieve motoneuronen varieert van gezonde relatief normale 
cellen tot cellen met een zeer ziek uiterlijk, o.a. gekenmerkt door een platte kern en 
een cellichaam dat grotendeels is gevuld met geklonterd SOD1 en mogelijk andere 
abnormale eiwitten. (3) Geprogrammeerde celdood treedt pas op nadat de 
motoneuronen dit zieke stadium hebben bereikt.  
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